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Abstract 
African trypanosomiasis is caused by a unicellular eukaryote that parasitizes 
multicellular organisms and causes medically and economically important 
diseases in humans (Human African Trypanosomiasis) and their domestic animals 
(African Animal Trypanosomiasis). Incidence is currently declining due to the 
application of present chemotherapy, although the drugs are old, toxic, difficult 
to administer and in some cases expensive, and of diminishing efficacy due to 
resistance. However, this trend needs to be sustained with the discovery of new 
compounds active against the resistant strains. These new treatment options 
must meet the current pharmacological requirements, must be parasite specific 
and must be relatively cheap to produce. Pharmacological manipulation of 
phosphodiesterases (PDEs), which hydrolyse cyclic Adenosine Monophosphate 
(cAMP), have been extensively studied in humans and found to have great 
therapeutic effect. Kinetoplastid genomes code for the same set of cyclic 
nucleotide-specific class 1-type phosphodiesterases, with catalytic domains 
similar to those of human PDEs. The locus of Trypanosoma brucei PDEB1/2 was 
found to be essential, by either genetic manipulation or the use of the 
pharmacological inhibitor CpdA, but therapeutic exploitation of TbPDEB1 has so 
far been hampered by its catalytic domain similarity to human PDEs. However, 
investigating the unique downstream cAMP signalling cascade, which includes 
the recently identified cAMP Response Proteins (CARPs), could reveal potentially 
new trypanosome-specific therapeutic targets.   
 
In this study we show that single knockout (sKO) of the CARP genes causes a 
decreased susceptibility to CpdA, and that null mutants of CARP2-4 display 
significantly increased intracellular and extracellular cAMP levels. A double 
knockout (dKO) of CARP2 also shows a significant growth defect. Conversely, 
overexpression of CARP3 causes a growth delay in both WT s427 and CpdA 
resistant (R0.8) cells, when exposed to CpdA, and were more sensitive to CpdA 
compared to other CARP overexpressing cells as well as the WT s427 and R0.8 
controls. These cells also have significantly higher intracellular and extracellular 
cAMP levels relative to the control lines and the other CARP overexpressors. In 
the cells overexpressing CARP3, whether WT s427 or R0.8, the cellular content 
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of both CARP3 messenger Ribonucleic Acid (mRNA) and protein decreases 
extensively within 6 h of CpdA exposure.  
 
The CARP3 protein has domains that are indicative of a role in protein-protein 
interaction, signalling, regulation and degradation and probably undergo 
acylation. Some experimental confirmation of these traits was obtained, using 
Co-immunoprecipitation (Co-IP) and Mass Spectrometry (MS), with the 
identification of Adenylyl cyclase (AC) GRESAG4s (also found through RNA-
interference Target Sequencing (RITseq) and confirmed by quantitative Reverse 
Transcription PCR), and proteasome regulatory proteins (PRNs) in addition to 
membrane and flagellar binding proteins, as potential interactors. Preliminary 
Immunofluorescence (IF) microscopy showed that CARP3 localizes to plasma 
membrane ad the flagellum, CARP2 to specific bodies/organelles in the cytosol 
and CARP1 in the cytosol. RNA sequencing of overexpressing CARP3 reveals 
differentially expressed proteins involved in cell cycle and cytokinesis as well as 
transport proteins with several transmembrane domains, consistent with the 
proposed acylated membrane localisation, and with interaction of CARP3 with 
membrane proteins and ACs (GRESAG4 isoforms).Thus CARP3 has the domains, 
interactions and localization consistent with a regulatory role in cAMP 
metabolism.  
 
Thus the CARPs and especially CARP3 are interesting biological molecules 
providing key new insights into signalling and the cell biology of the 
trypanosome.
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RPNs   Regulatory Protein Networks 
QRT-PCR  Quantitative Reverse Transcription PCR 
RHS   Retrotransposon hot spot 
SIF   Stumpy induction factor 
sKO   Single knockout 
Tb427   Trypanosoma brucei strain 427 
TbAT   Trypanosoma brucei adenosine transporter  
TbrPDEB  Trypanosoma brucei phosphodiesterase enzyme B 
TcrPDEB  Trypanosoma cruzi phosphodiesterase enzyme B 
TPR   Tetratricopeptide Repeats 
TM   Trans-membrane 
UTRs   Untranslated regions 
VSG   Variant surface glycoprotein 
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WHO   World Health Organization 
+/-   Single knockout 
-/-   Double knockout  
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General Introduction 
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1.1 Trypanosomiasis and Human African 
Trypanosomiasis (HAT) 
1.1.1 Definition and classification 
Human African trypanosomiasis (HAT) also known as African sleeping sickness is a 
vector-borne parasitic disease caused by the protozoan pathogen Trypanosoma 
brucei (WHO, 2011) and transmitted by several Glossina species, commonly 
called tsetse flies (Stich et al., 2002). There are three sub-species of 
Trypanosoma brucei that infect mammals: T. b. brucei, T. b. gambiense and T. 
b. rhodesiense. However, only T. b. gambiense and T. b. rhodesiense infect and 
cause clinical disease in humans.  
 
T. b. rhodesiense causes the acute form of HAT in which the patient’s condition 
deteriorates rapidly as the parasite moves from the blood and lymphatic systems 
(early stage infection) into the central nervous system (CNS). The process starts 
with a tsetse bite and an immunological response (inflammation) which leads to 
the development of a chancre at the site of the infection (Moore et al., 2002). 
Parasites then move to the lymph nodes and are distributed in the circulation, 
multiplying in the blood and lymph. Inflammation of brain tissues (meningo-
encephalitis) follows parasite invasion of the CNS as well as infiltration of spinal 
nerve tissue and inflammation of the meninges. This results in severe 
neurological symptoms followed by coma (Brun et al., 2010; Moore et al., 2002). 
In the absence of treatment, death usually occurs in 6-8 months. However, 
recent evidence implicates geographical variation in the speed at which T. b. 
rhodesiense infections progress to the late stage (MacLean et al., 2004). 
 
T. b. gambiense is usually described as the chronic form of HAT, often with a 
long pauci-symptomatic stage of some years, and a chronic meningo-encephalitic 
condition during the late stage (Fevre et al., 2006; Taelman et al., 1987).  
 
Although either T. b. gambiense and T. b. rhodesiense infection is considered 
HAT, staggering differences in clinical features of the infections, the treatment 
protocols used, the geographical range of the parasites, the epidemiology and 
transmission and the control options available suggests that each form of HAT is 
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in effect a separate disease entity (Fevre et al., 2006). Although the important 
epidemiological distinction in the clinical conditions lies in the length of the 
clinical course and the degree of disability, these differences have profound 
impact on disease transmission and control policies.  
 
1.1.2 Disease burden and distribution 
HAT is considered one of the world’s Neglected Tropical Diseases (NTDs). These 
are diseases that cause substantial morbidity among the world’s poorest people 
but have historically not been targeted for intensive drug development because 
of limited financial incentives in the private sector (Hotez et al., 2007; Molyneux 
et al., 2005). It has been estimated that the core group of NTDs results in 
greater than 57 million disability-adjustable life years (DALY) lost which are 
greater than those for malaria and HIV (Hotez et al., 2006). The features of 
NTDs are the fact that they lead to poverty, that they can be eliminated using 
low-cost and highly cost-effective control approaches and that their control 
would have a simultaneous and sustainable effect on poverty reduction (Hotez et 
al., 2009).  
 
Human African trypanosomiasis is endemic in many countries between latitudes 
14o north and 29o south across many countries in sub-Saharan Africa with an 
estimated 60 million people in 38 nations at risk of infection (Brun et al., 2010; 
Kennedy, 2004; Simarro et al., 2011) (Figure 1.1).  
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Figure 1.1: Disease distribution and burden of the Human African Trypanosomiasis. 
Reproduced from Simarro P.P et al. (2011).  
 
 
It is estimated that approximately 98% of reported HAT infections leading to 
sleeping sickness is caused by T. b. gambiense which results in the chronic form 
of the disease, while T. b. rhodesiense represents fewer than 2% of the reported 
cases and causes an acute infection (Brun et al., 2010; Kennedy, 2004). 
However, T. b. rhodesiense  have been shown to be a potential hazard in 
travellers from Europe and the USA returning from visits to east Africa game 
parks, where the parasite exists as a zoonotic infection in wild animals (Blum et 
al., 2012; Simarro et al., 2012b) (Figure 1.2). 
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Figure 1.2: Distribution of human African trypanosomiasis with incidences and risk for 
travelers.  The black line divides the areas in which Trypanosoma brucei gambiense 
prevails and those in which Trypanosoma brucei rhodesiense predominates. Reproduced 
from Blum J et al, 2010  
 
The two human-infective species of African trypanosomes are also distinguished 
by ecology, animal reservoir and geographical differences. T. b. rhodesiense is 
transmitted by the vector G. morsitans which are found in woodlands and dry 
bush environments and it infects wild animals like antelope (Gooding and 
Robinson, 2004). T. b. rhodesiense also infects domestic animals which usually 
serve as reservoirs. Epidemiological studies have shown that cattle are important 
reservoirs (Fevre et al., 2001; Welburn et al., 2001). T. b. rhodesiense is 
primarily a zoonosis (Stich et al., 2002).Transmission of the disease is by contact 
with infected vectors through activities such as safaris, which bring humans into 
contact with infected vectors; only little human-fly-human transmission occurs.  
The Glossina palpalis group are involved in the transmission of T. b. gambiense. 
These vectors are found along lakes and are often in close proximities to human 
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habitation (Gooding and Krasfur, 2004). T. b. gambiense appears to be almost 
exclusively transmitted via a human-fly-human transmission cycle. Although it 
can be found (with some difficulty) in wild and domestic animals the 
epidemiological role of this is uncertain since humans are the main reservoir 
(Welburn et al., 2001). The clinical features of HAT also vary relative to 
geographical location in Africa, both in different countries and different regions 
in the same country. There have been cases of differences in neurological 
symptoms and signs in T. b. rhodesiense HAT in Tanzania and Uganda, whilst 
within Uganda itself, variations have been observed in the speed and severity of 
disease progression in different foci (Kuepfer et al., 2011; MacLean et al., 2010). 
Major international efforts by the World Health Organization (WHO), partner 
agencies and governments in infected regions have resulted in a dramatic 
improvement in both human case detection and treatment as well as vector 
control, leading to a sharp decline in the number of reported cases to levels 
below 10,000 for the first time in decades (Simarro et al., 2011). However, there 
are fears of possible unreported and under-reported cases to the WHO such as 
occurred in Uganda and the Democratic Republic of Congo in 2005 and 2007 
respectively (Mumba et al., 2011; Odiit et al., 2005). These fears are 
exacerbated by the possibility of co-infection due to the existence of both HAT 
forms in Uganda (Picozzi et al., 2005) as well as documented incidence of HAT in 
Europe and the USA from travellers (Blum et al., 2012).  
1.1.3 Lifecycle of the trypanosome 
African trypanosomes have their life cycle in their invertebrate host and their 
mammalian host. The tsetse fly takes a bloodmeal by piercing the skin of the 
mammalian host. An infective vector transfers the parasite into the host during 
feeding. The infective stage for the human host is the metacyclic trypomastigote 
which is introduced with the saliva of the tsetse during feeding. Inside the host, 
they transform into bloodstream trypomastigotes, are carried to other sites 
throughout the body, reach other blood fluids (e.g., lymph, spinal fluid), and 
continue the replication by binary fission. The entire life cycle of African 
trypanosomes is represented by extracellular stages. Metacyclic and bloodstream 
forms are covered with a surface coat. When the tsetse fly feed off the blood of 
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an infected human, it picks up the bloodstream form and this differentiates into 
a procyclic trypomastigote and replicates in the gut of the vector before 
migrating to the salivary glands and converting to an epimastigote form. The 
epimastigotes convert to metacyclic trypomastigotes to complete the life cycle 
(Wiser, 2011). The cycle in the fly takes approximately 3 weeks. A schematic 
representation of this is shown in figure 1.3. 
 
Figure 1.3: The life cycle of Trypanosoma brucei. Reproduced from the CDC website: 
http://www.dpd.cdc.gov/dpdx/HTML/TrypanosomiasisAfrican.htm 
 
1.1.4 Diagnosis 
The direct detection of parasites in HAT remains essential as a result of the grim 
outcome of the natural disease and the toxicity of the drugs used for its 
treatment. Although time spent in a HAT-endemic region as well as suggestive 
clinical presentation will point to the possibility of infection, several alternative 
diagnoses or coexisting diseases must be investigated and excluded (Kennedy, 
2008a).  
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Microscopical detection of parasites is the ‘gold standard’. This is especially the 
case in T. b. rhodesiense HAT, where due to the typically high level of 
parasitaemia trypanosomes can easily be identified on a thin or thick smear of 
the peripheral blood (Kennedy, 2006). The cyclical nature of parasitaemia in T. 
b. gambiense makes parasite detection difficult although it is still mandatory to 
identify parasites in the peripheral blood or lymph node aspirate using methods 
of concentrations (Brun et al., 2010).  
The Card Agglutination Test for Trypanosomiasis (CATT) is a serological test 
designed especially for the detection of T. b. gambiense, and it  has been 
heavily relied upon since its development in 1978 (Magnus et al., 1978). This is a 
simple and quick test which is particularly effective in population screening with 
a high sensitivity and specificity (Truc et al., 2002). There are however, issues 
with the high frequency of equivocal results due to differences in titre values 
that make the decision whether to treat or not difficult (Chappuis et al., 2005).  
Another serological test, the Latex/IgM can be used to detect elevated IgM in 
the CNS of second stage patients as a result of inflammatory response to T. b. 
gambiense invasion of the CNS and could have similar application in T. b. 
rhodesiense where similar changes in antibody levels have been observed (Lejon 
et al., 1998; Lejon et al., 2002).  
DNA amplification techniques such as Polymerase Chain Reaction (PCR) has been 
shown to improve diagnosis substantially due to its high sensitivity and 
specificity (Mugasa et al., 2012) The loop-mediated isothermal amplification of 
DNA has been developed for rapid detection of both T. b. rhodesiense  and T. b. 
gambiense  with a high potential for diagnosis of HAT in endemic countries 
(Kuboki et al., 2003; Njiru, 2012) coupled with its improved sensitivity as a 
result of the inclusion of detergents in the reaction mix (Grab et al., 2011).  
Besides the need for positive diagnosis, there is also the critical need for 
accurate staging of the disease as a result of the potential risks associated with 
the pharmacological treatment of CNS. The currently used WHO staging methods 
for diagnosing late-stage HAT implicates the presence of trypanosomes in the 
lumbar puncture (Kennedy, 2008b) of Cerebrospinal fluid (CSF) or a white blood 
cell count of more than 5 cells/µl or both (WHO, 1998). However, controversy 
rages as to the accuracy of this diagnostic measure primarily due to the need to 
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weigh the potential good of therapeutic treatment to the harm of drug toxicity. 
Several diagnostic staging techniques are being pursued as an adjunct or 
separate detection technique, including the determination of CSF IgM 
concentrations (Lejon et al., 2002; Lejon et al., 2003), the loop-mediated 
isothermal amplification assays, chemokine assays (CXCL10 and CXCL8) (Hainard 
et al., 2009) and the identification of biomarkers (neopterin) (Tiberti et al., 
2012). Clearly, the need for a reliable and validated non-invasive staging 
technique would be of great benefit in the fight against HAT. In the meantime a 
good microscope and a trained microscopist at a health centre especially in T. b. 
rhodesiense affected areas should improve the level of detection of HAT and 
reduce the disease burden suffered by patients.  
 
1.1.5 Treatment of HAT 
The differences in the epidemiological characteristics and clinical course of T. b. 
rhodesiense and T. b. gambiense HAT infections necessitate that drugs used to 
treat them differ. However, common to drugs used in treating either disease is 
the fact that they are unavailable orally, often toxic, and sometimes ineffective 
(Fairlamb, 2003).  
Pentamidine administered intramuscularly or intravenously has been used as a 
first-line treatment for early-stage T. b. gambiense since the 1940s with good 
clinical outcomes whilst early stage. However, pentamidine treatment has the 
potential of complications of hyperglycaemia or hypoglycaemia, prolongation of 
the QT interval on electrocardiogram, hypotension, and gastrointestinal features 
in T. b. gambiense and potential complications such as renal failure, skin 
lesions, anaphylactic shock, bone marrow toxicity, and neurological 
complications such as peripheral neuropathy (Barrett, 2010; Brun et al., 2010; 
Burri, 2010; Jacobs et al., 2011a). T. b. rhodesiense HAT is treated usually 
effectively especially in the early stages of the disease with intravenous suramin 
which was first used in the early 1920s. Just as pentamidine, suramin is also 
saddled with adverse clinical outcomes including neuropathy, rash, fatigue, 
anaemia, hyperglycaemia, hypocalcaemia, coagulopathies, neutropaenia, renal 
insufficiency and transaminitis (Barrett et al., 2007; Brun et al., 2011). 
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Treatment of the late stage is usually more problematic due to the fact that the 
available drugs are more toxic. Historically, melarsoprol (a highly toxic arsenic 
compound) is the only drug that is effective in treating late-stage T. b. 
rhodesiense by acting on trypanothione, a kinetoplastid-specific thiol that 
maintains an intracellular reducing environment (Fairlamb et al., 1989). 
Melarsoprol is usually effective, despite its painful route of administration and 
toxicity. It produces a post-treatment reactive encephalopathy in 10% of 
patients, half of whom die, leading to an overall mortality from treatment of 
about 5% and treatment failures due to drug resistance are major drawbacks 
(Kennedy, 2008a, 2012; Pepin and Milord, 1994).  
 
Eflornithine, also called difluoromethylornithine (DFMO), is an ornithine 
carboxylase inhibitor and an effective anti-trypanocidal drug that was initially 
developed as an anti-cancer agent; it is effective against late-stage T. b. 
gambiense HAT (Burri and Brun, 2003; Wickware, 2002). However, there arose 
concerns of development of resistance to eflornithine due to the fact that it is 
trypanostatic and has a short half-life in the body. Eflornithine is also difficult to 
administer and requires huge doses, raising serious issues of drug compliance 
(Simarro et al., 2012a) – a potential risk factor for resistance development. 
Additionally, eflornithine resistance was easily selected in the laboratory 
(Vincent et al., 2010). Thus nifurtimox, which was used mainly for Chagas 
disease (caused by Trypanosoma cruzi) but displayed some reported efficacy in 
second-stage HAT (Pepin et al., 1992) was added to eflornithine as a nifurtimox-
eflornithine combination therapy (NECT) and this has now become the standard 
first-line treatment for CNS-stage T. b. gambiense HAT, with intravenous 
melarsoprol now being used as second line treatment for this disease form 
(Simarro et al., 2011; Simarro et al., 2012a).  NECT has a mortality rate of 0.7% 
compared with 2.1% for eflornithine monotherapy and 5% for melarsoprol leading 
to a substantial switch to combination therapy for late-stage T. b. gambiense 
HAT (Simarro et al., 2011). However, like all current treatment of HAT, NECT 
has some drawbacks: it is ineffective against T. b. rhodesiense HAT; the 
eflornithine component still has to be given intravenously; it can have many 
side-effects, such as bone marrow toxicity, alopecia, seizures, and 
gastrointestinal symptoms and there is the potential for drug resistance to occur 
in the affected areas in Africa through loss of the putative amino acid 
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transporter TbAAT6, as has been shown in vitro (Burri and Brun, 2003; Kennedy, 
2004; Vincent et al., 2010). 
 
The prospect of more effective and less toxic drugs in trypanosomiasis is looking 
more promising over the past decade and into the future. This is mainly due to 
concerted and impressive efforts, primarily by WHO and various non-
governmental organisations, but aided by partnerships between governments, 
universities, and the pharmaceutical industry. These have resulted in more 
effective drug regimens and also the development of several promising oral drug 
candidates (Barrett, 2010; Brun et al., 2011; Simarro et al., 2011). Two of these 
promising candidates are fexinidazole (Torreele et al., 2010) and the oxaboroles 
of which the orally available SCYX-7158 (AN5568) is the lead candidate (Jacobs 
et al., 2011b). Fexinidazole, is an oral treatment with good clinical outcomes 
against both T. b. gambiense and T. b. rhodesiense HATs with the ability to cross 
the blood-brain and also effective against both drug sensitive and resistant 
trypanosomes (Kaiser et al., 2011). It is a prodrug that is rapidly metabolized in 
vivo into two metabolites, sulfoxide and sulfone through the cytochrome P450 
and flavin containing monooxygenase. It is presently in a phase II/III randomised 
clinical trial having met clinical requirements in a phase I trial (Eperon et al., 
2014; Torreele et al., 2010). SCYX-7158 (AN5568) is also an oral drug with good 
bioavailability, blood-brain barrier penetration and is quick acting with a low 
IC50 (Jacobs et al., 2011b). Having passed all preclinical studies, SCYX-7158 
(AN5568) is presently in phase I clinical trials. 
 
1.1.6 Cell biology of the trypanosome 
The trypanosome’s elongated cell shape is defined by the highly polarized 
microtubule cytoskeleton that remains intact and elongated throughout the cell 
cycle and is semi conservatively inherited by daughter cells  (Sherwin and Gull, 
1989). The microtubules show a uniform polarity: minus ends are anterior and 
plus ends are posterior (Robinson et al., 1995b). The single-copy organelles in 
the trypanosome cell (i.e. the flagellar pocket, flagellum, kinetoplast, 
mitochondrion and nucleus) are precisely positioned within the cytoskeletal 
corset and are concentrated between the posterior end and the centre of the 
cell. The flagellum exits at the most posterior point, the mouth of the flagellar 
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pocket is tethered along the exterior length of the parasite and  is the only site 
of endo- and exocytosis (Overath and Engstler, 2004). The flagellar pocket and 
its associated endo- and exocytosis is essential in the ability of the parasite to 
evade the host immune system through Variable Surface Glycoprotein (VSG) 
switching to protect against the alternative pathway of complement activation 
and to shield common antigenic determinants from immune recognition (Engstler 
et al., 2004; Grunfelder et al., 2002). The motility of the trypanosome is 
dependent upon its single flagellum (a semi-rigid structure found in the 
kinetoplastids and Euglenoids), which has a conventional axonemal structure 
plus an associated paraflagellar rod (Vaughan and Gull, 2003). The trypanosome 
flagellum originates in a basal body that is, in turn, linked through the 
mitochondrial membrane to the mitochondrial genome, which comprises a mass 
of catenated DNA termed the kinetoplast. In T. brucei only the distal tip of the 
flagellum is free with the rest laterally connected to the cell body along its 
entire length. This lateral attachment is both important in cell motility and cell 
division. It also tends to divide the cell into several discrete membrane 
subdomains (Gadelha et al., 2009; Langousis and Hill, 2014). The kinetoplast and 
basal body are linked by a tripartite attachment complex that must traverse 
both the cell and the mitochondrial membranes (Ogbadoyi et al., 2003). This 
comprises a series of filaments providing guide ropes through which 
mitochondrial genome segregation is linked to replication and segregation of the 
basal body and flagellum. The kinetoplast is linked to the microtubule 
cytoskeleton, such that drugs that disrupt the cytoskeleton prevent both basal 
body and kinetoplast segregation (Gull, 2003). The mitochondrion itself is a 
single elongated structure that runs from the posterior to the anterior of the cell 
with varying requirements dependent on the growth cycle stage of the 
trypanosome (Matthews, 2005)(Figure 1.4). 
 
Trypanosome regulation of cell cycle and other processes is highly dependent on 
the degree of structural organization such as the fact that the mitochondrial 
genome has a discrete periodic S phase and G2 phase that is coordinated with 
nuclear genome replication and segregation. The first example is the strict 
regulation of organelle positioning during division. Thus, the kinetoplast nuclear, 
and kinetoplast-posterior dimensions are fixed during the cell cycle of the 
procyclic form, cell growth at the posterior end occurring between the 
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segregating basal bodies and being maintained throughout S, G2 and M phase 
(Robinson et al., 1995a). The second is the observation that cytokinesis is not 
dependent upon the completion of nuclear mitosis: disruption of the mitotic 
spindle by drugs or genetic perturbation of trypanosome cyclin-dependent 
kinases (CDKs) generates cytoplasts that have a mitochondrial genome but no 
nucleus (these are termed zoids) (Hammarton et al., 2003; Li and Wang, 2003). 
The most obvious morphological difference between the different life cycle 
stages of the trypanosome is the position of the kinetoplast relative to the 
posterior end of the cell. In bloodstream forms, the kinetoplast lies close to the 
posterior end of the cell, and each daughter kinetoplast remains in this region 
throughout the cell cycle until cytokinesis. By contrast, the kinetoplast lies 
midway between the cell nucleus and posterior in procyclic forms; in 
epimastigote forms (in the tsetse salivary gland), the kinetoplast is anterior to 
the central nucleus. The reasons for these shape changes during the life cycle 
are completely unknown, although they are clearly required to establish the cell 
architecture necessary for cell division of each life cycle stage. Perhaps an 
increased length of attached flagellum along the cell body assists motility in 
bloodstream forms, whereas the longer anterior flagellum aids substrate 
attachment of the epimastigote stage (Matthews, 2005). 
 
The trypanosome cell structure and the changes in the cell biology of the 
parasite as it traverses from the mammalian bloodstream to the tsetse fly and 
back again must be highly regulated and interconnected. The present available 
armoury of genetic tools, molecular markers and tractable biology makes these 
organisms an excellent model in their own right for addressing fundamental 
questions of broad interest and applicability as well as the importance of 
tackling the disease itself. 
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Figure 1.4: Schematic diagram of a trypanosome of the Trypanosoma brucei group in its 
intermediate bloodstream form. The arrow shows the direction of travel of the parasite. 
Reproduced from 
http://ilri.org/InfoServ/Webpub/fulldocs/ILRADre1989v7n1/endocytosis.html 
 
 
1.2 Signal transduction  
1.2.1 Introduction to signal transduction 
Signal transduction pathways in mammalian cells are known to be of supreme 
importance in cellular function and indeed in the pharmacology of human and 
veterinary disease by converting extracellular stimuli into specific cellular 
responses (Maurice et al., 2014). Signal cascades frequently results in the 
amplification of a small signal into a large response leading to significant cell 
changes such as expression of DNA or activity of enzymes (Campbell and Reece, 
2004). Signal transduction usually occurs with the binding and activation of a cell 
surface receptor by an extracellular molecule (ligand). This combination of a 
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messenger with a receptor causes a change in the conformation of the receptor, 
a process known as receptor activation and often triggers changes in (the 
concentration of) intracellular molecules. All this ultimately results in changes in 
the cell, either in the expression of the DNA in the nucleus or in the activity of 
enzymes in the cytoplasm. Through either process a single molecule can cause 
signal amplification and result in several cellular responses (Rodbell, 1980). 
Unicellular organisms such as slime moulds and yeast have been shown to 
respond to environmental stimuli either to aggregate or to locate and 
participate in mating respectively (Hanna et al., 1984; Sprague, 1991). Several 
environmental stimuli are able to initiate signal transmission processes in 
multicellular organisms and numerous signal transduction processes are required 
for coordinating the behaviour of individual cells to support the function of the 
organism as a whole (Campbell and Reece, 2004). Many disease processes, such 
as diabetes, heart disease, autoimmunity and cancer, arise from defects in 
signal transduction pathways further highlighting the critical importance of 
signal transduction to biology as well as the development of medicine (Huang et 
al., 2010). Receptors involved in signal transduction are divided into two main 
classes: extracellular and intracellular receptors. 
 
1.2.1.1 Extracellular receptors 
Extracellular receptors are integral transmembrane proteins that span 
the plasma membrane of the cell, with one part of the receptor on the outside 
of the cell and the other on the inside and make up most receptors. Signal 
transduction occurs as a result of a ligand binding to the outside without the 
molecule passing through the membrane. This binding stimulates a series of 
events inside the cell with different types of receptor stimulating different 
responses, whilst receptors typically only respond to the binding of a specific 
ligand. Upon binding, the ligand induces a change in the conformation of the 
inside part of the receptor (Rubenstein et al., 2006). This results in either the 
activation of an enzyme activity that is part of the receptor (e.g. adenylate 
cyclase) or the exposure of a binding site for other intracellular signalling 
proteins (e.g. G-proteins) within the cell, eventually propagating the signal 
through the cytoplasm. 
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In eukaryotic cells, most intracellular proteins activated by a ligand/receptor 
interaction possess an enzymatic activity; examples include tyrosine 
kinase and phosphatases. Some of them create second messengers such as cyclic 
AMP and inositol trisphosphate (IP3), the latter controlling the release of 
intracellular calcium stores into the cytoplasm. Other activated proteins interact 
with adaptor proteins that facilitate signalling protein interactions and 
coordination of signalling complexes necessary to respond to a particular 
stimulus. Enzymes and adaptor proteins are both responsive to various second 
messenger molecules. Many adaptor proteins and enzymes activated as part of 
signal transduction possess specialized protein domains that bind to specific 
secondary messenger molecules. For example, calcium ions bind to the helix-
loop-helix structural domain (EF hand domains) of calmodulin, allowing it to bind 
and activate calmodulin-dependent kinase. Phosphatidylinositol 4,5-
bisphosphate (PIP3) and other phosphoinositides do the same thing to 
the Pleckstrin homology domains of proteins such as Protein Kinase B (PKB), also 
known as AKT.  
The G protein-coupled receptors (GPCRs) constitute the largest protein family 
of external receptors that sense molecules and activate intracellular signal 
transduction pathways and, ultimately, cellular responses. Others are Receptor 
tyrosine kinases (RTKs) which are transmembrane proteins with an 
intracellular kinase domain and an extracellular domain that binds ligands; 
examples include growth factor receptors such as the insulin receptor (Li and 
Hristova, 2006). Toll-like receptors (TLRs) which are involved in the innate 
immune response, take up adaptor molecules involved in signalling into the 
cytoplasm. Integrins and Ligand-gated ion channel are also involved in signalling. 
 
1.2.1.2 Intracellular receptors 
The main intracellular receptors are nuclear receptors and cytoplasmic 
receptors made up of soluble proteins localized within their respective areas. 
Nuclear receptors have the ability to directly bind to DNA and regulate the 
expression of adjacent genes, hence these receptors are classified as 
transcription factors (Olefsky, 2001). Nuclear receptors have two subclasses: 
Steroid hormone receptors found on the plasma membrane, in the cytosol and 
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also in the nucleus of target cells, and the retinoic acid receptor (RAR) a type 
of nuclear receptor which can also act as a transcription factor (Germain et al., 
2006). The cytoplasm is involved in the regulation of the movement of calcium 
ions in and out of the cell and this is considered to be a signalling activity for 
metabolic processes since calcium is one of the key secondary messengers. 
Certain intracellular receptors of the immune system are cytoplasmic receptors. 
This includes the recently identified NOD-like receptors (NLRs) that reside in the 
cytoplasm of some eukaryotic cells and interact with ligands using a leucine-rich 
repeat (LRR) motif similar to TLRs. Some of these molecules like NOD2 interact 
with Receptor-interacting serine/threonine-protein kinase 2  (RIP2 kinase) that 
activates NF-κB signalling, whereas others like NALP3 interact with inflammatory 
caspases and initiate processing of particular cytokines like interleukin-1β 
(Delbridge and O'Riordan, 2007). 
Many intracellular receptors bind secondary messengers and the cascade effect 
brings about changes in the cell such as gene regulation and metabolism. Some 
secondary messengers include calcium, lipophilic second messenger molecules 
(diacylglycerol and ceramide), Nitric oxide (NO) and redox signalling 
(superoxide, hydrogen peroxide, carbon monoxide, and hydrogen sulphide) 
(Forman, 2009). One of the major signalling pathways is the cAMP dependent 
pathway. 
1.2.2 G-Proteins, Adenylate cyclases and Protein Kinase A (PKA) 
in mammalian cells 
Cyclic adenosine 3′,5′-monophosphate (cAMP) is an evolutionary conserved and 
important second messenger that plays fundamental roles in cellular responses 
to many hormones and neurotransmitters. Cyclic AMP is both produced and 
regulated by Adenylyl cyclases through the mediation of G-protein-coupled 
receptors (GPCRs) and catabolised from cAMP to AMP by cAMP 
phosphodiesterases (PDEs) (Conti and Beavo, 2007). Protein Kinase A (PKA) is one 
of the most important targets of cAMP and further regulates cAMP through the 
existence of a feedback loop involving PKA, both in yeast (Nikawa et al., 1987) 
and in mammals (Jin et al., 1998).     
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GPCRs are important regulators of several cellular functions through the 
activation of intracellular signals in response to a wide variety of agonists or 
stimulants. Recent estimates put drugs that exert therapeutic influence to 
GPCRs to be between 30-40% (Garland, 2013).  G-proteins which are distinct are 
able to form heterodimer complexes through direct physical interaction resulting 
in an integrated physiological response. A recent review by Luttrell et al, 
discussed the regulatory role and complexity of GPCRs as a result of the ability 
of several G-proteins to couple with different G-protein families, that structural 
differences in ligands causes differential stimulations as well as the ability to 
signal through either G-protein and non G-protein effectors (Luttrell et al., 
2015). The most important regulatory function of G-proteins is the mediated 
production of cAMP through the stimulation of ACs which are also directly 
stimulated by G-proteins.  
Mammalian cells have two AC, transmembrane ACs (tmACs) regulated by GPCRs 
and Soluble ACs (sACs) regulated by bicarbonates and Calcium with structural 
similarity to tmACs but without transmembrane domains as well as discrete 
localization in different part of the cell (Schmid et al., 2014). Due to its location 
on the surface of the cell, the tmACs are considered the target where the 
majority of hormone sensitive cAMP stimulation occurs. ACs, together with other 
components of the cAMP signalling pathway, tend to be compartmentalized in 
lipid rafts. This compartmentalization helps to explain the nature of the discrete 
foci and tight spatial control of cAMP signalling and the resultant formation of 
microdomains. The formation of these large complexes and how they achieve 
this spatial regulation of cAMP is reviewed by (Dessauer, 2009). PKA is one of the 
key targets for cAMP produced from activation of ACs. 
Cyclic AMP-dependent PKA is ubiquitous in mammalian cells where it exists in 
two forms made up of the inactive tetrameric holoenzyme and the active 
dissociated catalytic subunit (C-subunit) (Das et al., 2007). It has been shown to 
be an important down regulator of cAMP accumulation through several 
mechanisms so as to prevent the overstimulation of the cAMP signalling pathway. 
This includes the inhibition of cAMP synthesis, stimulating its hydrolysis, 
enhancing its excretion or a combination of these processes (Vandamme et al., 
2012). Recently it is been shown that PKA is able to reset the mammalian cAMP 
signalling by forming an active site coupling in a PDE and PKA regulatory subunit 
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complex (Krishnamurthy et al., 2014). Several nuclear and cytosolic proteins act 
as substrate for PKA. One of the important means of regulation by PKA is through 
phosphorylation, such as phosphorylation of several metabolic enzymes, and 
transcriptional regulation by direct phosphorylation of transcriptional factors. 
PKA also regulates other signalling pathways such as the activation of MAPK, 
decreases the activities of Raf and Rho and modulates ion channel permeability 
as well as regulates the expression and activity of various ACs and PDEs (Sassone-
Corsi, 2012) (Figure1.5).  
 
Alternative and independent to PKA activation, cAMP are able to stimulate 
Exchange Proteins Activated by cAMP (EPACs). These are specific guanine 
nucleotide exchange factors (GEFs) for the Ras GTPase homologues, Rap1 and 
Rap2 (de Rooij et al., 2000). Mammals have two EPAC isoforms EPAC1 and EPAC2 
which varies both in distribution as well as structure with EPAC2 having an 
additional Cyclic Nucleotide Binding (CNB) domain. Several researchers have 
shown the importance of EPAC proteins in mediating and regulatory of several 
and important actions of cAMP in humans. A previous review by Borland and 
colleagues, revealed the myriad effect of stimulation of EPAC by cAMP resulting 
in promotion and inhibition of cell division, promotion of cell differentiation, 
hyperthrophy, inflammation among others in several human cells (Borland et al., 
2009). Recently, Parnell et al, discussed strategies being developed in the design 
of pharmacophores and their therapeutic potential (Parnell et al., 2015). Thus 
the selective modulations of EPACs offer additional sources of therapeutic 
targets in the general cAMP-PDE-PKA pharmacology.  
 
It should however be noted that although cAMP signalling has been detected in 
all organisms except plants, there are varied differences in the components that 
make up the pathway in all these organisms. The underlying commonality which 
is also the only absolutely conserved signalling molecule is cyclic adenosine 3′,5′-
monophosphate (cAMP). 
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Figure 1.5: Components of cAMP signalling pathway showing adenylate cyclases and G-
proteins in humans. Adapted from Sassone-Corsi P, 2012  
 
1.2.3 Cyclic Nucleotide Phosphodiesterases 
1.2.3.1 PDE family and diversity 
Cyclic nucleotide phosphodiesterases class 1 (PDE-1) are a family of related 
phosphohydrolases that selectively catalyse the hydrolysis of the 3’ cyclic 
phosphate bonds of adenosine and/or guanosine 3’,5’- cyclic monophosphate. 
Increasing chemical and molecular biology techniques have revealed and 
continue to reveal the large diversity and complexity of PDEs.  
 
PDEs have been grouped into three classes based on their different catalytic 
domains. Class I PDEs are found in all eukaryotes and they are the only forms of 
PDEs in higher eukaryotes (Beavo, 1995). Class I PDEs are the only enzymes 
which are capable of efficiently hydrolysing cyclic nucleotides. The genome of 
known kinetoplastids encodes four different class I PDEs (PDE-A to PDE-D) and 
does not contain members of the other PDE classes (Beavo, 1995) just as is the 
case in the human genome (Seebeck et al., 2011). At least one copy of each of 
the four PDE genes is present in the genome database of T. brucei, T. cruzi and 
L. major (Vij et al., 2014). Class II PDEs are found in certain prokaryotes (e.g. 
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Vibrio fischeri) or fungi (e.g. Saccharomyces, Candida) and in many lower 
eukaryotes (e.g. Dictyostelium discoideum) (Figure 1.6). 
 
 
Figure 1.6: Non-rooted tree of Class I protozoan and human PDEs. The catalytic domains of 
many protozoan PDEs, including T. brucei (in red), are as closely related to the human PDEs 
(in blue) as these are among themselves. Hs, Homo sapiens; Pf, Plasmodium falciparum; 
Ca, Candida albicans; Tp, Theileria parva; Gl, Giardia lamblia; Ch, Chilomastix hominis; Ec, 
Encephalitozoon cuniculi; Dd, Dictyostelium discoideum. Figure courtesy of Professor T. 
Seebeck, University of Bern, Switzerland. 
 
 
The PDE superfamily of enzymes is classified into 11 families (PDE1-PDE11) in 
mammals based on amino acid sequence, substrate specificity, regulatory 
properties, pharmacological properties and tissue distribution (Keravis and 
Lugnier, 2010). The 11 PDE families code for 21 genes (Conti and Beavo, 2007), 
although variations exist such that some families are coded for by one gene 
whilst others are a product of multiple genes. This extensive variations is further 
enhanced by multiple, differentially regulated promoters that  influence 
expression of the PDE mRNA transcripts (Omori and Kotera, 2007b), as well as by 
extensive alternative splicing of the mRNAs resulting in a vast array of protein 
products, estimated to be close to 100 different protein products of these genes. 
These are distinguished by having different regulatory features, catalytic 
characteristics, tissue distributions, subcellular localizations, targeting to 
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signalling complexes and sensitivities to PDE inhibitors (Bender and Beavo, 2006; 
Francis et al., 2011b). 
 
This complexity of the cyclic nucleotide PDE system has forced increasingly more 
sophisticated and complex approaches to be adopted to understand the roles of 
PDEs in regulation of cAMP and cGMP in the cell. It is now very clear that any 
single cell type can express several different PDEs and also that the nature and 
localization of these PDEs is likely to be a major regulator of the local 
concentration of cAMP or cGMP in the cell. PDEs are regulated not only at the 
genetic level but also by diverse biochemical mechanisms including 
phosphorylation/dephosphorylation (Ang and Antoni, 2002; Pozuelo Rubio et al., 
2005), allosteric binding of cGMP or cAMP, binding of Ca+2/calmodulin, and 
various protein-protein interactions (Bender and Beavo, 2006; Omori and Kotera, 
2007a). Additional concepts of PDE regulations are being proposed. These 
include the concept that one of the major roles for PDEs is to modulate the 
three-dimensional shape, the amplitude, and the temporal duration of “clouds” 
of cyclic nucleotide in the cell as well as the possibility that some PDEs act as 
scaffolding proteins or use allosteric changes induced by binding of cyclic 
nucleotides to alter protein-protein interactions (Bender and Beavo, 2006; Conti 
and Beavo, 2007).    
 
 
1.2.4 Therapeutic potential of PDEs 
Although the therapeutic potential of PDEs was realised quite early, the first PDE 
inhibitors lacked specificity and thus had a very narrow therapeutic index. This 
has changed with the identification and classification of the different types of 
PDEs (Conti and Beavo, 2007). One important general reason that PDEs have 
been pursued as therapeutic targets is related to the basic pharmacological 
principle that regulation or degradation of any ligand or second messenger can 
often make a more rapid and larger percentage change in concentration than 
comparable regulation of the rates of synthesis (Pierre et al., 2009; Potter, 
2011). This is true for either pharmacokinetic changes in drug levels or changes 
in amounts of an endogenous cellular regulatory molecule or metabolite. It has 
been recognized long ago that the complexity of the cAMP signalling pathway 
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and the several effectors involved implies that several of these effectors can be 
simultaneously affected in response to either cAMP or cGMP. This together would 
result in an integrated, fine-tuned and possibly multiple cellular signalling 
response (Maurice et al., 2014).  
 
Additionally, it is clear that an extraordinary large diversity of PDE family is 
expressed in mammalian tissues. This diversity is present in the unique 
architecture at the active site (Conti and Beavo, 2007; Francis et al., 2011c; 
Keravis and Lugnier, 2012). And although some of these properties challenge the 
development of drugs that target individual enzymes, nevertheless, many of the 
characteristics of PDEs are also viewed as unique opportunities to increase 
specificity and selectivity when designing novel compounds for certain 
therapeutic indications. Moreover, there is increasing evidence that many of 
these PDEs are tightly connected to different physiological functions in the body 
and by inference also to different pathological conditions. This provides the 
platform to develop isoform-selective inhibitors that can target specific 
functions and pathological conditions without a high likelihood of causing 
nonspecific side effects (Bender and Beavo, 2006; Francis et al., 2011c). It has 
also been shown that functional features of closely related PDEs can differ 
substantially and that there is differential expression of the various PDE families 
(Francis et al., 2011a). Even PDEs within the same families, with catalytic 
domain similarities >50%, have been shown to have extensively different 
selectivity for cAMP and cGMP (Omori and Kotera, 2007b). This has resulted in 
the discovery of several PDE inhibitors such as Sildenafil (used to treat erectile 
dysfunction) as well as several newly identified PDE inhibitors in a variety of 
diseases (Dorsey et al., 2010; Galie et al., 2010; Ghofrani et al., 2006; Jaski et 
al., 1985).  
 
Bender and Beavo discussed why PDEs are likely to be good drug targets, arguing 
that the concentrations of cAMP and cGMP (typically <1 – 10 µM) in most cells 
means that a competitive inhibitor would not need to compete with very high 
levels of endogenous substrate to be effective, unlike most protein kinase 
inhibitors that require a high enough affinity to displace millimolar 
concentrations of ATP (Bender and Beavo, 2006).  
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One of the reasons for this is the fact that the myriad forms of PDEs that serve 
as cellular targets of cyclic nucleotides (cN) and as major determinants of cyclic 
nucleotide action exceeds those of other targets, such as that of cN-dependent 
protein kinases, the cN-gated (CNG) channels and exchange-proteins activated 
by cAMP (EPACs). All PDEs contain a conserved catalytic site that interacts with 
cNs and hydrolyses them to respective 5’-nucleotides, with specificity for cAMP 
(4, 7, and 8), cGMP (5, 6, and 9) or both (1, 2, 3, 10, and 11) (Francis et al., 
2011a). Differences have been observed in selective inhibition in families with 
highly similar amino acid sequences (~42%) (Zhang et al., 2005) and even among 
catalytic sites of PDE isoforms in the same family with greater than ~75% 
sequence homology (Bender and Beavo, 2006). These data suggest that subtle 
differences in the topography and chemical characteristics of the active site can 
have profound effects on substrate preference, catalytic efficiency, and 
inhibitor potencies (Francis et al., 2011c). The structural subtleties that provide 
for these differences in such closely related enzymes are typically not fully 
understood but they could relate to differences in the catalytic site pocket, 
reflect the influence of interactions of the inhibitors with regions outside the 
catalytic pocket, or of interaction with protein binding partners and 
posttranslational modification (Burgin et al., 2010; Houslay et al., 2007). 
 
PDEs such as 2, 5, 10, and 11 contain cN-binding sites (Gross-Langenhoff et al., 
2006; Handa et al., 2008; Martinez et al., 2008; Zoraghi et al., 2004) that 
comprise of ~120 amino acids known as GAFs [an acronym derived from the 
proteins in which these domains were originally identified, i.e., cGMP-binding 
PDEs, Anabaena adenylyl cyclases, and Escherichia coli transcription factor FhlA 
(Aravind and Ponting, 1997)] within their respective regulatory domains. GAF 
domains are found in many different proteins in nearly all phyla, including 
histidine kinases, phosphotransferases, ATPases, cyclases, and PDEs. They are 
thought to function as regulatory elements that bind nucleotides or other small 
molecules. These GAFs are also structurally and evolutionary distinct from PDE 
catalytic sites cN-binding sites in the cN-dependent protein kinases, cN-
regulated channels, the bacterial catabolite-gene activator protein (CAP), and 
EPACs (Bos, 2006; Zoraghi et al., 2004). The regulatory nature of the GAF 
domains in binding both cAMP and cGMP in varied PDEs provides the basis for the 
functional activities of these PDEs as well as potential as targets for therapeutic 
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interventions. GAFs A and B are thought to be involved in dimerization of the 
PDE which in itself can regulate the functions of the PDEs. A specific example of 
the importance of GAF domains and cGMP allosteric interactions in the PDEs is 
illustrated by the H258D mutation in the GAF A domain of human PDE6B, which 
causes the autosomal dominant congenital stationary night blindness (Farber and 
Danciger, 1997).  
 
Thus PDEs provides the numbers, the structures, the functions, the diversity and 
the locations that make them great pharmacological targets. These advantages 
have been and are still being exploited by many different companies that are 
developing small molecules with substantially different affinities for most of the 
different PDE families. 
 
1.2.5 Cyclic AMP signalling of kinetoplastids 
The order of the kinetoplastida in the group of the Discicristates covers a vast 
empire of unicellular eukaryotes (Baldauf, 2003), many of whom have adopted a 
parasitic lifestyle. They are characterized by an elongated cell body of 10–20 µM 
in length that is propelled by a single flagellum. Besides the cell nucleus, the 
kinetoplastids contain the name-giving kinetoplast, a specialized compartment 
of the mitochondrion that contains a mass of concatenated DNA circles, 
amounting to up to 10 percent of the total cellular DNA mass. Kinetoplastids 
causes several diseases in men and animals, the majority of which are fatal if 
untreated, and is compounded by lack of vaccines and poor therapeutic options - 
almost all of which are under threat due to the development of resistance. Thus 
the need to understand cell signalling, which is one of the greatest sources of 
drug targets in human pharmacology, and the opportunities it offers in 
therapeutic interventions. 
 
The presence of cAMP in trypanosomes and its variation during the course of 
infection were recognized early on (Strickler and Patton, 1975). The completion 
of various kinetoplastid genome projects recently has, however, demonstrated 
that cAMP signalling in the kinetoplastids is starkly different from the pathways 
extensively studied in mammals. Some important differences include the fact 
that kinetoplastid genomes do not code for G-protein-coupled receptors, or for 
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heterotrimeric G proteins or protein kinase G; the adenylyl cyclases are 
structurally different from their mammalian counterparts although the basic 
catalytic mechanism seems to be conserved between them and may have 
assumed the role of receptors; few genes for cAMP effectors have been 
identified in these organisms; and the stringent need for regulation of cAMP in 
the small kinetoplastid cell to prevent flooding of the cell (Seebeck et al., 2001; 
Tagoe et al., 2015). The majority of what we know about cAMP signalling in 
kinetoplastids is derived from studies in trypanosomes. 
1.2.5.1 Adenylyl cyclases of kinetoplastids 
cAMP in most eukaryotes including kinetoplastids is produced by stimulated or 
constitutively active Adenylyl Cyclases (ACs), whilst cyclic nucleotide PDEs 
degrade the phosphodiester bond in cAMP thus abrogating signal transduction 
(Dorsey et al., 2010).  
 
A putative kinetoplastid AC gene was first identified in T. brucei when the gene 
expression site of an active VSG was sequenced, revealing that there were 
multiple genes in the site that were co-expressed with VSG. These genes were 
termed expression site-associated genes (ESAGs), and one of them, ESAG4, 
showed homology with an AC from yeast (Pays et al., 1989). These paved the 
way for restriction mapping of the clones into two categories, with the largest 
from each further characterized and named GRESAG4.1 and GRESAG4.2 (genes 
related to ESAG4) (Gould and de Koning, 2011). Related genes were also found in 
T. gambiense, Trypanosoma congolense, Trypanosoma mega and Trypanosoma 
vivax. Through yeast complementation studies the Trypanosoma equiperdum AC 
genes were proven to actually code for AC enzymes as ESAG and GRESAG4.1 
complement AC-deficient yeast mutants in S. cerevisiae, (Paindavoine et al., 
1992; Ross et al., 1991). Further studies were undertaken on the differential 
expression of ESAG and GRESAG in bloodstream and stumpy forms (Rolin et al., 
1996). Trypanosomal ACs are either transiently expressed in the BSFs like the 
ESAGs or are expressed constitutively in all the life form stages like the GRESAGs 
(Bieger and Essen, 2001). Since then similar multigene families with high 
homology to ESAG4 and GRESAG4.1 have also been identified in Leishmania 
donovani and T. cruzi that share the same predicted protein architecture 
(Sanchez et al., 1995). T. brucei encodes for approximately 65 GRESAG4 
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proteins, which are localized along the flagellum in both BSFs and procyclic (fly 
midgut-stage) cells. Their similarity and tandem arrangements results in cross-
reactivity to some antibodies raised against ESAG4 (Oberholzer et al., 2011; 
Paindavoine et al., 1992). Whereas knocking out ESAG4 from the expression site 
does not affect parasite proliferation, a knockdown of all the AC family that 
includes ESAG4 and two ESAG4-like GRESAG4 (ESAG4L) genes led to a total 
decrease in AC activity resulting in a phenotype that is defective in cytokinesis 
(Salmon et al., 2012a). 
 
The genomes of all kinetoplastids contain multiple copies of genes for adenylyl 
cyclases. Interestingly, the genomes of African trypanosomes (T. brucei, T. 
congolense, and T. vivax; each about 35 Mbp) contain more than 50 different 
cyclase genes, while the similarly sized genomes of T. cruzi and the Leishmanias 
(L. major, L. infantum, and L. braziliensis) only contain 5 or 6 such genes. For 
instance the T. brucei genome encodes for more than 80 ACs, many of which are 
detected on the cell surface (Salmon et al., 2012a). The reason for the extensive 
numbers of ACs in trypanosomes is attributed to the size of the trypanosome and 
the need to tightly regulate cAMP levels. An additional reason for a greater 
number of ACs in T. brucei compared with other Trypanosoma and Leishmania 
species may be due to the need to evade the host immune system by 
continuously switching VSGs leading to a duplication of ESAGs. In fact it has been 
shown that ACs influence host-parasite interactions through the modulation of 
Tumour Necrosis Factor-alpha (TNF-α) and that AC activity of lysed 
trypanosomes favours early host colonization by parasites (Salmon et al., 2012b). 
This suggests that diversity in ACs provides an adaptive advantage to the 
extracellular T. brucei enabling host immune modulation and thus survival. All 
kinetoplastid cyclases exhibit a large, extracellular N-terminal domain, followed 
by a single transmembrane helix and a highly conserved class 3 catalytic domain 
(Naula and Seebeck, 2000; Schaap, 2005) which is different from mammalian ACs 
that contain several transmembrane domains and are regulated by G-protein-
coupled receptors. Structurally T. brucei ACs differ from mammalian Class I ACs 
as a result of the insertion of a 36-amino acid region into the catalytic domain, 
forming two extra helices and termed the D-subdomain. In Class I ACs, this 
region, without the kinetoplastid insert, is involved in the interaction with G-
protein subunits. The fact that trypanosomal ACs have such a variation at that 
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particular point in the structure suggests that the D-subdomain may play a 
regulatory role and provides a structural reason for interaction with 
kinetoplastid ACs. This is due to the fact that unlike in mammalian cells, 
trypanosomes have no GPCRs nor heterotrimeric G-proteins in their genome 
(Berriman et al., 2005). Thus the N-terminal domains of trypanosomal ACs may 
function as receptors akin to the mammalian receptor-type guanylyl cyclases. 
Although the catalytic domain is structurally very similar to those of mammalian 
adenylyl cyclases, it is not activated by forskolin, and may form homodimers 
(Bieger and Essen, 2001; Garbers et al., 2006; Gould and de Koning, 2011; Naula 
et al., 2001). The structural differences and the cellular localization of the ACs 
of kinetoplastids are also consistent with them acting as receptors. The result is 
the strong speculation of the possibility of the N-terminal extracellular domain 
of ACs acting as a receptor akin to GPCRs for signalling in the kinetoplastid 
(Laxman and Beavo, 2007; Seebeck et al., 2004). ESAG4 was shown to be present 
on the cell surface along the flagellum (Paindavoine et al., 1992) and the 
localization of ACs in BSFs was apparently identical to that in procyclics. 
Similarly, in T. cruzi epimastigotes, the calcium-stimulatable AC was found to be 
associated with the flagellum (D'Angelo et al., 2002). An Escherichia coli L-
leucine-binding protein (LBP) and a similar LBP in Pseudomonas aeruginosa have 
been shown to stimulate trypanosomal ACs (Emes and Yang, 2008; O'Hara et al., 
2000). Additionally, some extracts from T. cruzi and T. brucei insect vectors 
have been shown to activate ACs whilst a low-molecular-weight molecule, 
Stumpy Induction Factor (SIF), probably secreted by the trypanosome itself, was 
inferred to trigger the differentiation of long-slender bloodstream T. brucei to 
the non-replicating stumpy form via the cAMP signalling cascade (Garcia et al., 
1995; van den Abbeele et al., 1995; Vassella et al., 1997). 
 
Recently, ACs have been implicated in the conversion of epimastigotes of T. 
cruzi in the insect midgut and later hindgut into human infectious non-
proliferative metacyclic trypomastigotes, a process known as metacyclogenesis 
akin to cellular differentiation of BSF T. brucei to procyclic forms (Paindavoine 
et al., 1992). Here, both AC expression and intracellular cAMP levels in T. cruzi 
increase significantly in a two-step process from point of stimulation (nutrient 
deprivation) through a 6-48 h period (Hamedi et al., 2015). This may suggests 
that variation of intracellular cAMP in response to nutritional stress potentially 
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regulates differential gene expression resulting in cellular and life cycle changes 
in the parasite. 
 
Proteomic analysis of bloodstream T. brucei trypanosomes revealed receptor and 
transport-like proteins that likely play important roles in signalling as well as 
acting as potential effectors (Oberholzer et al., 2011). Recently, several 
receptor-type flagellar ACs have been shown to be specifically upregulated, are 
procyclic stage specific, glycosylated, surface–exposed and possess catalytic 
activity. Additionally, they are either distributed along the flagellum or localized 
to the flagellum tip (Saada et al., 2014). These observations suggest that ACs 
have specific subdomain localization and thus possibly a microdomain flagellar 
cyclic AMP signalling in T. brucei. These possibilities were further strengthened 
by the findings that one of these insect stage specific cyclases, AC6 (Adenylate 
Cyclase 6), is responsible for social motility and mutation and that knocking it 
down results in a hypersocial phenotype (Lopez et al., 2015). All these together 
coupled with the fact that cAMP levels are significantly increased in vitro during 
the differentiation of BSFs to procyclic forms suggests a probable role of cAMP 
involvement in parasite differentiation through ACs. 
 
1.2.5.2 Cyclic nucleotide-specific phosphodiesterases of kinetoplastids 
The kinetoplastid genomes all code for the same set of cyclic nucleotide-specific 
phosphodiesterases enzymes of the class 1 type of PDEs (Figure 1.7) with 
catalytic domains similar to those of the human PDEs (Beavo, 1995; Kunz et al., 
2006). 
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Figure 1.7: The conserved catalytic domain is the main functional domain of the PDEs and 
binds to cAMP. The GAF-A domains of PDEB1 and B2 binds cAMP and cGMP and regulate 
the function of the catalytic domain (Laxman et al., 2005). FYVE finger has been shown to 
bind two Zn2+ ions. Coiled-coil domains are important in stabilizing protein structure and 
thus for protein function. Phosphorylation of serine residue of PDEB1 has been observed in 
T. brucei phosphoproteome (Nett et al., 2009) whilst a probably functionally conserved PKA 
phosphorylation site is predicted in PDEB1/B2 (Shakur et al., 2011). 
 
1.2.5.2.1 PDEA 
PDEA is a high-Km (>200 µM), cAMP-specific PDE of about 620 amino acids. The 
polypeptide contains no discernible structural elements other than the PDE 
catalytic domain, which is located in the C-terminal part of the polypeptide. 
PDEA is a single copy gene (Kunz et al., 2006). It is a cAMP-specific PDE as it is 
neither inhibited nor activated by cGMP. In T. brucei, the enzyme is con-
stitutively expressed. Genetic deletion experiments, both in cell culture and in 
vivo, have demonstrated that it is not essential. Homologues of T. brucei PDEA 
(TbrPDEA) have been identified with both similar sequence and experimentally 
functional characteristics in L. major and T. cruzi (Alonso et al., 2007; 
Bhattacharya et al., 2009; Gong et al., 2001).  
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1.2.5.2.2 PDEB 
 
The two PDEB isoforms B1 and B2 are low-Km, cAMP-specific PDEs that are very 
similar to PDEA in their catalytic domain but differ in their N-terminal parts, 
which contain two GAF domains. The two closely related genes are tandemly 
arranged. The open reading frames predict proteins of 930 amino acids in length 
which contain the canonical Class 1 PDE signature motif in the catalytic region. 
The first and the second gene of the cluster are designated as B1 and B2, 
respectively. Characterization of these enzyme in T. brucei (Rascon et al., 
2002), T. cruzi (Diaz-Benjumea et al., 2006), and L. major (Johner et al., 2006), 
revealed a cAMP-specific binding with Km values in the 1 - 5 µM range. The GAF 
domains of TbrPDEB1 and TbrPDEB2 (Laxman et al., 2005) bind cAMP with high 
affinity. In TbrPDEB2, binding of cAMP to the GAF-A domain decreases the Km of 
the holoenzyme for cAMP as a substrate, suggesting an allosteric regulatory role 
of cAMP. The intracellular localization of TbrPDEB1 is exclusively along the 
paraflagellar rod complex of the flagellum, with which it remains tightly 
associated upon cell lysis. TbrPDEB2 is distributed between the paraflagellar rod 
structure and the cytoplasm (Oberholzer et al., 2007). In T. cruzi, the analysis of 
TcrPDEB2 has provided very similar results (D'Angelo et al., 2004). Early 
attempts to delete the PDEB genes in T. brucei showed no phenotype in 
procyclics (Zoraghi and Seebeck, 2002). However, later experiments using 
inducible RNAi confirmed that ablation of both TbrPDEB1 and TbrPDEB2 in either 
BSFs or procyclics led to a dramatic reduction in mRNA of both genes and was 
completely lethal for the BSF parasites, both in culture and in the mouse model. 
The resulting BSF phenotype is multinuclear, multikinetoplastic and 
multiflagellated with normal proliferation being completely disrupted leading to 
cell death approximately 50 h after induction (Oberholzer et al., 2007). There is 
about a 100-fold increase in intracellular cAMP in BSFs compared with 10-30-fold 
increase in procyclics as a result of the knockdown of both TbrPDEB1 and 
TbrPDEB2 and this correlates strongly with the observed phenotypes in BSFs and 
procyclics as well as experimental evidence of higher sensitivity of BSFs to 
membrane-permeable cAMP analogues (Oberholzer et al., 2007; Zoraghi and 
Seebeck, 2002). These findings show that kinetoplastid PDEBs represent 
interesting drug targets. The crystal structure of the catalytic domain of 
LmjPDEB1 has been solved, confirming the structural similarity of the kineto-
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plastid PDEs with their human counterparts (Wang et al., 2007), facilitating 
inhibitor design. More recently, a tetrahydrophthalazinone compound A (CpdA) 
has been pharmacologically validated in T. brucei and was found to be a very 
potent PDE inhibitor (de Koning et al., 2012). This was discovered from more 
than 400,000 compounds screened by scintillation proximity assay (SPA), which 
determines [3H]-cAMP hydrolyzing PDE activity. CpdA was identified to be the 
most potent inhibitor of TbrPDEB1 (IC50, ~10 nM) with similar activity on 
TbrPDEB2 with the resultant suppression of trypanosome proliferation. It has 
previously been shown to be a potent inhibitor of human PDE4 (Van der Mey et 
al., 2001a; Van der Mey et al., 2001b). Validation of the pharmacological 
importance of TbPDEB1 was further confirmed when homology modelling and 
docking studies was used to guide fragments of Catechol Pyrazolinones into the 
parasite pocket (P-pocket) of TbPDEB1 resulting in a low nanomolar inhibition 
(Orrling et al., 2012). The presence of the P-pocket is very important since it 
allows for the development of kinetoplastid specific PDE inhibitors with minimal 
or no cross reactivity with mammalian PDEs. 
1.2.5.2.3 PDEC 
 
PDEC is an intermediate-Km, dual-specificity PDE of 900–1000 amino acids. The 
PDE catalytic region is located in the middle of the polypeptide chain whilst the 
N-terminal contains a FYVE variant domain followed by two coiled-coil domains 
(Hayakawa et al., 2007) which have been found not to be essential for catalytic 
activity. However, this coiled region may serve to form homodimers of the 
enzyme (Kunz et al., 2005), which may facilitate the interaction of the FYVE 
domain with the target membranes. It has been shown that TcrPDEC hydrolyses 
cAMP with a Km value in the 20 - 30 µM ranges, and it can complement PDE-
deficient yeast strains (Alonso et al., 2006). It has been reported that TcrPDEC 
also hydrolyses cGMP with a Km of about 80 µM. The enzyme is sensitive to 
several PDE inhibitors (trequinsin, etazolate and dipyridamole) in the low micro-
molar range (Kunz et al., 2005). PDEC has also been identified in the genomes of 
T. brucei and L. major with the possibility of the L. major version hydrolysing 
cGMP (Johner et al., 2006). 
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1.2.5.2.4 PDED 
 
This is a predicted PDE of about 700 amino acids containing the PDE catalytic 
domain in the C-terminal part of the polypeptide. No other functional domains 
are predicted (Kunz et al., 2006). PDED has not been characterised yet in any of 
the kinetoplastid species, and it is not yet known whether it might be essential 
in any of the life cycle forms. 
 
1.2.6 Protein Kinase A 
The cAMP-dependent protein kinase family or protein kinase A (PKA) is a 
collection of serine/threonine kinases whose activity is dependent on levels of 
cAMP in the cell and is one of the most studied and best known members of the 
protein kinase (PK) family (Huang, 2011). 
 
The kinetoplastid genomes contain reasonably well-conserved genes for catalytic 
and regulatory domains of protein kinase A (Huang et al., 2006). In T. brucei, a 
499-amino acid protein with high homology to eukaryotic regulatory subunits of 
PKA was identified and named T. brucei Regulatory Subunit (TbRSU). This led to 
the first actual measurement of the cyclic nucleotide-dependent kinase activity 
in T. brucei. The protein has the usual two cyclic nucleotide-binding domains, 
which are predicted to retain all the conserved residues necessary for function, 
as well as a pseudo-inhibitor site, which interacts with the catalytic subunit 
(Shalaby et al., 2001). However, further research on the presumed catalytic 
subunit co-immunoprecipitated with TbRSU showed that although it displays 
phosphorylation activity and is also inhibited by the peptide inhibitor (PKI) both 
characteristics of PKA, it is not stimulated by cAMP but instead stimulated by 
cGMP (Shalaby et al., 2001) proving that T. brucei expresses a PKG activity – 
albeit with the caveat that there are few indications that trypanosomes produce 
or contain cGMP (Tagoe et al., 2015).  
 
The finding that cAMP signalling mediates T. cruzi differentiation (Flawia et al., 
1997), and the fact that PKAs are the major cAMP-dependent effectors in most 
eukaryotic cells, led to the need to identify PKA activity in T. cruzi. A cAMP-
stimulatable protein kinase fraction with a half-maximal effect at approximately 
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1 nM cAMP and activity not affected by cGMP, and phosphate-acceptor as 
expected for a cAMP-dependent protein kinase, was identified (Ulloa et al., 
1988). The subunits (catalytic and regulatory) were purified and it was predicted 
that they form a tetrameric conformation similar to mammalian PKA (Ochatt et 
al., 1993). Expression of both the T. cruzi PKA catalytic unit (TcPKAc) and T. 
cruzi PKA regulatory unit (TcPKAr) appeared to be coordinated, indicating that 
the two subunits may be associated in vivo, as also shown by 
immunoprecipitation of the holoenzyme (Huang, 2011; Huang et al., 2002). 
TcPKAc activity was inhibited by the PKA-specific inhibitor PKI and both TcPKAc 
and TcPKAr localized to the plasma membrane and the flagellar region (Bao et 
al., 2010; Huang et al., 2006; Huang et al., 2002). TcPKAr was found to interact 
with several P-type ATPases, which suggests that these P-type ATPases may play 
a role in anchoring PKA to the plasma membrane (Bao et al., 2009) as reported 
for some mammalian P-type ATPases (Xie and Cai, 2003). 
 
The functional importance of the TcPKAc in T. cruzi was examined by 
introducing into epimastigotes a gene encoding a PKI containing a specific PKA 
pseudo-substrate, R-R-N-A. Expression of PKI has a lethal effect in this parasite. 
Similarly, a pharmacological inhibitor, H89, killed epimastigotes at a 
concentration of 10 µM proving that PKA enzymatic activity is essential for the 
survival of the parasites (Bao et al., 2008). A yeast-two hybrid screen for the 
substrates of PKA identified 38 candidate proteins that interact with TcPKAc 
including 18 hypothetical proteins with unknown functions. Eight of the 
identified genes have potential regulatory functions with respect to 
environmental adaptation and differentiation, and are presumably important in 
regulating T. cruzi growth, adaptation and differentiation. These included a type 
III PI3 kinase (Vps34), a putative PI3 kinase, a MAPK, a cAMP-specific 
phosphodiesterase (PDEC2), a hexokinase, a putative ATPase, a DNA excision 
repair protein and an aquaporin. PKA phosphorylated the recombinant proteins 
of these genes (Bao et al., 2008). Additional findings also suggest that TcPKAc 
may play a role in invading cells by mediating protein trafficking that enables 
parasite adhesion to cells, enabling the invasion thereof, as trans-sialidases were 
found to be substrates of TcPKA (Bao et al., 2010). As discussed by Huang 
(2011), there seems to be co-incidence of cAMP production, PKA activity and 
trans-sialidase expression enabling the differentiation from late stage 
Daniel N.A Tagoe  Chapter 1, 55 
epimastigotes to invasive trypomastigotes – all consistent with a role for cAMP 
signalling in differentiation and invasion by T. cruzi. 
 
A Leishmania catalytic subunit of PKA (LdPKA) was first isolated and 
characterized from L. donovani promastigotes by column chromatography and 
found to be similarly inhibited by PKI activity as in T. brucei and T. cruzi, 
indicating that the kinetoplastid enzymes are likely to be structurally related 
and topologically similar to mammalian PKA (Banerjee and Sarkar, 1992). Indeed 
researchers went further to clone an L. major gene encoding a protein with high 
homology to other PKA genes (LMPKA-C1). This protein was shown to have 
important features involved in ATP and phosphatase-acceptor binding. However, 
some structural and functional differences were observed with other PKA-C 
subunits, such as a unique 8-residue C-terminal extension (Siman-Tov et al., 
1996; Siman-Tov et al., 2002). Expression of LmPKA-C1 was developmentally 
regulated with expression barely detectable in intracellular amastigotes, in 
contrast to a high expression level in insect-stage promastigotes (Duncan et al., 
2001; Siman-Tov et al., 1996). The role of cyclic nucleotide-regulated protein 
kinase activities in promastigote proliferation and infectivity was confirmed in 
Leishmania amazonensis, with PKA activity particularly high in metacyclic 
promastigotes, which are primed for macrophage invasion (Genestra et al., 
2004). PKA inhibitors PKI and H89 affected both replication and macrophage 
infection. Smaller effects were observed with the PDE inhibitors dipyridamole, 
rollipram and isobutyl-methyl-xanthine (IBMX) but to date there is no clear 
confirmation that these effects were mediated by one of the leishmanial PDEs, 
or which one. These effects were temporary and did not affect intra-
macrophage growth (Malki-Feldman and Jaffe, 2009).  
 
1.3 Cyclic AMP and cell cycle regulation in kinetoplastids 
The need for parasite survival implicates the need for developmental responses 
to adapt to different environments encountered within the mammalian host and 
the arthropod vector. This is especially so during preparation for transmission, 
where specialized developmental forms are often generated to promote survival 
in anticipation of a host change (Baker, 2010; MacGregor et al., 2012). The 
result is a dynamic balance of transmissible and proliferative stages within a 
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host ensuring that the population can maximize its longevity within the host but 
also optimize its capacity for spread to new hosts (Mony et al., 2014). The 
morphotypes that characterize a certain genus are cell shape, dimensions and 
the positions of the complex kinetoplast-flagellar pocket relative to the nucleus 
(Svobodova et al., 2007). The complex morphological and biochemical changes 
during cell differentiation in trypanosomatids are most importantly 
environmentally driven through different ligands and or stimulatory molecules 
present in these environments. Although some differences in ligands of 
kinetoplastids and mammals have been shown and some stimulatory molecules 
are yet to be identified, the few receptors and signalling molecules that have 
been described have much structural and functional similarity to that of 
mammals. These signalling molecules display a wide range of activities including 
induction or inhibition of target cell survival, proliferation and differentiation 
which are similar to activities that occurs in mammals (Parsons and Ruben, 
2000). 
The report of AC activity in Trypanosoma gambiense in 1974 (Walter et al., 
1974) implicated the possible role of cAMP signalling in the cell biology and 
virulence of kinetoplastids triggering the study of cAMP levels in the different 
life cycle stages of Trypanosoma lewisi (Strickler and Patton, 1975), T. brucei 
(Mancini and Patton, 1981), and L. donovani (Walter et al., 1978). Trypanosomes 
living in the bloodstream proliferate as morphologically ‘slender’ forms that 
evade host immunity by antigenic variation, generating characteristic waves of 
infection. As each wave of parasitaemia ascends, slender forms stop 
proliferating and undergo morphological and molecular transformation to stumpy 
forms, the parasite’s transmission stage (Vickerman, 1985). Earlier cAMP 
measurements showed increased cAMP levels in long slender bloodstream forms 
(BSF) during the cyclical wave of proliferation of this forms, and relatively low 
cellular cAMP concentrations when the abundance of stumpy forms increases 
(Mancini and Patton, 1981). This increase in cAMP in long slender blood stream 
forms however, may be metabolically induced due to their proliferative nature 
in comparison to stumpy form parasites. However, differentiation of longer 
slender forms to short stumpy forms have been shown to be density dependent 
(Vassella et al., 1997) with resemblance to quorum-sensing systems found in 
microbial communities (Waters and Bassler, 2005). The response to this density 
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dependent differentiation is triggered by a yet to be identified low molecular 
weight molecule called “stumpy induction factor” (SIF). Although the exact 
nature of SIF is yet to be identified, it has been shown to have some signalling 
characteristics that may implicate cAMP. Additionally, trypanosomes incubated 
with a conditioned medium containing SIF displayed a 2-3-fold increase in the 
intracellular concentration of cAMP compared with cells grown in a non-
conditioned medium (Breidbach et al., 2002; Vassella et al., 1997). For example, 
cAMP analogue 8-(4-chlorophenylthio)-cAMP was demonstrated to have the same 
differentiation-inducing effect as SIF. Differentiation of BSF to procyclic forms 
correlates with the shedding of VSG (Barry and McCulloch, 2001). Although much 
similarities have been observed in VSG shedding and AC stimulation, monitoring 
of AC activity and VSG shedding after triggering differentiation to procyclic 
forms showed that AC stimulation was not responsible for the release of VSG 
(Rolin et al., 1993) and that cAMP was not required for this differentiation to 
occur (Mancini and Patton, 1981; Strickler and Patton, 1975). An analogue of 
cAMP, 8-pCPT-cAMP  was able to induce a slender-to-stumpy differentiation in 
the pleomorphic bloodstream form (Vassella et al., 1997) although this did not 
correlated with the subsequent release of VSG either. High concentrations of 
extracellular cAMP, 5’-AMP or adenosine did not significantly affect the 
proliferation of T. brucei, suggesting that the antiproliferative effect caused by 
the nucleotide analogues was mediated by an intracellular “receptor”. And 
although 8-pCPT-cAMP did induce differentiation into stumpy-like non-
proliferative forms, a hydrolysis-resistant analogue did not, whereas the 
hydrolysis products of 8-pCPT-cAMP (i.e. the equivalent AMP and adenosine 
analogues) had a more potent effect than 8-pCPT-cAMP itself. The clear 
conclusions of this study were that (1) cAMP is not the primary effector of the 
differentiation signal and (2) the hydrolysis products of 8-pCPT-cAMP trigger a 
differentiation-like transformation in T. brucei long-slender bloodstream forms 
(Laxman et al., 2006). Additionally, 8-Br-cGMP but not 8-Br-cAMP was found to 
significantly increase infection in the midgut of Glossina m. morsitans tsetse 
flies by T. brucei (MacLeod et al., 2008). It is however not yet established 
whether the effect of cGMP is on the trypanosome or the tsetse flies. Recently, 
a genome-wide Ion Torrent based RNAi target sequencing was used to identify 
signalling components driving stumpy formation by exposing and selecting 
proliferative monomorphic cell lines unresponsive to 8-(4-chlorophenylthio)-
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cAMP (pCPT-cAMP) or 8-pCPT-2′-O-methyl-5′-AMP driven stumpy formation. This 
led to the identification of cohorts of genes implicated in each step of the 
signalling pathway, from purine metabolism, through signal transducers (kinases, 
phosphatases) to gene expression regulators a few of which may be involved in 
cAMP/AMP-analogue processing (Mony et al., 2014). Identified genes at each 
step of the signalling pathway were independently validated in cells naturally 
capable of stumpy formation, confirming their role in density sensing in vivo. 
The putative RNA-binding protein, RBP7, was required for normal quorum 
sensing and promoted cell-cycle arrest and transmission competence when 
overexpressed. This study reveals that quorum sensing signalling in trypanosomes 
shares similarities to fundamental quiescence pathways in eukaryotic cells, its 
components providing targets for quorum-sensing interference-based 
therapeutics (Mony et al., 2014).  
 
Whilst the role of cAMP in cellular differentiation is not conclusive, the role and 
importance of cAMP in flagellar motility and signalling is increasingly being 
dissected with interesting findings. For example it is commonly believed that the 
flagellum, as an important host-parasite interface, has many essential sensory 
functions (Rotureau et al., 2009; Tetley and Vickerman, 1985). An example 
occurs in C. reinhardtii, where triggering of zygote formation is initiated by 
cAMP signalling response as a result of flagellum adhesion in gametes (Pan and 
Snell, 2000). Recently, it has been shown that cAMP regulates social motility in 
T. brucei either by increasing  cAMP through the inhibiting of TbPDEB1 or using 
CpdA (Oberholzer et al., 2015). This is similar to social motility observation in 
Dictyostelium discoideum where cAMP signalling is critical for surface motility 
(Firtel and Meili, 2000).    
 
Several mammalian cells and tissue types (erythrocytes, fibroblasts, 
hepatocytes, cardiomyocytes, adrenocortical cells etc.) are known to extrude 
cAMP which is unidirectional and could be inhibited by agents such as metabolic 
inhibitors (oligomycin and cyanide), inhibitors of membrane transport 
(probenecid and verapamil) and other compounds (papaverine and 
prostaglandins) (Sager and Ravna, 2009). When stimulated by ACs, the time-
course for intracellular level cAMP shows a rapid rise to peak levels in a 
relatively short period of time whilst extracellular levels increased linearly for a 
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much longer time before plateauing which might be due to the enormously large 
volume of the extracellular medium verses the cell volume. There are 
considerable differences in the ability of cell types to extrude and it is believed 
that export and extrusion of cAMP plays a minor role in the control of 
intracellular cAMP levels in some cells (Ahlstrom and Lamberg-Allardt, 1999; 
Hamet et al., 1989; Sager and Ravna, 2009). Cellular unidirectional energy-
dependent cGMP efflux has also been observed in cells (pancreatic, liver glioma, 
etc.) and could be inhibited with probenecid. Stimulation of guanylate cyclase 
and inhibition of cyclic nucleotide phosphodiesterase in human platelet cells 
results in a 5-fold increase in intracellular cGMP levels but an almost 20-fold 
increase in extracellular cGMP levels (Hamet et al., 1989; Radziszewski et al., 
1995; Sager and Ravna, 2009).  
  
The above statements suggests that either cAMP, maybe cGMP or SIF alone, or a 
combination thereof, tends to drive differentiation of long slender bloodstream 
forms into stumpy forms through a quorum sensing mechanism where cells that 
have started differentiating releases these factors that drive other cells in their 
environment to also differentiate. 
1.4 Drug discovery for Neglected Tropical Diseases 
(NTDs)  
Current drugs used in kinetoplastid treatments are old, toxic, and extremely 
difficult to apply as well as facing a serious threat of redundancy as a result of 
increasing parasitic resistance. However, about 73 million people are estimated 
to be at risk of infections caused by HAT, leishmaniasis and Chagas’ disease 
globally, whilst the disability-adjusted life-years (DALYs) lost due to these 
diseases are estimated to be 5.6 million (WHO, 2013). A drive from the WHO 
with partner support has led to an increased interest and commitment to 
develop new drugs for these diseases, leading to several new therapies becoming 
available whilst other compounds are in clinical trials (Chatelain and Ioset, 
2011). This drive needs to be sustained to overcome problems associated with 
the high attrition rate in drug development and to maintain a sustained effort to 
achieve landmark goals of eliminating HAT in Africa and visceral leishmaniasis 
(VL) in India, as well as to bring Chagas disease and the many forms of 
Daniel N.A Tagoe  Chapter 1, 60 
leishmaniasis under control by 2020 (Barrett and Croft, 2012). To achieve that, 
strategies must be developed to make drug discovery easier and cheaper and 
target purposed for this NTDs considering that pharmaceutical companies will 
not even recoup expenditure to consider making profits in discovery of drugs for 
NTDs. 
 
1.4.1 Potential of PDE inhibitors in kinetoplastids 
The discovery of PDEs and cAMP activity in the kinetoplastids led to the logical 
question as to whether these PDEs can be targeted with inhibitors to bring about 
a therapeutic outcome. This question was legitimized when RNA interference 
(RNAi) against TbrPDEB1 and TbrPDEB2 found them to be essential for parasite 
survival both in vivo and in vitro.  
Based on these findings, a library of compounds was screened at Altana Pharma 
and Nycomed for inhibition of TbrPDEB1. This revealed a few compounds with 
IC50 values in the nanomolar range. The lead compound BYK54826, later 
renamed CpdA, displayed a trypanocidal activity at EC50 80 ± 10 nM as well as 
increases intracellular cAMP levels in cells within minutes (Shakur et al., 2011). 
1 µM of CpdA raised cAMP levels by 50-fold (de Koning et al., 2012), similar to 
levels seen when RNAi is induced in TbrPDEB1 and B2 (Zoraghi and Seebeck, 
2002). Although CpdA does not have an immediate effect on the viability of the 
cells except at very high concentrations (>50 µM), it rapidly halts cell division 
and growth, indicating that PDE inhibition leads to defects in cytokinesis during 
cell division resulting in multinucleated cells that were not ultimately viable 
(Shakur et al., 2011).  
 
CpdA, a tetrahydrophthalazinone  (Figure 1.8) has been pharmacologically 
validated in T. brucei and confirmed to be a very potent PDE inhibitor (de 
Koning et al., 2012). It is effective against the trypanosome because it displays 
similar activity against TbrPDEB1 and TbrPDEB2, with the resultant suppression 
of trypanosome proliferation. Its trypanocidal activity is similar to that of 
suramin and diminazene, and ≥10-fold better than nifurtimox (de Koning et al., 
2012). It also showed similar potencies against wild-type and clinical and 
veterinary resistant cell lines. At 1 µM, CpdA causes a several fold (44) increase 
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in intracellular cAMP after 3 h incubation in contrast to low-potency PDE 
inhibitors such as dipyridamole (40 µM) and etazolate (100 µM) which did not 
significantly affect cAMP concentrations. This action is immediate and time and 
dose dependent although cell lysis and death only occurred after 15 h even at 3 
µM concentration (de Koning et al., 2012). 
  
Figure 1:8: Structure of Cpd A and B showing their IC50 on TbrPDEB1. Reproduced from de 
Koning et al, 2012) 
 
However, CpdA has previously been shown to be a potent inhibitor of human 
PDE4 (Van der Mey et al., 2001a; Van der Mey et al., 2001b). This was 
independently pharmacologically validated by Bland et al using the hPDE4 
inhibitor piclamilast and a number of analogues (Bland et al., 2011). Thus it 
became clear that the TbrPDEB family is pharmacologically closest to this human 
PDE. In contrast, human PDE5 inhibitors including sildenafil and tadalafil 
analogues displayed only weak inhibition of TbrPDEB1 (Ochiana et al., 2012; 
Wang et al., 2012). This scenario presented a problem of designing trypanosomal 
PDE inhibitors with enough specificity and selectivity to prevent toxicity or at 
least reduce it to current pharmaceutical standards.  
 
The resolution of the catalytic structure of L. Major PDEB1 in complex with the 
nonspecific inhibitor IBMX (Wang et al., 2007), the first for a kinetoplastid PDE 
confirmed the expected similarities with that of human PDEs especially in the 
catalytic domain (Ke and Wang, 2007). However, it also revealed subtle 
differences in key regions such as the active site and a unique pocket for 
inhibitor binding present in all members of the kinetoplastid PDEB family 
examined including TbrPDEB1 (Jansen et al., 2013), (Figure 1.9) as well as 
TcrPDEC (Wang et al., 2007). The question as to whether these subtle 
differences provide good enough basis to target PDEs in Kinetoplastids was 
tested when homology modelling and docking studies was used to guide 
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fragments of Catechol Pyrazolinones into the parasite pocket (P-pocket) of 
TbrPDEB1. The result was a discovery of a new series of compounds with  
nanomolar EC50 values against the enzyme while also displaying promising 
trypanocidal activity and stimulating cellular cAMP levels (Orrling et al., 2012).  
 
          
Figure 1.9: Model of the binding pocket of TbrPDEB1 and hPDE4. Model of the 
superimposed binding pockets of TbrPDEB1 (turquoise ribbons and carbon atoms) and 
hPDE4B (orange ribbons, grey carbon atoms). The figure depicts chain A from the 
published 4I15 PDEB1 structure and chain B of hPDEB structure 1XM4 (alignment RMSD 
1.847 Angstrom). A. ribbon model of the cAMP binding pocket. B. Same view but with the 
molecular surface for TbrPDEB1 residues shown. Side chains for the conserved 
hydrophobic clamp phenylalanine residue in PDEB1 (Phe877, turquoise) and hPDE4B 
(Phe446, grey carbons) are shown to illustrate the orientation of the P pocket relative to this 
canonical binding site feature. Side chains for the pair of amino acid residues at the 
entrance to the P pocket in PDEB1 and hPDE4B are also shown - Met861 and Gly873 in 
PDEB1 (turquoise), and Met431 and Ser442 in hPDE4B (colored by element - carbon gray, 
hydrogen white, nitrogen blue, oxygen red, sulfur yellow). For TbrPDEB1 the P-pocket is 
clearly visible in Frame B, directly adjacent to the main ligand binding site and delineated by 
M861 and G873, where in hPDE4B this space is filled entirely by M431 and S442. The models 
were constructed by Dr R.K. Campbell of the Marine Biology Laboratory, Woods Hole, MA, 
USA, using Maestro software release 2015-2 (Schrodinger, Portland, OR, USA). 
 
1.4.2 Potential effectors of PDE inhibition and cAMP signalling 
Although cAMP has been noted to play important roles in cell differentiation in 
T. b. brucei and that inhibition of PDE results in increased cAMP, the effectors 
that mediate this differentiation are yet to be identified. These downstream 
effectors of cAMP signalling are important mediators of PDE inhibition effect in 
cells and will provide valuable information of drug action as well as offer 
additional potential therapeutic targets. Thus to study these downstream 
effectors, Gould et al, (2013) generated two CpdA resistance lines. The first 
method involved growing T. b. brucei in the mutagen Methyl methanesulfonate 
(MMS; Sigma), and the subsequent passage in incrementally sublethal 
concentrations of CpdA. The second method employed the use of a T. b. brucei 
A B 
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RNAi library approach (Alsford et al., 2012a; Alsford et al., 2012b; Alsford et al., 
2011b; Baker et al., 2011) to select for resistance line under CpdA pressure. The 
RNAi library screen of resistance to the phosphodiesterase inhibitor CpdA 
revealed four distinct genes that were knocked down. These genes were 
designated cAMP Response Protein (CARP) (Gould et al., 2013).              
 
One of the genes knocked down in the CpdA-resistant cultures was 
Tb427tmp.01.7890 (CARP1; Tb927.11.16210 in T. brucei brucei reference strain 
TREU 927), encoding a 705-amino-acid protein containing two apparently intact 
and one partial cyclic AMP binding-like domains that is conserved in synteny in 
each of the kinetoplastid genomes sequenced. No close orthologues were 
identified in other organisms, but cyclic nucleotide-dependent kinases and ion 
channels appear to be the most closely related proteins outside the 
Kinetoplastida. CARP1 RNAi resulted in a slight growth phenotype (Gould et al., 
2013). Mitochondrial RNA expression of CARP1 in pleomorphic cells at different 
time points in the lifecycle stages relative to a stably expressed gene 
(Tb10.389.0540) was performed using a whole-genome microarray analysis. The 
results showed that expression of CARP1 is relatively low in long slender forms 
and at 0 and 1 h with lower expression at 6 h in Stumpy form cells. However, 
expression level rose steadily and was highest at 18 h to coincide with procyclic 
cell proliferation (Kabani et al., 2009). Recently, the homologue of CARP1 in T. 
cruzi (TcCLB.508523.80) has been revealed to bind cyclic nucleotides using cAMP 
and cGMP displacement assays (Jäger et al., 2014), further validating the role of 
CARP1 as a downstream cAMP signalling effector.  
 
CARP2 (Tb427tmp.52.0004; Tb927.11.12860 in TREU 927) codes for a 
hypothetical protein of 302 amino acids, but a downstream alternative start 
codon may produce a shorter protein of 235 amino acids (Siegel et al., 2010a). 
This corresponds to the ORF length of the majority of CARP2 homologues that 
are well conserved across the Kinetoplastida (82% amino acid identity in all 
Trypanosoma spp. and 59% identity in Leishmania spp.) and many other species, 
including humans (47.7% identity). The apparent molecular mass of the C-
terminally tagged T. brucei brucei protein (Broadhead et al., 2006) shows that 
the first ATG is in fact used and that the trypanosomal CARP2 carries an N-
terminal extension. There is no known function, and no recognizable functional 
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domains could be identified in any of the homologues. It has been detected in 
proteomes of the T. brucei brucei flagellum (Broadhead et al., 2006) and of 
cytoskeletal and plasma membrane fractions (Bridges et al., 2008), and its 
homologue was part of an in silico predicted proteome of the flagellar and basal 
body of Chlamydomonas reinhardtii (Li et al., 2004; Merchant et al., 2007). 
Similar mRNA analysis as performed in CARP1 showed that CARP2 is also not 
highly expressed in long slender forms and at the point of differentiation (0 h) 
into short stumpy forms. However, unlike CARP1, mRNA levels increased steadily 
from 1 h, plateauing at 18 h and continue through to 48 h (Kabani et al., 2009). 
This shows that CARP2 is steadily expressed in the differentiation into procyclics 
and continued throughout the insect stages of the trypanosome lifecycle. 
 
CARP3 (Tb427.07.5340; Tb927.7.5340 in TREU 927) encodes a hypothetical 
protein of 498 amino acids with orthologues only in Trypanosoma spp. and 
strains. A BLASTP search identified the putative stibogluconate resistance gene 
family in Leishmania spp. as the closest homologue outside trypanosomes 
(Leishmania braziliensis LBRM_31_1110; 20.4% identity); amplification of this 
gene family in Leishmania tarentolae resulted in resistance to antimony-
containing drugs (Haimeur and Ouellette, 1998). The protein was found in the 
plasma membrane-enriched fractions of bloodstream T. brucei brucei (Bridges et 
al., 2008) and in mitochondrial fractions of procyclic trypanosomes (Panigrahi et 
al., 2009) and is possibly palmitoylated (Emmer et al., 2011b). At the N-terminal 
end of the protein, a weak TPR-like domain (tetratricopeptide repeat) signature 
is detected. TPR domains can mediate protein-protein interactions such as 
dimerization and the assembly of multiprotein complexes (D'Andrea and Regan, 
2003). Unlike CARP1 and CARP2, CARP3 levels are almost 3-fold higher in long 
slender forms than in stumpy forms. Although the level of expression in short 
stumpy forms are unchanged in CARP1 and CARP2 at 0 h, CARP3 levels increased 
rapidly to >1-fold at 1 h through to 6 h and reducing at 18 h to rise again (Kabani 
et al., 2009). This shows that CARP3 exhibit a cyclical expression level through 
the differential life stages which coincides with rapidly dividing prolific life 
forms of long slender forms, procyclic, and metacyclic forms.  
 
The fourth ORF identified from the RNAi target fragments, CARP4 
(Tb927.3.1040/60), is a hypothetical gene that spans three automatically 
Daniel N.A Tagoe  Chapter 1, 65 
annotated ORFs in release 5.0 of TriTrypDB (T. brucei brucei TREU 927 strain; 
the respective sequence segment of strain Lister 427 is annotated as 
incomplete). However, the middle ORF appears to be a sequence contaminant 
disrupting a single open reading frame encompassing Tb927.3.1040 and 
Tb927.3.1060. The middle ORF is absent from all RNA sequencing (RNAseq) data 
on the TriTrypDB website and has no homologues or orthologues in any of the 
other kinetoplastid genomes on the database. The full-length Tb927.3.1040/60 
ORF, on the other hand, is conserved in synteny in all kinetoplastid genomes 
sequenced to date, with amino acid identity of 53.6% in Leishmania major and 
96.3% in T. brucei gambiense. The combined Tb927.3.1040/60 ORF codes for a 
hypothetical protein of 779 amino acids and is predicted to have three DM10 
domains and one EF-hand domain located at the C-terminal end. BLASTP and 
domain architecture (NCBI CDART) searches uncovered sequence assembling 
error and mis-annotation in that region of the reference TREU 927 genome 
sequence. Similar to CARP3, mRNA of CARP4 (Tb927.3.1060) is highly expressed 
compared with the stably expressed gene (Tb10.389.0540) in long slender forms 
and not expressed in short stumpy forms at 0 h. Significantly different from 
CARP3 however, its expression is relatively lower (-1.5-fold) at 1 h in short 
stumpy forms rising to that of control at 6 h and remaining relatively unchanged 
over the period of differentiation (Kabani et al., 2009). This expression profile 
showed that CARP4 is probably only abundantly expressed in bloodstream long 
slender forms.  
 
1.4.2.1 CARPs affect CpdA sensitivity 
All four CARP genes were targeted with RNAi constructs and transfected into T. 
b. brucei for tetracycline-inducible expression. RNAi induction for 24 h caused a 
substantial reduction of the specific tagged CARP protein as shown by Western 
blot; all were reduced by at least 2-3-fold, but CARP3 expression appeared to be 
down to approximately 5% (Gould et al., 2013). The RNAi-mediated knockdown 
resulted in significant resistance to CpdA. CARP1 showed the highest resistance 
of 117-fold followed by CARP2 (10.1-fold), CARP3 (7.9-fold) and CARP4 (5.4-fold) 
in that order. CARP1 knockdown also resulted in a 5.0- and 3.7-fold decrease in 
resistance to 8-bromo-cAMP and dibutyryl-cAMP, respectively, whilst knockdown 
of CARP2 showed 2.2- and 1.9-fold increases in EC50 to 8-bromo-cAMP and 
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dibutyryl-cAMP, respectively. CARP3 and CARP4 showed no significant sensitivity 
changes to these analogues. No cross-resistance was observed for several 
trypanocidal drugs in use such as pentamidine, suramin and DMFO (eflornithine) 
under RNAi induction. The discovery of the CARPs constituted a potential 
breakthrough in understanding a crucial cellular regulation pathway in 
kinetoplastids, especially as it begins to fill in some details of cAMP signalling in 
T. brucei of which there is paucity of knowledge compared with that in 
mammals (Figure 1.10). 
 
Figure 1.10: Schematic diagram of cyclic nucleotide signalling in T. brucei, emphasising the 
lack of investigative tools compared with the classical mammalian model, where 
manipulation of receptors, G-proteins and cyclases are all possible. EPAC, exchange 
protein directly activated by cAMP. 
 
1.5 Hypothesis 
We hypothesise that the trypanocidal effect of high cAMP levels is mediated by a 
pathway that includes the RNAi-identified CARP proteins. As these, in contrast to 
TbPDEB1/2, are mainly trypanosomatid-specific; their study will provide 
important new insights into unique parasite biology and into the mode of action 
of potential new trypanocides based on inhibition of PDEB. Whereas it is not 
proposed that the CARP proteins encoded by the genes under study are 
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necessarily drug targets, this study will greatly expand our understanding of 
cAMP-directed processes and cascades and is expected to identify additional 
genes involved in these pathways, beyond CARP1-4, some of which could be of 
therapeutic value as drug targets. 
 
1.6 Aims 
The primary goal of the project is to characterise the T. brucei CARP proteins as 
well as investigate some wider aspects of cAMP signalling in trypanosomes. 
Reverse genetics, genomics, proteomics and immunofluorescence microscopy 
will be used to elucidate potential pathways targeted by changes in cellular 
cAMP levels. These approaches together should investigate the trypanosomal 
processes regulated by cAMP. 
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Material and Methods 
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2.1 Introduction 
This chapter describes the materials and the methods used to probe the 
hypothesis and resolve the aims of the project. It includes molecular biological 
techniques (gene knockout and overexpression), biochemical assays (drug 
sensitivity assays, growth assays, Enzyme Linked Immunosorbant Assays (ELISA)), 
Immunofluorescence assays; Transcriptomics; Ribonucleic Acid Interference 
Sequencing (RIT-Seq), Ribonucleic Acid Sequencing (RNA-Seq) and Proteomic; 
Co-Immunoprecipitation (Co-IP) and Mass Spectrometry (MS).  
 
 
2.2 Materials 
Bloodstream forms of T. b. brucei MiTat 1.2 lines (WT s427) and BSF Lister 427 
cells, clone 221a (2TI) were routinely cultured in HMI-9 medium (InvitrogenTM), 
supplemented with 10% heat Inactivated Fetal Bovine Serum Gold (FBS with 
tetracycline; PAA Laboratories) in vented culture flasks (Corning, Sigma Aldrich), 
at 37 °C, in a 5% CO2 atmosphere. A CpdA resistant line (R0.8) generated from 
WT s427 (Gould et al., 2013) was cultured similarly as WT s427 with occasional 
checks to ensure retention of CpdA resistance. To retain the tetracycline 
promoter, BSF Lister 427 cells clone 221a (2TI) cells were placed under 
phleomycin (0.5 µg/ml) and puromycin (0.2 µg/ml) antibiotic pressures. DNA was 
extracted from cell pellets using Nucleospin Tissue Kit (Machery and Nagel®) 
following manufacturers protocol. Concentration of DNA was checked on the 
Nanodrop (Thermo Scientific®). All primers were synthesized at Eurofins 
Genomics® (see primer table for list of primers). PCR amplification of UTRs were 
performed using Phusion High Fidelity Polymerase (New England Biolabs®), Gel 
and PCR products were cleaned using Nucleospin Gel and PCR clean kit (Machery 
and Nagel®), plasmids were extracted using Nucleospin plasmid extraction kit 
(Machery and Nagel®) and RNA was extracted using Nucleospin RNA extraction kit 
(Machery and Nagel®). All clean ups and extractions were performed following 
manufacturers protocols. CpdA was provided by Geert Jan Sterk of Mercachem, 
The Netherlands and Pentamidine (Sigma Aldrich®). Additional materials used 
are described with the required experiment.   
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2.3 Design and making of constructs for genetic 
manipulation of trypanosome 
2.3.1 Making of CARP1-4 KO Plasmids 
The homologous gene replacement method with antibiotics was used to generate 
knockout cells. Un-translated regions (UTRs) flanking the open reading frames 
(OFRs) of the genes of CARP1-4 were obtained from TriTrypDB based on 
Trypanosoma brucei TREU 927 (http://tritrypdb.org/tritrypdb/). Primers 
(forward and reverse) each were designed using CLC Genomic workbench version 
7.0 for both the 5′ and 3′ UTRs of each gene adding the desired restriction sites 
(Appendix 1: Table 1.1) designed for Plasmid pMB G97 a kind donation of Prof 
Mike Barrett, (University of Glasgow, UK) (Figure 2.1).  
 
 
Figure 2.1: Plasmid map of pMB97 showing 5’ and 3’ UTRs and hygromycin antibiotic 
cassette. 
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A gradient PCR was performed to determine the best melting temperature (Tm) 
for each primer after which each UTR was amplified from200 ng of the isolated 
DNA with their respective primers. The PCR product was cleaned and 
concentration determined using the Nanodrop. The respective UTRs were 
restriction double digested using NotI and XbaI for 5′ UTRs and NsiI and XhoI for 
3′ UTRs (Promega®) in a 50 µl total reaction volume of 2 µg PCR product, 5 µl 
10X reaction buffer D, 5 µl 10X Bovine Sheep Albumin (BSA) and 2.5 µl enzyme 
each supplemented with double deionized H2O (dd H2O) with incubation at 37 °C 
for 1 h. The digested UTRs were PCR cleaned and the concentration determined. 
Plasmid DNA was extracted from pMB97 (hygromycin selectable cassette) from 
an overnight culture and the 5′ UTR region of pMB97 digested in a similar 
reaction as the CARPs 5′ UTRs using 5 µg of DNA and 5.5 µl of enzyme (NotI and 
XbaI), 10 µl 10X reaction buffer D and 10X BSA each in a 100 µl total reaction 
volume to allow for the ligation into the plasmid of the 5′ UTRs of each gene. 
The digest was run on a 1% agarose gel, the backbone cut with a sharp clean 
blade, gel extracted and concentration determined. 
 
Each UTR was ligated to the backbone of pMB97 in a ligation reaction mix made 
up of 50 ng of 5′ UTR insert and 150 ng of pMB97 backbone, 1 µl 10X ligase buffer 
and 1 µl T4 ligase supplemented with ddH2O to a total of 10 µl. This was 
incubated at room temperature for 3 h after which the ligation was ready for 
transformation.  
 
Following ligation the plasmid was transformed into XL1 blue (Agilent 
Technologies®) competent E. coli cells as follows: 5 µl of ligation reaction was 
pipetted into a sterile 1.5 ml Eppendorf tube (Eppendorf®) and a 50 µl aliquot of 
XL1-blue cells defrosted on ice was then added; the mixture was incubated on 
ice for 30 minutes, heat-shocked for 45 s at 42°C and then incubated on ice for 
another 2 minutes. 200 µl of LB broth was added and incubated at 37°C for 1 
hour with shaking. Finally, 50 µl of the transformation reaction was spread on a 
Luria agar supplemented with ampicillin (100 µg/ml Ampicillin (Sigma-Aldrich®) 
and incubated at 37°C overnight.  
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Colonies from the overnight transformation were PCR screened using primers 
that check for integration of the respective 5′ UTR of each CARP1-4 gene into 
pMB97. Screening was performed by picking a bacteria colony from each agar 
plate with a sterile 200 µl pipette tip, streaking on a fresh LB agar plate, 
numbering each streak and dipping each tip thereafter in the PCR tube bearing 
corresponding number. After colony plasmid amplification, correct integration 
was checked by electrophoresis on 1% agarose gel. The new agar plate was then 
incubated at 37°C overnight. Positive clones were identified as colonies that 
gave bands on the agarose gel corresponding to the desired molecular weight 
(~1.2 kb band) of which bacteria was inoculated into 10 mL Luria broth (LB) 
supplemented with 100 µg/ml Ampicillin overnight. Plasmid DNA was extracted 
from each positive overnight culture and sent for Sanger sequencing of the 
respective 5′ UTRs. One plasmid from each gene with the right 5′ UTR integration 
was selected for 3′ UTR integration which was performed exactly as that of 5′ 
UTR integration. However, the enzymes NsiI and XhoI were used to digest the 3′ 
UTR inset and the 5′ UTR-integrated plasmid of each of CARP1-4. The knockout 
constructs were then sent for Sanger sequencing of the 5′ UTR, 3′ UTR and the 
hygromycin selectable cassette. 
 
The hygromycin cassette in pMB97 is flanked by two EcoRI restriction sites. To 
generate additional selectable marker constructs, primers were designed with 
EcoRI to amplify blasticidin and neomycin. DNA from plasmids with these 
markers were amplified, restriction digested and PCR cleaned. Each hygromycin 
selectable knockout construct of the CARPs was digested with EcoRI and treated 
with antartic phosphatase (New England Biolabs®) to prevent self-ligation due to 
the similar restriction sites on the ends of the cut region followed by 
electrophoresis on 1% agarose gel. The backbone (without the hygromycin gene) 
was gel cleaned. Each of blasticidin and Neomycin were ligated individually into 
the backbone of each of CARP1-4 genes with transformation, screening and 
overnight cultures performed as described above for the integration of 5′ UTR. 
Each generated construct was Sanger sequenced both to check for the presence 
of the UTRs as well as the correct sequence of the selectable cassettes to ensure 
appropriate gene expression and thus resistance selection. Constructs were 
ready for transfection (Figure 2.2). 
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Figure 2.2: KO constructs designed with the various resistant cassettes to replace CARP1-4 
genes. F-forward primer; R-reverse primer.  
 
 
2.3.2 Making of CARP1-4, TbPDEB1 Overexpressing (O.E) and N-
Terminal GFP tagged plasmids  
Open Reading Frames (ORFs) of CARP1-4 and TbPDEB1 were obtained from 
TriTrypDB (http://tritrypdb.org/tritrypdb/). Primers (forward and reverse) each 
to the ORF of each gene were designed using CLC Genomic workbench version 
7.0 adding the desired restriction sites for each gene (Appendix 1: Table 1.2-3). 
Two sets of knockin constructs were made using the vector pHD1336 (Biebinger 
et al., 1997; Munday et al., 2013; Munday et al., 2015) (Figure 2.3) and the 
pRPaGFP (Figure 2.4) which has the Tet-promoter for tetracycline induction 
(Alsford et al., 2005). A gradient PCR was performed to determine the best 
melting temperature (Tm) for each primer after which each ORF was amplified 
using 200 ng of the isolated DNA with their respective primers. The PCR product 
was cleaned and concentration determined using the Nanodrop. The respective 
ORFs were restriction sequentially digested using ApaI and BamHI (Promega®) 
for pHD1336 or XbaI and BamHI for pRPaGFP in a 50 µl total reaction volume of 2 
µg PCR product, 5 µl 10X reaction buffer Multicore, 5 µl 10X Bovine Sheep 
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Albumin (BSA) and 2.5 µl enzyme each supplemented with double deionized H2O 
(dd H2O) with incubation at 25 °C for 1 h followed by 37 °C for another hour for 
pHD1336 and 37 °C for pRPaGFP. The digested ORFs were PCR cleaned and the 
concentration determined. Plasmid DNA was extracted from pHD1336 from an 
overnight culture and the restriction region of ApaI and BamHI (pHD1336) or XbaI 
and BamHI (pRPaGFP) digested in a similar reaction as the ORFs using 5 µg of DNA 
and 5.5 µl of ApaI and BamHI and XbaI and BamHI, 10 µl 10X reaction buffer D 
and 10X BSA each in a 100 µl total reaction volume to allow for the ligation into 
the plasmid of the ORFs of each overexpressing CARP construct. The digest was 
run on a 1% agarose gel, the backbone cut with a sharp clean blade, gel 
extracted and concentration determined. Ligation, transformation and colony 
screening was performed just as described for making of KO construct. After 
sequencing, pHD1336 CARP1-4 and TbPDEB1 (Figure 2.5), as well as pRPaGFP 
CARP1-3 were ready for transfection (Figure 2.6). 
 
Figure 2.3: Plasmid map of pHD1336 showing the restriction sites and region for ORF 
integration.  
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Figure 2.4: Plasmid map of pRPaGFP showing the restriction sites, GFP and region for 
expression cassette. CARP1-3 replaces expression cassette. 
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Figure 2.5: pHD1336 overexpression constructs with the CARPs and TbPDEB1. F-forward 
primer; R-reverse primer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: N-Terminal GFP tagged (pRPaGFP) overexpression with CARP1-3. F-forward 
primer; R-reverse primer. 
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2.3.3 Transfection and selection of clonal CARP1-4 KO cells, 
CARP1-4 and TbPDEB1 overexpressing cells and N-terminal 
GFP tagged cells 
The generated CARP1-4 KO constructs were digested using NotI and XhoI to 
create a vector that can integrate into the 5′ UTR and 3′ UTR flanking each CARP 
and replace each gene with the appropriate antibiotic cassette whilst CARP1-4oe 
and TbPDEB1oe were linearized with NotI to integrate as a vector into the 
ribosomal RNA locus. CARP1-3GFP constructs were linearized with AscI and 
integrates to replace an in-house puromycin cassette allowing selection with 
hygromycin. 10 µg of each construct was digested in a 200 µl reaction volume 
using 11 µl each of their respective enzyme, 20 µl of 10X buffer D, 20 µl of BSA 
and ddH2O with incubation at 37°C for 4 h. The digests were PCR cleaned and 
ethanol precipitated to concentrate the vectors for transfection. KO Vectors of  
CARP1-4  were transfected into WT s427 whilst CARP1-4oe, TbPDEB1oe were 
transfected into WT s427 and R0.8 cells (Gould et al., 2013). N-Terminal GFP-
Tagged pRPaGFP vectors were transfected into 2TI cells.  
 
Bloodstream form T. b. brucei WT s427 strains, 2TI and R0.8 were cultured to a 
density of 1 x 106 cells/ml. 5 mL (5 x 106 cells) of culture for each transfection 
were transferred into a 15 mL centrifuge tube (Corning®) and centrifuged at 
2600 rpm for 10 minutes at 22°C in a Heraeus Biofuge centrifuge. The 
supernatant was decanted off and the pellet washed into 100 µl Human T-Cell 
solution for transfection with 10 µg ethanol-precipitated vector DNA (10 µl) using 
an Amaxa Nucleofector™ II electroporator (Amaxa Biosystems) program X-001. 
The transfections were transferred into pre-warmed HMI-9 with 10% FBS medium 
and allowed to recover for 8 – 16 h at 37°C and 5% CO2. Appropriate antibiotics 
corresponding to the selection marker of the vector used in transfection were 
added.  Cells transfected with pHD1336 constructs were selected with blasticidin 
(5 µg/ml) whilst pRPaGFP were selected with hygromycin (2 µg/ml) and 
respective antibiotic for KO vectors and neomycin (2 µg/ml) (Sigma-Aldrich®) 
before the cells were cloned. The cells were cloned out using limiting dilution 
into three 96 well plates (1/24 dilution for plate 1, 1/288 dilution for plate 2 
and 1/576 for plate 3). Three clones were selected for each gene and the 
preference was for the lowest dilution to select for transfectants.  
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Two selectable markers (blasticidin and hygromycin) were initially used for 
transfection for KO lines.  Thus two sets of heterozygote cell line of three clones 
each of CARP1-4 (CARP1-4+/- blasticidin) and (CARP1-4+/- hygromycin) were 
obtained from the first transfection. The generated sKO and overexpressing 
CARP cell lines were immediately analysed for correct heterozygosity, gene 
integration and overexpression and used for downstream experiments whilst 
attempts were made to generate dKO CARP cell lines.  
 
To generate a homozygote allele deletion of each of CARP1-4 (CARP1-4-/-), the 
antibiotics were swapped in a repeated transfection in an attempt to delete the 
second allele of both CARP1-4+/- blasticidin and CARP1-4+/- hygromycin using 
hygromycin and blasticidin respectively as well as neomycin selectable cassettes 
were performed. As a control, the neomycin selectable vector was used for a 
single allele deletion. All neomycin single allele deletion yielded clones. Several 
attempts were made in an attempt to obtained double gene deleted CARP cell 
lines. There were double deletions of CARP2-/-, CARP3-/- and CARP4-/-.There 
were however no viable clones for CARP1-/- double gene deletion after three 
attempts. 
 
 
2.3.4 Confirmation of CARP1-4 single (sKO) and double 
KO (dKO), O.E and N-TerminalGFP generated lines.  
Successful gene deletion, correct antibiotic cassette integration and presence of 
expression vectors were confirmed with PCR, qRT-PCR and restriction digest 
Southern blotting.  
 
2.3.4.1 PCR confirmation of antibiotic integration of sKO CARP1-4, dKO 
CARP2-3 and vector integration of pHD1336 and pRPaGFP. 
For KO confirmation, primers were designed to bind to a region pre 5′ UTRs and a 
post 3′ UTRs and normal PCR reaction performed with the reverse and forward 
primers of the integrated antibiotic cassette to the respective UTR primers 
(Appendix 1: Table 1.4). To confirm O.E in WT s427 and R0.8 and GFP-tagged in 
2TI cells, primers were designed to bind to a region pre ORF and use in a normal 
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PCR reaction with the reverse primer of the integrated antibiotic cassette. In 
these reactions, Wild type s427, R0.8 and 2TI cells were used as controls for the 
respective experiments. 
 
2.3.4.2 Quantitative Real Time-PCR (qRT-PCR) confirmation of reduction and 
increase in mRNA transcripts of sKO and O.E cells respectively. 
Confirmation of sKO CARP1-4, CARP1-4oe and TbPDEB1oe using qRT-PCR was 
carried out as previously described (Ali et al., 2013). Primers for qRT-PCR were 
designed using Primer3® (Appendix 1: Table 1.5). The constitutively expressed 
gene GPI8 was used as an endogenous control (Wilson et al., 2012). Primer 
efficiency was performed for each of the primers and the endogenous control 
(GPI8) (5′- TCTGAACCCGCGCACTTC-3′ and 5′-CCACTCACGGACTGCGTTT-3′) using 
the previously described method of Pfaffl (Pfaffl, 2001). Generated cell lines and 
their respective controls were grown to log phase densities in HMI-9 with 10% 
FBS medium. Cells were counted and 2 x 106 cells were spanned down at 2600 
rpm for 10 min and the supernatant decanted. RNA was isolated from the pellets 
following manufacturer’s protocols and quantified using a Nanodrop (Thermo 
Scientific). 200 ng of RNA from each generated cell and control was converted 
into complementary DNA (cDNA) using a Reverse-Transcriptase (RT) kit 
(Primerdesign®). The cDNA for each sample was subsequently diluted with RNase 
free water to 20 ng/µl for Real Time-PCR. Amplification of cDNA was performed 
in a 7500 Real Time PCR System (Applied Biosystems®). A dissociation curve was 
used to ensure the amplification of only one product; samples without RT or 
without cDNA were used as controls. The entire experiment was performed on 
three independent occasions, starting from cell culture and RNA isolation of the 
different cell lines. Fold change was calculated using the determined primer 
efficiency (Pfaffl, 2001).  
 
2.3.4.3 Southern blot confirmation of CARP2-3 dKO lines 
Double allele deletions of CARP2, CARP3 AND CARP4 were confirmed using 
Southern blot restriction digest of genomic DNA from knockout cell lines as 
previously described (Ali et al., 2013). 10 μg of DNA from each of the cell lines 
were digested overnight (O/N) with EcoRI and SacII (CARP2-/-), EcoRI and XhoI 
(CARP3-/-) and EcoRV and XhoI (CARP4-/-). These were then run on a 0.8% gel for 
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24 h at 20 V. Thereafter, the DNA was blotted O/N onto Hybond Nylon 
membrane (Amersham®). The DNA was cross-linked onto the membrane using a 
UV cross-linker and then hybridized for 2 h at 42°C. Probes were prepared using 
50 ng restriction digested DNA (ApaI and BamHI) of CARP2, CARP3 and CARP4, 10 
μl random oligo primers (Prime-it II Radom Primer Labelling, Stratagene®) and 
ddH2O to a volume of 37 μl. This was heated 95-100 °C for 5 mins. 10 μl 5x 
primer buffer, 2 μl α32 Phosphorous dATP and 1 μl Klenow (5U/μl) added after 
brief centrifugation. The probe was further incubated at 37-40 °C for 10 mins 
after which the reaction was stopped with 2 μl Stop mix. Finally, the reaction 
was purified with a resin column, heated to 95 °C for 5 min and immediately 
added to the hybridisation solution and membrane. This was incubated for more 
than 16 h. The filters were washed twice using standard high stringency solutions 
at 55 °C for 20 and 45 min in the rotisserie respectively after which they were 
heat sealed in a plastic film and exposed to Amersham Hyperfilm™ MP for an 
initial 3 h and O/N at -80 °C. The films were developed using the KODAK® RP X-
omat developer.  
 
2.3.4.4 Western blot confirmation of loss, decrease and increase in protein 
levels of CARP3-/-, CARP3+/-, s427 CARP3oe and R0.8 CARP3oe.  
Peptide antigens were designed for CARP1 (N-DREKGKRRIKENSKAC-C), CARP2 (N-
DYFHRRKRLTPRRTD-C) and CARP3 (N-QSNMSEESGGEGGDTN-C) and antibody 
raised against them in rabbits (by Eurogentec, Belgium). Out of these three anti-
CARP antibodies, only CARP3 gives the right Molecular Weight (MW) and size for 
Western blotting. Thus to determine if gene deletion or overexpression of CARP3 
results in a concomitant change of CARP3 protein, Western blotting was 
performed as previously described (Gould et al., 2013).  
 
CARP3-/-, CARP3+/-, s427 CARP3oe, R0.8 CARP3oe, WT s427 and R0.8 cells were 
cultured in HMI-9 media to log phase. Two sets of 1 x 107 cells each were 
centrifuged at 2600 RPM for 10 mins at 4°C. The supernatant was discarded. 100 
μl of protein sample buffer was added to the pellet and heated at 100°C for 5 
min. 15 μl of the sample was run on a 8-12% Novex® NuPAGE® Bis-Tris gels (life 
Technologies, UK) at 80 V for 2 h. Gels were blotted for 3 h at 20 V onto 
Amersham® Hybond ECL, (GE Healthcare Life sciences, UK) using the Xcell 
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Surelock™ mini-cell electrophoresis system. Blots were blocked using 5% milk in 
PBS-Tween (0.01%)      (Sigma-Aldrich®) for 1 h. Primary antibodies of Anti-CARP3 
polyclonal antibody and control antibody of Elongation factor 1-α (EF1-α) were 
added in blocking solution of 5% milk in PBS-Tween (0.01%)  to respective blots 
on a shaker O/N at 4 °C. Blots were washed and incubated in blocking solution 
containing secondary antibody of Horse-Radish anti-Rabbit IgG (Sigma-Aldrich®) 
for 1 h. After washing blots, Pierce™ ECL Western Blotting Substrate (Life 
Technologies) was added and the blots exposed to Amersham® Hyperfilm. Films 
were developed using KODAK® RP X-omat developer.  
 
 
2.3.5 Effect of CpdA on transcript (mRNA) of CARP1-4oe in s427 
and R0.8 and CARP3 protein levels of sKO CARP3 and 
CARP3oe  
2.3.5.1 Determination of CpdA effect on mRNA levels of CARP1-4oe and 
TbPDEB1oe.  
To determine the effect of CpdA on mRNA of the overexpressing CARP1-4 and 
TbPDEB1 genes in WT s427 and R0.8, the generated trypanosomes were seeded 
at 2 x 104/ml in 20 ml culture media and incubated at 37 °C, in a 5% CO2 
atmosphere.  WT s427 and R0.8 were also similarly seeded as controls. 2 x 106 of 
the overexpressing cells in both WTs427 and R0.8 and their controls were 
pelleted for RNA extraction as 0 h samples. 100 nM of CpdA was added to s427 
CARP1-4oe, TbPDEB1oe and WT s427 whilst 3 μM of CpdA was added to R0.8 
CARP1-4oe, TbPDEB1oe and R0.8 respectively. At 6 h, 2 x 106 cells were pelleted 
and at 24 h and 48 h for RNA extraction. Pelleted cells for RNA extraction were 
frozen at -20 °C after each incubation period. RNA was extracted after 48 h 
incubation for all the samples. All the RNA samples were reverse transcribed into 
cDNA and qRT-PCR performed as previously described. This experiment was 
repeated independently on three different occasions.  
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2.3.5.2 Determination of CpdA effect on protein levels of CARP3+/-, s427 
CARP3oe and R0.8 CARP3oe 
To investigate the effect of CpdA on protein expressions in CARP3+/-, s427 
CARP3oe and R0.8 CARP3oe, cells were grown without and in 100 nM and 3 μM 
CpdA over a period of 48 h. 5 x 106 cells were seeded in 50 ml culture media and 
incubated at 37 °C, in a 5% CO2 atmosphere. 1 x 107 cells overexpressing CARP3 
in both WT s427 and R0.8 and their controls were pelleted and 100 μl of protein 
loading buffer added and heated at 100 °C as 0 h samples. Subsequently, 100 nM 
CpdA was added to CARP3+/-, s427 CARP1-3oe and WT s427 whilst 3 μM of CpdA 
was added to R0.8 CARP3oe and R0.8 respectively. At 6 h, 1 x 107 cells were 
pelleted and at 24 h and 48 h and prepared as above for protein gel 
electrophoresis and Western blotting. Ready loading protein samples were 
frozen at -20 °C after each incubation period. Western blotting was performed 
as previously described.   
 
2.3.6 Drug sensitivity assays of sKO CARP1-4, dKO CARP2-3, 
s427 CARP1-4oe and TbPDEB1oe, R0.8 CARP1-4oe and 
TbPDEB1oe and controls.  
Sensitivities of CARP1-4+/-, CARP2-4-/-, s427 CARP1-4oe and TbPDEB1oe, R0.8 
CARP1-4oe and TbPDEB1oe and controls cells to CpdA and pentamidine (Sigma-
Aldrich®) were determined using the Alamar Blue assay (de Koning et al., 2012). 
Alamar blue dye was prepared by dissolving 12.5 mg of resazurin sodium salt 
(Sigma-Aldrich®) in 100 ml of PBS (Sigma-Aldrich®) at pH 7.4. The mixture was 
then filter-sterilized and stored at -20°C in foil-wrapped tubes to avoid exposure 
to light. Starting from a 5 mM stock solution in dimethyl sulfoxide (DMSO; Sigma-
Aldrich®), CpdA was diluted to 200 µM in HMI-9 media for CARP1-4+/-, CARP2-4-/-, 
s427 CARP1-4oe and TbPDEB1oe and WT s427 control and 1 μM for R0.8 CARP1-4oe 
and TbPDEB1oe and R0.8 control. Starting from a 20 mM stock solution in DMSO, 
pentamidine was diluted to 200 µM in HMI-9 media. 200 µl of CpdA solution was 
then added to the first well in a 96-well plate, while 100 µl of fresh medium was 
added to the remaining wells (24 wells for each compound). Doubling dilutions 
were done by pipetting 100 µl from the first well into the second well, mixing 
well by pipetting up and down several times then removing 100 µl from the 
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second well to the third, and so on. The last well was left drug free. 100 µl of 
2×105 cells/ml were added to all the wells, giving a final drug concentration of 
either 100 µM (KO and s427 overexpressing cells) or 500 µM (R0.8 overexpressing 
cells) in the first well and 2x103 cells in all wells. The plates were incubated at 
37°C and 5% CO2 for 48 hours. After 48 h, 20 µl of alamar blue dye was added to 
all wells and incubated for a further 24 hours at 37°C and 5% CO2. The plates 
were read using the FLUOstar Optima (BMG Labtech) fluorimeter at 530 nm and 
590 nm, excitation and emission respectively. EC50 values were subsequently 
determined using the GraphPad® Prism 5 software.  
 
2.3.7 Growth curves of sKO CARP1-4, dKO CARP2-3, s427 
CARP1-4oe, R0.8 CARP1-4oe and controls. 
Growth of sKO CARP1-4, dKO CARP2-3, s427 CARP1-4oe, and WT s427 control 
were assessed in HMI-9 only and in HMI-9 supplemented with 100 nM of CpdA 
whilst that of R0.8 CARP1-4oe and R0.8 control were performed in 3 μM CpdA 
similar to (Ali et al., 2013). Bloodstream forms of each cell type were seeded at 
2 × 104 cells ml-1 and for this purpose grown in 24-well plates, with each 
condition set up in 2 wells; incubation was at 37 °C and 5% CO2. Cells were 
counted every 24 h using a haemocytometer. Cells in drug free medium and 100 
nM or 3 μM of CpdA supplemented media were diluted every 48 h to 
concentrations of 2 × 104 or undiluted if density is lower than 1 × 106. Based on 
the results, an additional growth curve was performed for s427 CARP1oe and 
CARP3oe against WT s427 (100 nM) and R0.8 CARP1oe and CARP3oe against R0.8 (3 
μM) without diluting cells over the period of the growth curve.  The entire 
experiments were performed on three independent occasions. GraphPad® Prism 
5 software was used to generate linear regression curves. 
 
2.3.8 Immunofluorescence microscopy of CARP cellular 
localizations 
To determine protein localization, IFA was performed by expressing the full ORF 
of CARP1-3 attached to an N-terminal GFP. Additionally, the availability of a 
peptide polyclonal anti-CARP3 antibody allowed for a direct IFA of CARP3oe, WT 
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s427 and CARP3-/- cell lines. IFA was performed similar to previously described 
(Saada et al., 2014).   
 
The N-terminally tagged GFP cells (pRPaGFP) are tetracycline inducible. Thus to 
ensure maximal protein expression, cells were induced with 1 μg/ml tetracycline 
for 48 h.10 ml of 1 x 106/ml induced log phase cells were pelleted and washed 
twice with 1ml PBS. This was re-suspended in 200 ml of PBS and 50 μl spread on 
a clean labelled frosted slide. The slides were air fixed after which additional 
fixing was performed in 4 % paraformaldehyde/PBS solution for 10 min. The cells 
were washed twice with PBS and then permeabilized with 0.1% Triton x-100 
(Sigma-Aldrich®) for 5 min. The Triton was washed off with PBS and 1% BSA/PBS 
used to block unspecific binding for 45 min. The cells were incubated with 
primary anti-GFP antibody (Sigma-Aldrich®) diluted (1:1000) in 1% BSA/PBS for 
O/N at 4 °C with gentle rocking. The primary antibody was washed with PBS 
after which the cells were incubated in a secondary antibody; HRP anti-Rabbit 
IgG coupled with FITC (1:500) dilutions at room temperature for 1 h. Cells were 
rinsed 3X with PBS. Coverslips were mounted in mounting medium with DAPI 
(4’,6-diamidino-2-phenylindole) VectaShield® (Vector Laboratories Inc., USA). 
Similar protocol was used to prepare s427 CARP3oe, WT s427 and CARP3-/- for 
imaging using anti-CARP3 antibody (1:125) instead of anti-GFP. Samples were 
imaged on a Zeiss® Axioskop II microscope (Zeiss, Inc) and DeltaVision Core 
(AppliedPrecision®). Images were processed using GIMP 2.8.10 
(http://www.gimp.org/).  
 
2.3.9. Cyclic AMP measurements in sKO, dKO and O.E cell lines 
Cyclic AMP measurement was performed exactly as previously described (de 
Koning et al., 2012; Gould et al., 2013) with minor modifications. 
 
For extracellular cAMP, log-phase Bloodstream form trypanosomes at 2 x 106 
were inoculated into 20 ml of HMI-9 media and incubated at 37 ºC overnight. The 
cells were counted and then split into two. 300 nM of CpdA was added to one set 
of flasks (CpdA +) whilst the other was retained as a control (CpdA -). Both were 
further incubated for 3 h. After the 3 h incubation, a total of 5 x 106 cells were 
counted using a haemocytometer for both CpdA + and CpdA – and the 
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trypanosomes pelleted at 2600 RPM, 10 min at 4 ºC. 1 ml of the supernatant was 
carefully removed into labelled eppendorfs and kept at -80 °C for extracellular 
cAMP assay.   
 
For intracellular cAMP, the rest of the supernatant was removed and the cell 
pellet resuspended in 100 µl 0.1 M HCl and left on ice for 20 minutes to 
complete cell lysis. The samples were centrifuged at 12,000 RPM, 10 min at 4 ºC 
and the supernatant transferred to new labelled eppendorf and stored in a 
freezer at -80 ºC. Cyclic AMP content was assessed exactly as per the Cyclic AMP 
ELISA Immunosorbent Assay (EIA) Kit (Cayman Chemical Company, Missouri, USA) 
instructions from the manufacturers. Briefly, assay specific buffers, standards 
and samples were prepared according to recommended protocols (intracellular 
samples were diluted 1 in 2 with EIA buffer). Non-acytelated cAMP assay was 
performed in 96 well plates pre-coated with mouse monoclonal cAMP-specific 
rabbit antiserum. Eight serially diluted standards (double wells), blanks, buffer, 
tracer and antiserum together with the samples were added to the 96 well 
plates. The plates were incubated for 18 h, washed and developed with Ellman’s 
reagent for 2 h. The plates were read on Dynex® Technologies Revelation plate 
reader. Each sample was assayed in duplicate whilst the whole experiment from 
sample preparation to cAMP measurement was performed independently on at 
least three occasions.  
 
2.4.0 Effect of extracellular cAMP on growth of overexpressing 
CARP1, CARP3 and WT s427 cells 
Overexpressing CARP1, CARP3 and WT s427 cells at 2 x 106 were inoculated into 
40 ml of HMI-9 media and incubated at 37 ºC overnight. The cells were counted 
and then split into two. 100 nM of CpdA was added to one set of flasks (induced) 
whilst the other was retained as a control (un-induced). Both were further 
incubated for 3 h. After the 3 h incubation, a total of 1 x 108 cells were counted 
using a haemocytometer for both induced and un–induced and the trypanosomes 
pelleted at 2600 RPM, 10 min at 4 ºC. The supernatant was carefully removed 
into labelled eppendorfs and kept at -80 °C for growth curve assays. CARP1, 
CARP3 and WT s427 cells were inoculated in either their respective induced or 
un-induced media as well as HMI-9 + 100 nM CpdA, HMI-9 + 100 nM CpdA + 1 uM 
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cAMP (Sigma-Aldrich®), HMI-9 + 100 nM CpdA + 10 uM AMP (Sigma-Aldrich®), 
HMI-9 only, HMI-9 + 5 uM cAMP and HMI-9 + 50 uM AMP. Cells were counted every 
24 h using the haemocytometer. Each cell line and condition was double seeded 
from two different flasks each whilst the whole experiment was independently 
repeated at least twice. To confirm that 100 nM CpdA causes the release of 
cAMP into the media, induced and un-induced supernatants were both assayed 
for cAMP levels same as described previously.  
 
2.4.1 Transcriptomics and Proteomic investigations of CARPs 
and their interactions 
2.4.1.1 Ribonucleic Interference Sequencing (RIT-Seq) 
RNAi interference knockdown approach was performed to discover downstream 
effectors of cAMP signalling. Here, blood stream forms T. brucei trypanosomes 
were transfected with the RNAi library and grown in HMI-9. After recovery from 
the transfection, the cells were grown under CpdA pressure with RNAi induction 
using tetracycline (Gould et al., 2013). DNA was extracted from surviving cells 
and separated on a 1% gel. Distinct bands were excised and sequenced revealing 
four distinct genes that were designated cAMP Response Proteins (CARPs).  
Characterization of these CARPs has been described in the previous chapters. 
However, to maximize the discovery of distinct genetically induced loss of 
function phenotype as well as survey the representation of genetically distinct 
cells in a complex population, RIT-seq was performed on some of the DNA 
extracted from the surviving cells from which the initial CARPs were discovered.  
    
RNAi library screen that generated resistance clones for the RIT-Seq has been 
previously described (Baker et al., 2011; Gould et al., 2013). Firstly, a genome 
RNAi library of T. brucei brucei Lister s427 trypanosomes was induced with 
tetracycline under CpdA pressure to select for resistant clones. DNA was 
extracted from the surviving cells and the RNAi target DNA fragment amplified 
from the genomic DNA using primers Lib2 forward, 5’-TAGCCCCTCGAGGGCCAGT-
3’, and Lib2 Reverse, 5’-GGAATTCGATATCAAGCTTGGC-3’ which are RNAi insert 
specific for amplifying RNAi inserts from genomic DNA. This was run on a gel and 
the specific bands excised and sequenced. The sequence was mapped to the 
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reference genome sequence. Some of this DNA was sent to the Glasgow 
Polyomics Centre for library preparation and illumina sequencing. Library 
preparation was performed using the TrueSeq® Stranded mRNA Sample Prep Kit 
(Illumina) similar to previously described (Alsford et al., 2012b; Alsford et al., 
2011b; Baker et al., 2011). Briefly, DNA from the RNAi libraries were PCR 
amplified (19-22 cycles, 95 ◦C for 30 s, 57 ◦C for 30 s and 72 ◦C for 130 s; 0.5 μg 
of substrate DNA) using upstream primer (LIB2f 5’- TAGCCCCTCGAGGGCCAGT’-3) 
which includes RNAi vector tagged sequence and downstream primer (LIB2r 5’-
GGAATTCGATATCAAGCTTGGC’-3). Band sizes of ~150-300 bp of both WT s427 
and resistant clones were excised, shredded, DNA extracted and indexed 
together. WT s427 showed no PCR amplification due to the absence of vectors. 
Adapters were ligated to the ends of the libraries after which the libraries were 
amplified and quantified. Paired-end sequencing was performed on illumina 
Genome Analyzer II. Reads from the illumina sequencing were firstly trimmed of 
adapters and RNAi-vector junctions   and then mapped to the T. brucei 927 
genome (Berriman et al., 2005) obtained from TryTripDB 
(http://tritrypdb.org/tritrypdb/) using Bowtie (Langmead et al., 2009) to obtain 
coverage, uniqueness of plot, read counts and alignment score. This was 
followed by normalization of CDS using DEGseq R to the control. Data analysis 
was performed by Dr Jon Wilkes (Wellcome Trust Centre for Molecular 
Parasitology, University of Glasgow, UK). 
 
2.4.1.2 Co-Immunoprecipitation (Co-IP) and Mass Spectrometry (MS) 
Peptide antigens were designed for CARP1 (N-DREKGKRRIKENSKAC-C), CARP2 (N-
DYFHRRKRLTPRRTD-C) and CARP3 (N-QSNMSEESGGEGGDTN-C) and antibody 
raised against them in rabbits (by Eurogentec, Belgium). Out of these three anti-
CARP antibodies, only CARP3 gives the right Molecular Weight and size in 
Western blotting and thus was considered specific enough for pull-down studies 
with CARP3. However, anti-CARP1 and 2 were thus used in a tandem pull-down 
assay as controls instead of beads to provide a much stronger filter for CARP3 
specific pull-down proteins.  
 
A total of 2.5 X 108 log-phase of each of CARP1oe, CARP2oe and CARP3oe and WT 
s427 T. brucei cells growing in HMI-9 were pelleted, washed with PBS and 
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immediately frozen at -800C until ready for Co-IP. Cells were resuspended in 500 
μl ice cold IP Lysis/wash Buffer (0.025mL Tris, 0.15M NaCl, 0.001M EDTA, 1% NP-
40, 5% glycerol; pH7.4) as previously described (Paterou et al., 2006) and 
incubated on ice for 5 min with periodic mixing. Supernatant was separated from 
cell debris at 13,000 x g for 10 min according to manufactures protocol (Pierce® 
Crosslink Immunoprecipitation Kit, Thermo Scientific, Illinois, USA). Protein 
concentrations were determined using the Nanodrop (Thermo Scientific®). CARP3 
antibody as well as non-specific CARP1 and CARP2 (150 μg) were coupled to 
protein agarose resin and then crosslinked with disuccinimidyl suberate (DSS). 
Protein lysates were immunoprecipitated on the resin-bound and crosslinked 
CARP antibodies for 2 h at 40C followed by three steps of washing with IP 
Lysis/Wash buffer and elution of bond antigens. Eluates were quantified on 
nanodrop and prepared for MS. The FASP protein digestion kit (FASP™ Protein 
Digestion Kit; Expedeon, Cambridgeshire) was used to prepare samples following 
manufacturer’s protocol for MS analysis. Briefly, gel free eluate was added to 
spin columns together with urea sample solution and centrifuge at 14000 x g 12 
mins, repeated twice. This was followed by 10 X Iodoacetamide solutions with 
urea and 30 min incubation in the dark. The spin column is washed with Urea 
Sample Solution followed by 100 μl of 50 mM Bicarbonate solution. Trypsin digest 
was performed overnight at 370C after which samples were acidified with 
Triflouroacetic acid (TFA) followed by drying in 96 well plates in a vacuum 
chamber. Samples were sent to Glasgow Polyomics Centre were it was loaded 
into MS Instrument for amaZon speed ETD Ion Trap mass spectrometer with 
UltiMate™ 3000 RSLC nanoseparation system: <200ppm (external); <200ppm 
(internal): for High-sensitivity protein identification. Three independent co-
immunoprecipitations and MS analysis were carried out for CARP3 and CARP1 and 
once for CARP2 overexpressing cells. MS/MS data were firstly converted into mgf 
file which were then searched against T. brucei predicted proteome 
(Trypan.Brucei_PEP 20070228 (10409 sequences; 5108677 residues)) data using 
the mascot search algorithm (Mascot Science). Fixed modification was set as 
carbamidomethyl (C), variable modifications of oxidation (M) as previously 
described (Adung'a et al., 2013). Missed cleavage was set at 1. Both Peptide Mass 
and Fragment Mass Tolerance were set at ±0.4 Da. Expectation value was set at 
0.05 and used as a cut off.  
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One of the hits from RIT-seq and Co-IP, an adenylate cyclase (Tb927.4.4460; 
GRESAG4.4) was thought to be important and potentially involved in cAMP 
regulation through a feedback loop. To confirm that, already prepared cDNA 
from CARP3oe and WT s427 in HMI-9 only, 0 h (no CpdA) and in CpdA (6 h) used in 
gene expression in CpdA and freshly prepared cDNA of CARP3-/- were used in a 
qRT-PCR assay using GRESAG4.4 primers and endogenous GPI8 primers as 
previously described. Gene expression was performed independently on at least 
three occasions. 
 
2.4.2.3 Ribonucleic Acid Sequencing (RNA-Seq) 
To compare gene expression of CARP3oe, R0.8 and WT s427, 5 flasks each of the 
individual cell lines were inoculated from a single growing flask O/N. A total of 5 
x 106 log-phase trypanosomes were pelleted from each flask, RNA extracted as 
previously described using RNeasy kit (Machery-Nagel®) and quantified on the 
nanodrop. Three out of the 5 RNA samples of each cell type was sent to the 
Glasgow Polyomics for RNA-Seq. Library preparation and further sample 
preparation was performed using the TrueSeq® Stranded mRNA Sample Prep Kit 
(Illumina) as previously described (Kolev et al., 2010; Siegel et al., 2010b). 
Briefly, mRNA samples were purified using poly-T oligo attached magnetic beads 
and fragmented in preparation for cDNA synthesis. Reverse transcription and 
random primers were used to synthesis first stranded cDNA. A double cDNA 
strand was generated through the synthesis of a second strand by removing the 
last RNA and replacing dUTP with dTTP followed by adenylation of the 3’ end to 
prevent self-ligation. Adapters were added to the ends of the cDNA after which 
they were enriched through PCR amplification of only adaptor ligated cDNA. The 
library preps were validated, quantified and checked for quality using Agilent 
Technology 2100 Bioanalyzer (Life Technologies®). The preps were then paired-
end sequenced on NextSeq™ 500 (2x150bp). The quality of paired-end reads from 
the sequencer were firstly checked with FastQC and then trimmed of library 
adaptors with Tophat followed by mapping to the trypanosome genome 
(http://tritrypdb.org/common/downloads/release-8.1/TbruceiTREU927/) using 
Bowtie (Archer et al., 2011; Kolev et al., 2010; Langmead et al., 2009). The 
mapped reads were then assembled into sets of transcripts and their relative 
abundance estimated using Cufflinks. Cuffdiff is then performed to determine 
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log2-fold differential expression in the transcripts between the test sample 
(CARP3oe and R0.8) against the control. RNAseq data analysis was performed by 
Graham Hamilton of the Glasgow Polyomics, University of Glasgow, Glasgow, UK. 
Significant log2-fold expression was set at P-value 0.05. Of the significantly 
expressed genes, 0.5 and 0.75 log2-fold difference were used as cut-offs for s427 
CARP3oe and WT s427 and R0.8 CARP3oe and R0.8 respectively. TIBCO® Spotfire® 
Desktop 7.0.0 (Boston, MA) was used for visualization. 
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Chapter 3 
Deletion of alleles of CARP1-4 and its effects on 
sensitivity, growth and cyclic AMP levels 
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3.0 Deletion of alleles of CARP1-4 and its effects on 
sensitivity, growth, cAMP and protein levels of 
CARP3 
In order to investigate whether the CARP proteins are essential for Trypanosoma 
brucei bloodstream forms, knockout constructs with three antibiotic selectable 
cassettes (hygromycin, blasticidn and neomycin) were made for CARP1-4 and 
transfected for the generation of CARP1-4+/-. Additional transfection with 
alternate antibiotics of the CARP1-4+/- yielded CARP2-4-/-. Attempts were made 
to obtain a double gene deletion for CARP1 but no viable clones were obtained. 
Although three clones were selected for each selectable marker and gene, only 
one clone of one selectable maker was used for downstream experimental assays 
after confirmation of both single and double gene deletions. 
 
3.1.0 Evidence of gene deletion of CARP1-4 
After transfections and selection, gene deletion and antibiotic integration was 
confirmed using PCR, qRT-PCR and restriction digest Southern blotting. All of 
these techniques together ensure that the experiment was successful allowing 
for the study of downstream effect of the loss of these genes in trypanosomes. 
 
3.1.1 PCR evidence of plasmid integration of sKO and dKO CARP cell lines  
Primers that bind pre 5’ UTR and reverse of antibiotic cassette and post 3’ UTR 
and forward of antibiotic cassette were used to check for correct integration of 
the knockout vector (refer to Figure 2.2 for construct design and primer 
positions). The PCR product of CARP1-4+/-, CARP2-3-/- and WT s427 were run on a 
1% gel. Single and double gene deleted CARP cells showed bands of the right 
sizes indicative of correct vector integration for both 5′ UTR (F) and 3′ UTR (R) 
and presence of antibiotic cassettes compared with WT s427 (Figure 3.1). The 
bands visible for WT s427 PCR in Figure 3.1C, were a result of unspecific primer 
products and does not correspond to the expected sizes of ~1.5-1.8 kb for 
blasticidin and ~2.0-2.5 kb for neomycin integrations. 
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3.1.2 Reduced messenger RNA expression of single deleted CARP1-4 genes 
in trypanosome cells 
To further confirm CARP1-4 single allele gene deletion, RNA was extracted from 
the generated cells and converted into cDNA using reverse transcriptase for qRT-
PCR analysis of gene expression. All four genes showed significant reductions in 
gene expression compared with WT s427 cells. Expression of CARP1 was reduced 
by almost 50% whilst CARP2 expression only decreased by approximately 20% 
(Figure 3.2).  
 
 
 
 
Figure 3.1: PCR evidence of plasmid integration and antibiotic gene replacement. A) Single 
gene deletion confirmation PCR using primers pre 5’UTR of each gene of CARP1-4 and 
reverse primer of antibiotic and post 3’ UTR and forward of antibiotic cassette. B-D) Double 
gene deletion of CARP2-4 (CARP2-/-, CARP3-/- and CARP4-/-) using same primers as before 
and for both antibiotic integration as well as UTR’s into antibiotics. F, forward primer; R, 
reverse primer, B, blasticidin; N, neomycin); M, maker (refer to Figure 2.2 for construct 
design and primer positions). 
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Figure 3.2: Quantitative Reverse Transcriptase PCR (qRT-PCR) of sKO CARP1-4 cells. RNA 
was extracted from each single gene deleted CARP cell line, reverse transcribed into cDNA 
and used for qRT-PCR. All single gene deleted cell lines showed significant fold reduction 
in transcript levels. Error bars show ± standard error. T-test single-tailed, unpaired (* p>0.05, 
** p>0.01, *** p>0.001; n=3).  
 
 
 
3.1.3 Southern Blot confirmation of double gene deletion 
Double gene deletions of CARP2-4 (dKO) were confirmed using Restriction digest 
Southern blotting. DNA from CARP2-3-/- were digested using EcoRI and SacII and 
XhoI to yield specific size fragments. Genomic DNA of CARP4-/- was digested 
using EcoRV and XhoI restriction enzymes. These were then probed with 
restriction digest (ApaI and BamHI) excised open reading frames of CARP2-4. 
When ran on agarose gel, the digests produced a smear of DNA whilst the blots 
showed specific bands for WT s427 for CARP2-4, sKO CARP2 and CARP4. sKO 
CARP3 showed 2 bands which is due to the presence of additional EcoRI 
restriction sites in the resistant cassette present in the sKO cell line.  sKO CARP4 
showed a drop in band size due to the presence of an additional XhoI site in the 
sKO construct. There were no bands for CARP2-/-, CARP3-/- and CARP4-/- 
confirming double gene deletion (Figure 3.3). 
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Figure 3.3: Restriction digest and Southern blot confirmation of dKO CARP2-4 cells. A) 
Restriction digest of CARP2 using EcoRI and SacII showing fragment binding size. B) 
Restriction digest of CARP3 using EcoRI and XhoI showing possible fragment sizes. C) 
Restriction digest of CARP4 using EcoRV and XhoI showing possible fragment sizes. D) 
Shows a band for WT s427, CARP2+/- (2.8 kb) and no band for CARP2-/-. E) Shows a band for 
WT s427 (7 kb) dual bands for CARP3+/- (7 and 5.5) kb and no band for CARP3-/- . F) Shows a 
band for WT s427 (5.5 kb), CARP4+/- (4) kb and no band for CARP4-/-. 
 
 
3.1.4.1 Effect of CARP3 gene deletions and CpdA on protein levels of 
CARP3+/- 
Western blotting was performed to confirm presence (WT s427), decrease 
(CARP3+/-) and loss of protein (CARP3-/-). The effect of CpdA on protein levels of 
CARP3+/- was investigated by keeping the cells under pressure with periodic 
sampling for protein analysis by Western blotting. There was a noticeable 
reduction in protein levels of CARP3+/- after 6 h and 24 h under CpdA pressure. 
At 48 h, protein levels have returned to pre-incubation level. WT s427 CARP3 
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protein levels remained significantly low over the period of incubation (Figure 
3.4). 
 
Figure 3.4: Western blot confirmation of CARP3 protein levels in genetically manipulated 
CARP3 cell lines. A-B) Western blot and image quantification of WT s427, CARP3+/- and 
CARP3-/-. C) Protein levels of CARP3+/- over 48 h. D) CARP3 levels in WT s427 over 48 h. E. 
quantification of C. F, quantification of panel D. Quantification was normalized to 
constitutively expressed EFI-α. 
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3.3.0 Effect of CARP1-4 gene knockouts on CpdA 
sensitivity 
The alamar blue drug sensitivity assay was used to determine the effect of a 
single CARP gene deletion on CpdA sensitivity. CARP1-4+/-, CARP2-4-/- and control 
WT s427 cells were added to serially diluted wells of CpdA and pentamidine in a 
96 well plate. Viable cells after 48 h will convert alamar blue dye to the 
fluorescent metabolite (convert resazurin to the fluorescent resorufin) which 
will be measured in a fluorimeter after 24 h incubation. A sigmoid curve of 
fluorescence intensities gives the EC50 value. All 4 single CARP gene deleted cells 
displayed significantly reduced susceptibility to CpdA. Double gene deleted 
CARP2-4-/- showed a further reduction in CpdA susceptibility ranging from ~3-
fold reduction (CARP3-/- and 4-/-) to approximately 17-fold (CARP2-/-). Both sKO 
and dKO Cells of CARP2 and CARP3 also showed a significantly increased 
susceptibility to pentamidine (Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Alamar blue drug sensitivity assay of sKO CARP1-4 and dKO CARP2-4 using 
CpdA and Pentamidine. A) and C) CpdA. B) and D) Pentamidine. Error bars show ± standard 
error. T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** p>0.001; n>4). 
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3.4.0 Effect of CARP1-4 gene deletions on cell 
proliferation in the presence and absence of CpdA  
A cell proliferation assay was used to determine the effect of gene deletion on 
cell growth compared with WT s427 in a cumulative log phase growth curve with 
cells continuously grown in the presence or absence of CpdA. Cells were passage 
back to starting concentrations into fresh media with and without CpdA every 48 
h.  There were no differences in growth rates of single CARP gene deleted cells 
compared with WT s427 cells without and with CpdA. Both slopes and intercept 
were not significantly different nor were the mean cell counts at individual time 
points. Strains with double gene deletions of CARP3-/- and CARP4-/- followed 
similar trends as single allele deleted cells with and without CpdA. However, 
CARP2-/- showed a significant growth delay (p=0.0201) resulting in differences in 
slope and intercept for growth without CpdA. However, growth rates were 
identical in the presence of CpdA (Figure 3.6). 
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Figure 3.6: Cell proliferation assay of gene deleted CARP cells in the presence and absence 
of CpdA. Each generated cell and control were seeded (2 x104) in duplicates, counted every 
24 h and passaged back to seeding concentration without or with same concentration of 
CpdA every 48 h. A), C), E), G) and K) show cumulative growth of the respective cells 
without CpdA whilst B), D), H), J) and L) show same cells grown in 100 nM CpdA.  Growth 
curve was repeated independently on 3 occasions. Graph show cumulative average cell 
counts of all 3 experimental replicates. 
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3.5.0 Cyclic AMP levels in gene deleted CARP1-4 cells 
The effect of gene deletion on cAMP was determined by incubating sKO and dKO 
CARP cells in 300 nM CpdA for 3 h. Both intracellular and extracellular cAMP 
levels were measured pre and post incubation in CpdA. 
 
3.5.1 Intracellular cAMP levels in sKO and dKO CARP cells  
Single CARP gene deletion did not significantly increase intracellular cAMP levels 
without and with CpdA compared with WT s427. However, as expected, CpdA 
inhibiting TbPDEB1 causes a general significant increase in intracellular cAMP 
levels in both the sKO and WT cells (Figure 3.7A). Double gene deletion in CARP2 
however resulted in a significant increase in intracellular cAMP levels both in the 
absence (~3-fold) and presence of CpdA (~3-fold) in comparison with WT s427 
cells. Cyclic AMP levels also significantly increased in dKO CARP3 cells without 
CpdA (~4-fold) and with CpdA (~2-fold). Cyclic AMP levels only increased slightly 
(~1.3-fold) in the addition of CpdA to dKO CARP4 cells (Figure 3.7B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Intracellular Cyclic AMP measurements in sKO CARP1-4 and dKO CARP 2-3 
cells. Each generated cell and control were divided into 2, either without or with 300 nM and 
incubated for 3 h. 5 x106 from each cell type and control were pelleted and processed for 
cAMP measurement (ELISA). A) cAMP levels in CARP1-4+/- cells in the absence and 
presence of CpdA was not different from WT s427. B) cAMP levels in CARP2-4-/- cells in the 
absence and presence of CpdA was significantly different from Wt s427. Error bars show ± 
standard error. T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** p>0.001; n=3-5) 
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3.5.2 Extracellular cAMP levels in sKO and dKO CARP cells  
Extracellular cAMP levels in single gene deleted CARP1-4 cells were similar to 
WT s427 showing a similar trend as that of intracellular cAMP in the same cell 
lines. CpdA however increased extracellular cAMP within the same cell lines 
(Figure 3.8A). Double knockout CARP2-4 cells displayed significantly increased 
extracellular cAMP relative to the WT control both without (~2.5-fold) and with 
CpdA (~1.5-fold) (Figure 3.8B).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Extracellular Cyclic AMP measurements in sKO CARP1-4 and dKO CARP 2-3 
cells. Each generated cell and control were divided into 2, either without or with 300 nM and 
incubated for 3 h. 5 x106 from each cell type and control were pelleted and the incubating 
media used for cAMP measurement (ELISA). A) Single gene deletion of CARP1-4 did not 
result in any significant differences in cAMP levels without and with CpdA compared with 
WT s427. CpdA significantly increased cAMP levels within the same cell line. B) Deletion of 
both allele of CARP2-4 causes significant increases in cAMP levels without and with CpdA 
when compared to WT s427. Error bars show ± standard error. T-test single-tailed, unpaired 
(* p>0.05, ** p>0.01, *** p>0.001; n=3-5) 
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3.6.0 Discussion 
The phosphodiesterase inhibitor , CpdA has been reported to have trypanocidal 
activity in the range of 30-70 nM which is similar in activity to suramin and 
diminazene, and ≥10-fold more active than nifurtimox with similar potencies 
against clinical and veterinary resistant cell lines as against  wild-type T. brucei 
cell lines (de Koning et al., 2012). CpdA (1 µM) causes a strong increase in 
intracellular cAMP after 3 h incubation compared with low-potency PDE 
inhibitors such as dipyridamole (40 µM) and etazolate (100 µM) which did not 
significantly affect cAMP concentrations. CpdA had an immediate and time and 
dose dependent effect on cellular cAMP levels although cell lysis and death only 
occurred after 15 h, even at a concentration of 3 µM (de Koning et al., 2012). 
Recently, a genome-scale RNAi library screen of resistance to CpdA revealed 
four distinct genes that were knocked down. These genes were designated cAMP 
Response Protein (CARP) 1-4. RNAi against CARP1-4 resulted in significant 
increases in resistance to CpdA but no cross resistance to other trypanocides 
(Gould et al., 2013). Thus CARP1-4 represents the first downstream effectors of 
cAMP signalling in T. Brucei. However, there was the further need to understand 
how these effectors act to bring about cellular regulation such as control of 
cAMP levels and the phenotype of cytokinesis inhibition. The question as to 
whether these effectors act individually or as a complex, and whether there is a 
“single” most important effector is very important in the understanding of the 
parasite’s cell biology and the answers may provide trypanosome- specific cAMP-
dependent therapeutic targets. 
 
Results of drug sensitivity of CpdA on sKO CARP1-4 confirmed both the CARPs as 
well as the RNAi knockdown observed previously. RNAi knockdown and single 
gene deletion did not affect normal cell growth. The sequential increase in 
resistance to CpdA in the dKO CARP2-3 further showed the importance of these 
proteins as downstream effectors of cAMP signalling. The inability to delete both 
genes of CARP1 likely indicates that this protein is essential in bloodstream 
forms. CARP1 codes for a 705-amino-acid protein containing two apparently 
intact and one partial cyclic AMP binding domains that are conserved in synteny 
in each of the kinetoplastid genomes sequenced. Recently, it has been shown 
that the orthologue of CARP1 in T. cruzi TcCLB.508523.80 binds to cyclic 
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nucleotides, using cAMP and cGMP displacement assays (Jäger et al., 2014) 
further validating the role of CARP1 as a downstream cAMP signalling effector. 
Thus it is expected that cAMP produced from CpdA inhibition of TbPDEB1 will 
mostly likely firstly bind to CARP1 after which it will cascade down the signalling 
pathway. Thus the absence of CARP1 will results in an important break point in 
the signalling pathway and, judging by the inability to create a double knockout, 
seems to result in cell death. 
 
The significant increase in both intracellular and extracellular basal and CpdA-
induced cAMP levels of the dKO cells demonstrates the effect these proteins 
have on cAMP levels in the cells. The increase in cAMP shows that the proteins 
are important in direct regulation since their absence could result in increased 
accumulation of cAMP within the cell, compensating for the lack of effectors to 
transmit the cAMP signal. The cells similarly extrude more cAMP at a higher 
production level, to maintain physiological balance which is likely to be ATP-
dependent similar to what occurs in mammals.  
 
Single gene deletion of CARPs did not affect the growth rate of trypanosomes in 
standard culture. Similarly, cell proliferation of single KO CARP1-4 cells in 
continuous culture with CpdA 100 nM (2/3 EC50) of WT s427 was unaffected. This 
was expected since gene knockout significantly increased resistance to CpdA in 
sKO cells compared with WT s427.  However, dKO CARP2 showed a significant 
delay in growth in the absence of CpdA an observation similar to that seen in the 
CpdA-resistance cell line R0.8. Thus the growth phenotype might be linked to 
the significant increase in resistance to CpdA (17-fold). Additionally, CARP2 is 
annotated as a conserved protein detected in the flagellar proteome, implying a 
possible flagellar function. The flagellum has increasingly been shown to have 
important roles in determining cell shape, size as well as the fact that the 
regulation of its formation governs the morphological transitions that define T. 
brucei development (Langousis and Hill, 2014). Additionally, the role and 
importance of cAMP in flagellar motility and signalling is increasingly being 
dissected with interesting findings. For example it is commonly believed that the 
flagellum, as an important host-parasite interface, plays essential sensory 
functions (Rotureau et al., 2009; Tetley and Vickerman, 1985). For example in C. 
reinhardtii, triggering of zygote formation is initiated by a cAMP signalling 
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response, as a result of flagellum adhesion in gametes (Pan and Snell, 2000). 
Recently, it has been shown (either by increasing  cAMP through the inhibiting 
TbPDEB1 or using CpdA) that cAMP regulates social motility in T. brucei 
(Oberholzer et al., 2015). This is similar to social motility observations in 
Dictyostelium discoideum where cAMP signalling is critical for surface motility 
(Firtel and Meili, 2000). Thus it is possible that CARP2 plays a very important 
role in regulating flagellar activity which in turn then affects cell survival hence 
the delayed defect in growth observed.   
 
Double gene deleted CARP3 showed a minimal growth delay whilst dKO CARP4 
also grew similar to WT s427. CARP3 and CARP4 dKO cell lines however, showed 
slightly better growth in CpdA whilst growth of dKO CARP2 was similar to WT 
s427. CpdA causes significant decrease in protein levels of CARP3+/- and in WT 
s427 cells. As significant reductions in mRNA levels of CARP3, using RNAi, has 
previously identified CARP3 as one of downstream effectors of cAMP (de Koning 
et al., 2012),  it is not unexpected that WT s427 trypanosomes reduce the levels 
of this protein to minimise cAMP signal transmission in the presence of CpdA.  
We interpret the observations that CARP3 may directly influence cAMP 
production in trypanosomes, as well as mediate (part of) the signal transduction 
from cAMP to the ultimate cellular effect, as CARP3 having a regulatory role in 
modulating the (effects of) this signalling cascade. This is further explored in the 
chapters below. 
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Chapter 4 
Over-expression of CARP1-4 and TbPDEB1 genes 
and its effects on CpdA sensitivity, cell 
proliferation, cAMP levels and localization 
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4.0 Over-expression of CARP1-4 and TbPDEB1 genes and 
its effects on CpdA sensitivity, cell proliferation, 
cAMP levels and localization. 
RNAi Knockdown of the CARPs resulted in reduced susceptibility to CpdA (Gould 
et al., 2013) confirming their role as downstream effectors of cAMP. This raised 
the question of the possibility of a reverse effect when these proteins are 
overexpressed. This will allow a correlation of mRNA and/or protein levels to 
any observable phenotype seen when the overexpressing cells were challenged 
with CpdA in comparison with WT s427. Finally, to relate function to location, 
immunofluorescence was performed on tagged and untagged overexpressing 
CARP1-3 genes expressed in WT s427 T. brucei cells. 
 
WT s427 and CpdA resistant (R0.8) cells were transfected with overexpressing 
constructs of CARP1-4 and TbPDEB1 to overexpress the desired genes. Three 
colonies each were selected after transfection, confirmed by PCR and assayed 
for mRNA expression. One out of the three was then selected for further 
downstream assays such as drug sensitivity, growth curves, mRNA and protein 
level expressions etc. Three of the proteins were N-terminally GFP-tagged and 
transfected into an inducible cell line for IFA. Anti-CARP3 antibody was also used 
for immuno-fluorescence of CARP3oe.  
 
4.1.1 PCR evidence of plasmid integration of CARP1-4 and 
TbPDEB1 in WT s427 and R0.8 cells 
PCR was performed on both transfected clones of WT s427 and R0.8 using 
primers binding to a region on the plasmid pre-start MB0274 (5′-
TTGAAGACTTCAATTACACC-3′) codon of the ORF of each gene and the middle of 
the blasticidin resistant gene HDK0035 (5′-ATGCAGATCGAGAAGCACCT-3′) in 
pHD1336. Similar PCR was performed for pRPaGFP transfected lines using primers 
binding to the pre-start codon of the N-terminal GFP MB0274 (5′-
TTGAAGACTTCAATTACACC-3′) and the middle of the T. brucei aldolase mRNA 
processing 3′, MB0302 (5′-TAACCAACCTGCAGGCG-3′). The results showed 
presence of plasmid (indicated by gene sizes plus additional bases into the 
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resistant gene) in transfected overexpressing and tagged cell lines which are not 
present in the control cell lines of WT s427 and R0.8 (Figure 4.1). 
 
 
Figure 4.1: PCR confirmation of plasmid integration into genome of CARP1-4 and TbPDEB1 
of WT s427 and CpdA resistant (R0.8) cells as well as N-terminal GFP tagged into 2TI cells. 
A-B) PCR was performed using plasmid primer flanking the start codon of the respective 
ORFs and the reverse of blasticidin antibiotic cassette for both WT s427 and R0.8. Band 
sizes correspond to sizes of the respective genes plus plasmid regions and indicative of 
plasmid (pHD1336) integration. None transfected WT s427 and R0.8 have no bands. C) PCR 
was performed as described in A and B but using reverse of hygromycin which is the 
resistant cassette in the pRPa plasmid. Upper band sizes correspond to respective gene 
sizes and lower bands are GFP amplification. 
 
 
4.1.2 Increased Messenger RNA expression of CARP1-4 and 
TbPDEB1 in WT s427 and R0.8 cells 
To verify that the CARPs and TbPDEB1 genes were being overexpressed above 
wild type levels (WT s427 and R0.8), primers were designed and qRT-PCR 
performed to determine expression levels normalized to the constitutively 
expressed internal control (GPI8). In both transfected WT s427 CARP1-4 and 
TbPDEB1 as well as R0.8 CARP1-4 and TbPDEB1, the genes showed significant 
fold increases in mRNA levels. In WT s427 cells overexpressing CARPs, CARP2 and 
CARP4 showed almost 2.5-fold increase expression above wild type levels. CARP3 
was the highest expressed CARP in R0.8 (~4-fold) greater than base level 
expression. TbPDEB1 was ~3-fold and ~7-fold overexpressed above WT s427 and 
R0.8 levels (Figure 4.2).  
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Figure 4.2: Quantitative RT-PCR confirmation of CARP1-4 and TbPDEB1 overexpression in 
WT s427 and R0.8 cells. RNA was extracted from log phase overexpressing CARP cells, 
reverse transcribed into cDNA and used for qRT-PCR. A) s427CARP1-4oe against WT s427. 
B) R0.8 CARP1-4oe against R0.8. C) WT s427 TbPDEB1oe and R0.8 TbPDEB1oe against WT 
s427 and R0.8 respectively. Expression levels of genes in both genetically manipulated cells 
and wild type/R0.8 strains were normalized to an internal control (GPI8). All CARPs and 
TbPDEB1 were overexpressed in both WT s427 and R0.8. Error bars show ± standard error. 
T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** p>0.001; n=3-6) 
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4.1.3 Increased level of CARP3 Protein in overexpressing cells in 
WT s427 and R0.8 cells 
Western blotting was performed using the available anti-CARP3 antibody on 
CARP3oe cells. Results (normalized to the loading control, EFI- α) showed a 
noticeable increase in CARP3 protein levels in both the WT s427 and the CpdA-
resistant strain R0.8 overexpressing CARP3 compared with WT s427 and R0.8 
controls confirming mRNA expression data as well as the effectiveness of 
pHD1336 as an overexpressing plasmid (Figure 4.3). However, it must be noted 
that the level of overexpression in the WT cells was relatively low, especially as 
this vector is known for a robust overexpression level (Biebinger et al., 1997). 
This appears to indicate that a much higher level of CARP3 is deleterious to the 
cell, and/or that CARP3 expression is under tight control. The protein 
overexpression levels in the WT and R0.8 strains appear to follow the observed 
mRNA levels (Figure 4.2) closely. 
 
 
4.2.0 Effect of CpdA on transcript (mRNA) and protein 
levels of generated lines 
To investigate how CpdA affects the increased levels of CARP genes and 
TbPDEB1, overexpressing cells were cultured in 100 nM and 3 μM CpdA for WT 
s427 and R0.8 respectively. Cells were separated for mRNA extraction, cDNA 
generation and qRT-PCR analysis at specific time points. For CARP3oe cells, 
protein was extracted at the same time points for Western blotting analysis. 
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Figure 4.3: Western blotting and image quantification of CARP3 protein levels in WT s427 
and R0.8 cells. Western blotting A) and image quantification B) of s427 CARP3oe and WT 
s427. Western blotting C) and image quantification D) of R0.8 CARP3oe and R0.8. Image 
quantification based on band intensity was performed with LiCOR software with images 
normalized to EFI- α (loading control). Band intensities indicate a noticeable difference in 
CARP3 protein expression in both WT s427 CARP3oe and R0.8 CARP3oe compared with WT 
s427 and R0.8 respectively.  
 
 
4.2.1 CpdA effect on transcript levels of CARP1-4 and TbPDEB1 
overexpressing cells in WT s427 and R0.8  
The effect of CpdA on gene expression of CARP1-4 and TbPDEB1 was investigated 
using qRT-PCR of cDNA generated from cells incubated in CpdA for 6 h, 24 h and 
48 h. 100 nM of CpdA was used for genes overexpressing in s427 whilst 3 μM of 
CpdA was used for genes in R0.8 cells. Expression levels were normalized to 
levels without CpdA incubation (0 h).  
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CpdA (100 nM) significantly reduced expression of genes of CARP1-4 in WT s427 
cells overexpressing these genes after 6 h incubation and these levels remained 
significantly decreased at 48 h in the same concentration of CpdA and below WT 
s427 level. Variable changes occur when the same genes were assayed in just the 
WT s427 under the same condition: only CARP2 and CARP3 levels of mRNA in WT 
s427 decreased significantly below that seen before addition of CpdA over the 
period of incubation. There were no changes in mRNA levels in CARP4 whilst 
after an initial 6 h decrease in CARP1 the levels returned to that of pre-
incubation with CpdA at 24 h and 48 h (Figure 4.4).  The effect of CpdA on PDEB 
expression is depicted in Figure 4.6. It shows that the overexpression of TbPDEB1 
in WT cells is also reversed by CpdA treatment, up to 48 h, whereas in the 
untransformed controls, expression was only reduced at the 6-h point. 
 
In R0.8 CARP1-4 and TbPDEB1 overexpressing cell lines, the trend was reversed 
except in CARP3 and TbPDEB1. Overexpressing CARP1, CARP2 and CARP4 in R0.8, 
resulted in increases in their mRNA levels after incubation in 3 μM CpdA from 6-
48 h. However, levels of CARP3 and TbPDEB1 decreased significantly after 6 h in 
CpdA and remained steadily below non-overexpressing R0.8 levels over the 
incubation period. Messenger RNA levels of CARP3 in non-overexpressing R0.8 
cells remained unchanged in the presence of CpdA whereas that of CARP1, 
CARP2, CARP4 and TbPDEB1 increased significantly after 6 h in CpdA, remaining 
steadily high at 48 h except TbPDEB1 which dropped significantly after 48 h 
(Figure 4.5).     
 
TbPDEB1 levels decreased significantly in both WT s427 and R0.8 overexpressing 
cells after 6 h in CpdA and remained at that level 48 h after incubation. Non-
transfected WT s427 levels of TbPDEB1 dropped significant 6 h after incubation 
but returned to pre-incubation levels from 24-48 h in CpdA whilst TbPDBE1 in 
R0.8 cells increased significantly from 6 h and at 48 h remains at levels higher 
than pre-incubation in CpdA (Figure 4.6).  
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Figure 4.4: Quantitative RT-PCR of WT s427 overexpressing CARP1-4  and CARP1-4 
expression in WT s427 in 100 nM CpdA at 0 h, 6-48 h of incubation. RNA was extracted from 
each single gene deleted CARP cell line under each condition, reverse transcribed into 
cDNA and used for qRT-PCR. CARP1-4oe in WT s427 A), C), E) and G). Expression of CARP1-
4: B), D) F) and H) in non-transfected WT s427. All overexpressed cell lines showed 
significant decrease in mRNA levels in CpdA from 6-48 h. Error bars show ± standard error. 
ANOVA, Tukey’s Multiple Comparison Test, (* p>0.05, ** p>0.01, *** p>0.001; n=3). 
 
0 h 6 h 24 h 48 h
0
2
4
6
8
10
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
*
*
*
0 h 6 h 24 h 48 h
0.0
0.5
1.0
1.5
2.0
*
**
0 h 6 h 24 h 48 h
0
2
4
6
8
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
***
**
**
0 h 6 h 24 h 48 h
0.0
0.5
1.0
1.5
2.0
**
*
**
*
0 h 6 h 24 h 48 h
0
1
2
3
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
***
***
***
0 h 6 h 24 h 48 h
0.0
0.5
1.0
1.5
2.0
***
***
***
*** **
*
0 h 6 h 24 h 48 h
0
2
4
6
8
10
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
*
**
*
0 h 6 h 24 h 48 h
0.0
0.5
1.0
1.5
2.0
A B 
C D 
E F 
G H 
Daniel N.A Tagoe  Chapter 4, 115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Quantitative RT-PCR of R0.8 overexpression CARP1-4 and CARP1-4 expression 
in R0.8 in 3 μM CpdA at 0 h, 6-48 h of incubation. RNA was extracted from each single gene 
deleted CARP cell line under each condition, reverse transcribed into cDNA and used for 
qRT-PCR. CARP1-4oe in R0.8: A), C), E) and G). Expression of CARP1-4: B), D) F) and H) in 
non-transfected WT s427. Only cells overexpressing CARP3 showed decrease mRNA levels 
under CpdA pressure whilst CARP3 levels in untransfected R0.8 remains largely unchanged 
over incubation period. Error bars show ± standard error. ANOVA, Tukey’s Multiple 
Comparison Test (* p>0.05, ** p>0.01, *** p>0.001; n=3). 
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Figure 4.6: Quantitative RT-PCR of TbPDEB1 overexpression and TbPDEB1 expressions in 
WT s427 and R0.8 in 100 nM and 3 μM CpdA 0 h, 6-48 h of incubation. Overexpressing 
TbPDEB1 in WT s427 A), and TbPDEB1 expression in untransfected WT s427. B). 
Overexpressing TbPDEB1 C) in R0.8 and TbPDEB1 expression D) in untransfected R0.8. 
Error bars show ± standard error. Both WT s427 and R0.8 overexpressing TbPDEB1 showed 
decreased mRNA levels in CpdA. ANOVA, Tukey’s Multiple Comparison Test (* p>0.05, ** 
p>0.01, *** p>0.001; n=3) 
 
 
4.2.2 Effect of CpdA on Protein levels of CARP3oe in WT s427 and 
R0.8. 
Using the commercially manufactured antibody to CARP3, an attempt was made 
to correlate mRNA levels of CARP3 overexpression WT s427 and R0.8 to that of 
protein levels in the same cells under the same drug concentrations and 
incubation period. Cells were prepared as already described and proteins 
separated on a gel and Westerns performed using WT s427 and R0.8 as cell 
control cells and Elongation Factor 1-α (EF1-α) as loading control.  
0 h 6 h 24 h 48 h
0
1
2
3
4
5
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
***
***
***
0 h 6 h 24 h 48 h
0.0
0.5
1.0
1.5
2.0
*
*
*
0 h 6 h 24 h 48 h
0
5
10
15
***
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
***
***
0 h 6 h 24 h 48 h
0
5
10
15
*
***
* **
A B 
C D 
Daniel N.A Tagoe  Chapter 4, 117 
There was a noticeable decrease in protein levels of CARP3 when overexpressed 
in both WT s427 and R0.8 over the incubation period correlating directly with 
the observed decrease in mRNA levels observed from the qRT-PCR. The trend in 
the controls of WT s427 and R0.8 were also similar to that of the mRNA 
quantification showing a decrease in protein levels over the incubation period in 
WT s427 but a relatively unchanged protein level in R0.8 (Figure 4.7). 
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Figure 4.7: Western blotting and image quantification of CARP3 protein levels in WT s427 
and R0.8 cells overexpressing CARP3 and non-transfected control WT s427 and R0.8 cells. 
A) Western blots and B) image quantification data of s427 CARP3oe. C) Western blots and D) 
image quantification data of CARP3 in WT s427. E) Western blots and F) image 
quantification data of R0.8 CARP3oe. G) Western blots and H) image quantification data of 
CARP3 in R0.8. CpdA causes a noticeable decrease in CARP3 levels in overexpressing both 
WT s427 and R0.8 cells 
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4.3.0 Effect of CARP1-4 and TbPDEB1 overexpression in 
WT s427 and R0.8 cells on CpdA sensitivity 
The effect of increased gene expression of the CARPs and TbPDEB1 on CpdA 
sensitivity was analysed using the Alamar blue drug sensitivity assay with 
pentamidine as a control for s427 CARP1-4oe, TbPDEB1oe and WT s427 and R0.8 
CARP1-4oe, TbPDEB1oe and R0.8 respectively. Results showed a significant 
increase in sensitivity of s427CARP3oe to 100 nM CpdA compared with WT s427. A 
similar trend was observed when CARP3 was overexpressed in R0.8. There were 
no differences in sensitivity to pentamidine except in s427CARP4oe which showed 
a slight but significant decrease in susceptibility to pentamidine (Figure 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Alamar blue drug sensitivity assay of overexpressing CARP1-4 and TbPDEB1 in 
WT s427 and R0.8 cells. A) WT s427 CARP1-4oe and WT s427 in CpdA. B) WT s427 CARP1-
4oe and WT s427 in Pentamidine. C) R0.8 CARP1-4oe and R0.8 in CpdA. D) R0.8 CARP1-4oe 
and R0.8 in Pentamidine. Overexpressing CARP3 sensitizes both WT s427 and R0.8 cells to 
CpdA. Error bars show ± standard error. T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** 
p>0.001; n>3). 
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As expected overexpressing TbPDEB1 leads to a significant decrease in sensitivity 
to CpdA in both WT s427 and R0.8. There were no significant differences in 
sensitivity to pentamidine (Figure 4.9). 
 
 
 
 
 
 
Figure 4.9: Alamar blue drug sensitivity assay of overexpressing TbPDEB1 in WT s427 and 
R0.8 cells. A) WT s427 TbPDEB1oe, WT s427, R0.8 TbPDEB1oe and R0.8 in CpdA. B) WT s427 
TbPDEB1oe, WT s427, R0.8 TbPDEB1oe and R0.8 in Pentamidine. Overexpressing TbPDEB1 
significantly leads to significant increase in resistance to CpdA in both WT s427 and R0.8. 
Error bars show ± standard error.  T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** 
p>0.001; n>3). 
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4.4.0 Effect of CARP1-4 and TbPDEB1 overexpression in 
WT s427 and R0.8 cells on cell proliferation in the 
presence of CpdA. 
The possibility of overexpression of CARP1-4 and TbPDEB1 genes in WT and R0.8 
affecting the growth rate of T. brucei was determined using a growth curve in 
the presence and absence of CpdA. In a cumulative growth culture, cells were 
repeatedly passaged back to starting concentrations in order to allow growth 
over 6 days. Cells were seeded in duplicates and the experiment was repeated 
on three independent occasions.  
 
In the absence of CpdA, overexpressing of CARP1-4 in WT s427 did not cause any 
growth phenotype when compared with the control strain over the period of the 
growth curve assay (Figure 4.10). Similarly, whereas 100 nM CpdA did not affect 
the growth of WT s427 cells overexpressing CARP1, 2 and 4 compared with 
growth of control under similar condition, number of cells overexpressing CARP3 
in media with 100 nM CpdA was consistently lower than that of WT s427 cells 
over the growth period (Figure 4.10F). A similar growth pattern was observed 
when CARP1-4 was overexpressed in R0.8 (Figure 4.11). Here just as in WT s427, 
overexpressing of CARP3 only in the presence of CpdA (3 μM), caused a growth 
delay (Figure 4.11F) whereas none of the other CARPs showed any growth 
differences either in the absence of in the presence of (3 μM) CpdA.    
 
To further verify the observed growth phenotype when CARP3 is overexpressed 
in both WT s427 and R0.8 strains, the experiment was repeated for CARP1 and 
CARP3 overexpressing cells in WT s427 and R0.8 with their respective controls. 
Only this time the cells were retained in a single growth media without passage 
into fresh media over the period of the growth curve.   
 
Whereas none of the overexpressing cells showed any growth phenotypes in the 
absence of CpdA similar to the observation in the continuous growth culture 
previously described, growing s427 CARP3oe in a single growth curve causes a 
much more pronounced growth delay (Figure 4.12F) compared with its control 
and growth in the continuous passaged culture (Figure 4.10F) in the presence of 
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100 nm CpdA. Overexpressed s427 CARP1 also showed a slightly delayed growth 
effect in 100 nM CpdA (Figure 4.12B) compared with growth in the continuous 
passaged culture (Figure 4.10B). The presence of 3 μM CpdA did not affect the 
growth of R0.8 cells overexpressing CARP1 and CARP3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Cumulative cell proliferation assay of WT s427 cells overexpressing CARP1-4. 
A), C), E), and F) growth in the absence of CpdA. B), D), F) and H) growth in the presence of 
100 nM CpdA. Cells were seeded in duplicates and the experiment repeated independently 
on 3 occasions. Graph show cumulative average cell counts of all 3 replicates. 
Overexpressing CARP3 in WT s427 cells leads to growth delay in CpdA. 
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Figure 4.11: Cumulative cell proliferation assay of R0.8 cells overexpressing CARP1-4. A), 
C), E), and F) growth in the absence of CpdA. B), D), F) and H) growth in the presence of 100 
nM CpdA. . Cells were seeded in duplicates and the experiment repeated independently on 3 
occasions. Graph show cumulative average cell counts of all 3 replicates. Overexpressing 
CARP3 in R0.8 cells leads to a growth delay in CpdA. 
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Figure 4.12: Single culture cell proliferation assays of WT s427 and R0.8 cells 
overexpressing CARP1 and CARP3. The experiment was repeated independently on three 
occasions. Cells were seeded in duplicates and the experiment repeated independently on 3 
occasions. Graph show average cell counts of all 3 experimental replicates. Overexpressing 
CARP1 and CARP3 in WT s427 causes growth delays in CpdA. 
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4.5.0 Cyclic AMP levels in cells overexpressing CARP1-4 
and TbPDEB1 in WT s427 and R0.8 cells 
CpdA inhibits TbPDEB1, resulting in increased cAMP levels. The effect of 
increasing expression levels of CARP and TbPDEB1 on intracellular and 
extracellular cAMP levels in both WT s427 and R0.8 cells was studied by 
incubating overexpressing cells in 300 nM CpdA for 3 h. The possibility of cAMP 
entering into the cell, when experimentally added to the media, and thereby 
influencing the growth of cells in a similar way as CpdA inhibition does (i.e. by 
raising cellular cAMP above a threshold) was investigated and compared with 
similarly added AMP and with ‘induced media’ from cells, containing CpdA -
induced cAMP extruded from the trypanosomes. Cyclic AMP release measured 
after a 100 nM CpdA, 3 h incubation. 
 
 
4.5.1 Effect of overexpressing CARP1-4 genes on intracellular 
cAMP levels in WT s427 and R0.8 
Overexpression of CARP3 led to a significant increase in both basal and CpdA-
induced cAMP levels in WT s427. The cAMP concentration in the CpdA-resistant 
line was, however, only significantly increased when R0.8 CARP3oe cells were 
incubated in CpdA for 3 h compared with just R0.8. There was no difference in 
cAMP levels, whether incubated with CpdA or not, in CARP1, 2 and 4 
overexpressing cells compared with WT s427. There was also no difference in 
basal and stimulated cAMP levels in R0.8 CARP1, 2 and 4 overexpressing cells 
(Figure 4.13).  
 
 
 
 
 
 
 
 
 
Daniel N.A Tagoe  Chapter 4, 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Measurement of intracellular cAMP in WT s427 and R0.8 cells overexpressing 
CARP1-4. A). CARP1-4 in WT s427 and control. B) CARP1-4 in R0.8 and control Error bars 
show ± standard error.  Overexpressing CARP3 significantly raises both basal and CpdA 
induced intracellular cAMP levels in WT s427 CARP3oe and CpdA induced cAMP in R0.8 
CARP3oe. T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** p>0.001; n>3). 
 
 
4.5.2 Effect of overexpressing CARP1-4 genes on extracellular 
cAMP levels in WT s427 and R0.8 
Extracellular cAMP levels were only increased in WT s427 cells overexpressing 
CARP3 and when pre-incubated with CpdA. Similarly overexpressing CARP3 in 
R0.8 increases both basal and CpdA induced extracellular cAMP levels. WT s427 
CARP4oe showed a significant decrease in basal cAMP level (Figure 4.14).    
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Figure 4.14: Extracellular cAMP measurements in WT s427 and R0.8 cells overexpressing 
CARP1-4.A). CARP1-4oe in WT s427 and control. B) CARP1-4 in R0.8oe and control. 
Overexpressing CARP3 significantly raises CpdA induced extracellular cAMP levels in WT 
s427 CARP3oe and both basal and CpdA induced cAMP levels in R0.8 CARP3oe Error bars 
show ± standard error.  T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** p>0.001; n>3) 
 
 
4.5.3 Effect of overexpressing TbPDEB1 genes on intracellular 
and extracellular cAMP levels in WT s427 and R0.8 
Overexpressing TbPDEB1 in both WT s427 and R0.8 significantly increases basal 
intracellular cAMP levels but not in the presence of CpdA. There were no 
significant differences in both basal and CpdA induced extracellular cAMP levels 
in both WT s427 and R0.8 cells overexpressing TbPDEB1 cells (Figure 4.15).   
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Figure 4.15: Cyclic AMP measurements in WT s427 and R0.8 cells overexpressing TbPDEB1. 
Intracellular cAMP levels in A) TbPDEB1oe in WT s427 and B) TbPDEB1oe in R0.8 and R0.8. 
Extracellular cAMP levels in C) TbPDEB1oe in WT s427 and D) TbPDEB1oe in R0.8 and R0.8. 
Overexpressing TbPDEB1 raises basal intracellular cAMP levels in both WT s427 and R0.8 
cells. Error bars show ± standard error.  T-test single-tailed, unpaired (* p>0.05, ** p>0.01, *** 
p>0.001; n>3) 
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4.5.4 Effect of extracellularly-added cAMP on cell proliferation of 
overexpressing CARP1, CARP3 and WT s427.  
To study the effect of extracellular cAMP on the growth of trypanosomes, 
extracellular cAMP was measured in CARP1 and CARP3 overexpressing cells after 
incubation for 3 h in 100 nM CpdA.  In CARP3 overexpressing cells, 300 nM CpdA 
significantly induces extracellular cAMP release compared with WT s427 and 
CARP1oe (Figure 4.16). Growth of CARP1oe and CARP3oe in HMI-9 in which 5 μM 
cAMP had been added was not different from that of cells growing in HMI-9 only, 
without added cAMP, or from WT s427 growing in either media. Similarly, 
addition of 50 μM AMP did not affect growth of either overexpressing or WT s427 
cells (Figure 4.17). However, CARP3oe cells growing in media in which 
overexpressing CARP3 cells had previously been induced with 100 nM CpdA for 3 
h during which cAMP had been extruded into the media (induced media) showed 
significant growth inhibition. Similarly, growth of the same cells in HMI-9 in 
which 100 nM CpdA + added cAMP (1 μM) also showed growth stagnation. 
CARP3oe cells in HMI-9 + 100 nM CpdA only (no cAMP added) and same cells in 
HMI-9 + 100 nM CpdA + added AMP (5 μM) showed better growth compared with 
induced media and cAMP added media (Figure 4.17). Neither CARP1oe nor WT 
s427 showed any growth inhibition in any of the media conditions comparatively 
nor CARP3oe in media without CpdA (Figure 4.18).  
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Cyclic AMP measurements in WT s427 overexpressing CARP1 and CARP3. 
Error bars show ± standard error.  Overexpressing CARP3 causes significant increase in 
both basal and CpdA (100 M) induced extracellular cAMP levels. T-test single-tailed, 
unpaired (* p>0.05, ** p>0.01, *** p>0.001; n=3) 
oe
C
AR
P1
 
+ 
C
pd
A
oe
 
C
AR
P1
 
oe
C
AR
P3
 
+ 
C
pd
A
 
oe
 
C
AR
P3
 
s4
27
 
s4
27
 +
 C
pd
A
0
5
10
15
20
p
m
o
ls
 c
A
M
P
 o
f 
T
ry
p
an
o
sm
e
 in
cu
b
at
e
d
 m
e
d
ia
**
***
Daniel N.A Tagoe  Chapter 4, 130 
 
 
Figure 4.17: Growth of Overexpressing WT s427 CARP1, CARP3 and control WT s427 in 
CpdA cAMP induced media and commercially supplemented cAMP and AMP media. A) 
CARP1oe, B) CARP3oe and C) WT s427. Cells were seeded in duplicates and the experiment 
repeated independently on 2 occasions. Graph show average cell counts of all 
experimental. Overexpressing CARP3 leads to a noticeable delay in growth in CpdA induced 
media and un-induced media + HMI9 and cAMP. 
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Figure 4.18: Growth of Overexpressing WT s427 CARP1oe, CARP3oe and control WT s427 in 
CpdA cAMP induced media and commercially supplemented cAMP and AMP media. A) 
CARP1oe, B) CARP3oe and C) WT s427. Cells were seeded in duplicates and the experiment 
repeated independently on 2 occasions. Graph show average cell counts of all 
experimental. Adding both cAMP and AMP alone does not lead to any growth effect in 
CARP1oe, CARP3oe, and WT s427. 
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4.6.0 Localization of CARP1-3 in trypanosomes 
Locations of protein are usually associated with their function as structure is 
related to function. The CARPs have been annotated to perform certain 
functions in the cell and have been detected as protein fractions in various 
regions of the cell from proteomic pulldown analysis. However, none of the 
CARPs have been confirmed to be localized to these regions using microscopy. 
Thus, a preliminary localization was performed to determine the location of the 
CARPs in the cell and to relate these to functions. 
 
 
4.6.1 Localization of CARP3 using anti-CARP3 antibody 
Immuno-fluorescence using CARP3 antibody shows CARP3 localizes to the plasma 
membrane and flagellum of the trypanosome (Figure 4.19). 
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Figure 4.19: Immunofluorescence assay (IFA) of overexpressing CARP3 using peptide 
produced rabbit anti-CARP3 antibody. DIC, differential interference contrast; DAPI, 4',6-
diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate. CARP3 localizes strongly to 
the plasma membrane and flagellum when overexpressed. WTs427 shows similar 
localization whilst the CARP3-/- shows no localization. 
 
 
4.6.2 Localization of N-Terminal GFP tagged CARP1-3 
Genes of CARP1-3 were N-terminally tagged with GFP and overexpressed in 2TI 
cells. Preliminary Immunofluorescence assay (IFA) showed that CARP1 associated 
with specific regions or bodies within the cytosol with proximity to the basal 
body. CARP2 also seem to localize in discrete cellular compartments in the 
posterior region of the trypanosomes after the nucleus whilst CARP3 localizes to 
the pellicular plasma membrane (Figure 4.20). 
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Figure 4.20: Immunofluorescence of N-terminal GFP tagged CARP1-3 using anti-GFP 
antibody and IgG coupled FITC for CARP3. A) CARP1GFP. B) CARP2GFP. C) CARP3GFP. DIC, 
differential interference contrast; DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein 
isothiocyanate.  
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4.7.0 Discussion  
Since RNAi and gene deletion of the CARPs led to decrease in susceptibility to 
CpdA, there was the need to study the concomitant effect of increasing the 
expression of the CARPs to study the effect on sensitivity, cell proliferation, 
cAMP, transcription and protein expression when CpdA is added to the cells. It is 
also important to know where these proteins localize in the trypanosome as a 
basis of relating location to function and appreciating the whole cell biology of 
the trypanosome in relation to downstream signalling of cAMP. 
 
PCR confirmed the presence of the overexpression constructs whilst qRT-PCR 
showed the extent of the increased expression of the CARP and TbPDEB1 genes 
in the WT s427 and R0.8 cell lines. Increases in CARP3 transcripts were reflected 
in increased protein levels in both WT s427 and R0.8 validating the expression 
system and qRT-PCR results. Overexpression of TbPDEB1 in both the WT s427 and 
the CpdA resistant R0.8 resulted in a decreased susceptibility to CpdA. This is 
expected since CpdA inhibits TbPDEB1 and thus more CpdA is required to inhibit 
more TbPDEB1 to bring about cell death according to standard pharmacological 
theory. There was no significant difference in sensitivity to pentamidine when 
TbPDEB1 was overexpressed in either WT s427 or R0.8, in agreement with our 
understanding of the mechanism of action of pentamidine, which is unrelated to 
the cAMP system (Baker et al., 2013; Bray et al., 2003). This result further 
validates pHD1336 as a good expression construct. Overexpressing CARP3 in both 
WT s427 and R0.8 lines significantly sensitizes the cells to CpdA when compared 
with WT and that of the other overexpressing CARPs in both cell lines. There was 
no significant difference in sensitivity to pentamidine in the overexpressed cells 
except in WT s427 CARP4oe. This implies that CARP3 plays a role in determining 
the final phenotype when CpdA is added to the cells that is parallel to that of 
TbPDEB1, as knockdown induces sensitivity and overexpression the reverse when 
overexpressed. Since CARP3 is downstream of TbPDEB1 in the cAMP signalling 
cascade, CARP3 might play an important role in the determination of the final 
growth phenotype which is impossible without the inhibition of TbPDEB1. 
 
In both WT s427 and R0.8, overexpressing CARP3 significantly increases both 
intracellular and extracellular cAMP when CpdA is added, compared to the WT 
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un-transfected s427 and R0.8 lines and with the other overexpressing CARPs. 
This is likely to be due to the fact that CARP3 plays a very important role in 
cellular regulation which in TbPDEB1 inhibition results in cytokinesis defective 
trypanosomes (de Koning et al., 2012) of which cAMP is required to trigger or 
drive to completion. This is because whereas the double deletion of CARP3 genes 
resulted in significant increases in both basal innate and CpdA induced cAMP, 
this did not sensitize the cells to CpdA but rather decreased sensitivity just as in 
dKOs of CARP2 and CARP4. This clearly means that both an increase in cAMP and 
CARP3 proteins must be present for cAMP induced cellular phenotype 
(cytokinesis defects followed by cell death) to occur. CARP3 appears to be the 
key parameter and for that matter an increase in the levels of CARP3 
significantly drove an increase in this cellular phenotype, as revealed by a shift 
in the CpdA IC50, reflecting a higher sensitivity to an elevated cAMP 
concentration. However, CARP3 does not seem to be only a link in the cAMP 
response chain, as overexpression of CARP3 in WT s427 increased the basal 
intracellular cAMP levels as well as increased extracellular extrusion of cAMP in 
both WT s427 and R0.8. The fact that cAMP extrusion is similarly increased as 
the intracellular level shows that the intracellular level is not increased as a 
result of reduced efflux. Moreover, the observation that this difference was also 
seen in the presence of the PDE inhibitor CpdA means that the difference cannot 
be explained in terms of a difference in cAMP degradation rate either, and we 
conclude that CARP3 overexpression increased the activity of cAMP production 
by the T. brucei adenylyl cyclases, in a direct or indirect way. 
 
Overexpressing TbPDEB1 in both cell lines caused a small but significant increase 
in basal intracellular cAMP levels. This must be the result of a feedback 
mechanism since an increase in TbPDEB1 protein is instead expected to increase 
breakdown of cAMP levels to that below normal cellular requirements. However, 
the increase was not pronounced and did not result in an increase release of 
cAMP from the cell. CpdA increased both intracellular and extracellular cAMP 
and although in both cases there was a reduction in cAMP levels as expected, in 
TbPDEB1oe; however, this was not significant.  
 
Increased sensitivity as a result of overexpression of CARP3 was further validated 
in growth phenotypes in WT s427 and R0.8. Both these overexpressed lines 
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showed delayed growth, in 100 nM and 3 μM CpdA, respectively, compared with 
media only incubations. None of the other overexpressed CARPs in either WT 
s427 and R0.8 showed any delayed growth phenotype either in normal media or 
media supplemented with CpdA. The delay in the growth of cells overexpressing 
CARP3 was further enhanced in WT s427 when the experiment was performed in 
single media and not in continuous passage into new media (every 48 h) with 
CpdA. The accumulation of cAMP in the media of the single growth experiment 
unlike the continuous growth were the media was refreshed every 48 h, cannot 
be interpreted as the creation of some sort of cAMP gradient in the media that 
works against the extrusion of further cAMP from the cells. This probably 
resulted in even higher intracellular cAMP levels in the single media growth 
curve and thus the increased growth delayed phenotype- although it can be 
excluded that other secreted factors contributed to the observed growth 
patterns. Although the effect of increased CARP3 transcript and protein was less 
pronounced on the growth rate of R0.8 CARP3oe, it resulted in continued cell 
survival when the control R0.8 cell population was already declining. One 
mechanism by which R0.8 cells got adapted to CpdA was to upregulate the 
extrusion of cAMP into the surrounding media, when challenged by PDE 
inhibitors. This may provide an explanation as to why CARP3 overexpression in 
WT427 caused a significant growth delay, but not in R0.8 where, in fact, it 
seems to give a longer survival time at high cell densities. Importantly, this was 
observed only in ‘single culture’ growth curves, and not when medium was 
replaced on alternate days. The interpretation of these results is that R0.8 is 
less sensitive to an excreted factor, presumably cAMP, but only in the presence 
of a minimum expression level of CARP3.  
 
The addition of 1 µM cAMP to the media inhibited growth of CARP3oe when added 
together with CpdA. These conditions are similar to growth in CpdA-induced 
extracellular cAMP from CARP3oe cells (in this case the conditioned medium also 
contains CpdA). The addition of AMP the breakdown product of cAMP, to the 
medium and under the same conditions did not cause growth stagnation thus 
confirming cAMP and not a metabolite was responsible for the observed growth 
inhibition, which was similar to that seen in the single growth curve of CARP3oe 
in HMI9 + 100 nM CpdA. One interpretation is that a build-up of cAMP in the 
media prevented further extrusion of cAMP resulting in much higher intracellular 
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cAMP levels than observed in any other cell line tested in parallel (see figure 
4.13); for instance, neither CARP1oe nor WT s427 showed a similar phenotype. 
Clearly, the amount of CARP3 protein present in the cell is important to bring 
about this effect. This is further substantiated by the fact that 100 nM CpdA, 3 h 
incubation significantly increased cAMP in media of CARP3oe and compared with 
either CARP1oe or WT s427. The most straightforward explanation is that in 
CARP3o.e cells, the rate of cAMP production is substantially increased, although 
this is usually masked by the continued activity of the phosphodiesterases, 
keeping the cAMP homeostasis intact. However, in the presence of CpdA, the 
much higher cAMP production rate is revealed and leads to a much higher 
intracellular level and therefore efflux, which in turn leads to an accelerated 
cAMP build-up in the media, which (assuming the cAMP efflux is passive and thus 
equilibrative) in turn drives up the intracellular concentration even higher.    
 
CpdA significantly decreases mRNA transcript levels of CARP1-4 and TbPDEB1- 
overexpressing WT s427 cells; the effect was highly significant within 6 h and 
maintained over the 48 h incubation period when normalized to pre-CpdA 
incubation.  Messenger RNA levels of CARP2 and CARP3 were similarly 
significantly reduced in WT s427 over the same period, whereas levels of CARP4 
remained steady, and mRNA of CARP1 and TbPDEB1 decreased significantly 
initially (6) h but returned to pre-incubation levels or higher for the rest of the 
48 h period in WT s427. CpdA inhibits TbPDEB1 leading to increased cellular 
cAMP, which might be expected to require, if anything, an increased PDEB1 
expression. Therefore, no direct explanation offers itself for the temporary 
reduction in TbPDEB1 mRNA levels at 6 h, similar to that of CARP2 and CARP3. A 
probable reason it could be that the presence of CpdA downregulates TbPDEB1, 
leading to a concomitant reduction in CARP2 and CARP3 expression thereby 
reducing the downstream effect of PDB1 inhibition in the initial 6 h period. It 
may be that this compensatory upregulation of PDEB1 after the initial 6 h 
reduction explains, in part, that the effects of CpdA with respect to cytokinesis 
are  only observed after 24 h and even that at high concentrations of CpdA (1 
μM) (de Koning et al., 2012) although there is a significant and immediate 
increase in cAMP, (de Koning et al., 2012). However, it is currently a matter of 
speculation whether the downregulation of CARPs 2 and 3 may not have a larger 
influence in protecting the cells that long against the elevated cAMP levels. 
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The need for the cellular response to immediately and significantly reduce 
transcript levels of CARPs in the presence of PDE inhibitors, which was especially 
prominent when the CARPs were overexpressed at the start of the incubation, 
CpdA confirms the importance of these proteins as downstream effectors of 
cAMP. The reduction in CARP3 transcript levels, after CpdA treatment, was 
directly correlated to a very similar reduction in protein levels confirming the 
overwhelming need of the cell to regulate both mRNA and protein levels of 
CARP3. The importance of CARP3 was further validated when expression of its 
transcript in R0.8 CARP3oe and R0.8 showed a similar pattern to that in WT s427. 
At 6 h and by 24 h, there was almost no production of CARP3 mRNA in the cell; 
this coincided with a total depletion of CARP3 proteins at the same time.  
Importantly, this pattern was only observed in R0.8 cells overexpressing CARP3 
and not in any of the other CARP over-expressors, as well as TbPDEB1oe. CARP3 
expression in un-transfected R0.8 was similar to levels pre incubation of CpdA. 
This is the reason for the observed CpdA sensitive phenotype observed in the 
drug sensitivity assay (only CARP3o.e was significantly sensitised to CpdA) and for 
the growth delay in the growth curve assays in R0.8 cells (only CARP3o.e were 
growth delayed in the presence of CpdA).  
 
Although CARP3 is unique to trypanosomes and its crystal structure has not been 
resolved yet, protein prediction software predicts very important motifs with 
high confidence providing probable insightful explanations to the activity of the 
protein and its role in cAMP signalling. The SWISS-MODEL (Biasini et al., 2014) 
and the Protein Homology/analogY Recognition Engine V 2.0 (Phyre2) (Kelley and 
Sternberg, 2009) predicted CARP3 proteins to have a tetratricopeptide repeat 
(TPR) and Protein database (PDB) annotations such as signalling protein, 
membrane protein, protein binding/transport protein, Peroxisome Targeting 
Signal 1 Receptor (PEX5), Regulatory Protein among others. It is also predicted 
to have a Nuclear Export Signal (NES) using the NetNES 1.1 Server (la Cour et al., 
2003) that targets it for export from the nucleus to the cytoplasm as well as a 
domain typical of proteasome non-ATPase 26S subunit from the ROBETTA Full-
chain Protein Structure Prediction Server (Bradley et al., 2005) and the 
proteasome regulatory particle subunit 6 (Rpn6) using the I-TASSER Protein 
Structure and Function predictions (Yang et al., 2015). The 26S proteasome is a 
protease with a core particle (CP) and a regulatory particle (RP) and is 
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responsible for the proteolytic breakdown of ubiquitinated proteins; a process 
which serves diverse and important cellular functions such as cell-cycle 
regulation, apoptosis, DNA repair, gene expression, transcription and signalling 
(Gu and Enenkel, 2014; Kaneko et al., 2009). The non-ATPase of the 26S 
proteasome is a regulatory particle that serves as receptor for poly-ubiquitined 
protein substrates (Gu and Enenkel, 2014). Ubiquitination prediction using 
UbPred: predictor of protein ubiquitination sites (Radivojac et al., 2010) 
revealed 9 ubiquitination sites on CARP3. Three of this prediction is of low 
confidence, 5 medium confidence and 1 high confidence.  Thus it is probable 
that cAMP above a certain threshold will cause ubiquitination of CARP3, priming 
it for transport to the proteasome for degradation. CARP3 protein degradation in 
turn could signal a reduction in the production of CARP3 leading to a halt or 
down regulation of its transcription. This explains both the down regulation and 
CARP3 protein turn over within 6 h after the addition of CpdA. Proteins known to 
have TPR domains have been discovered to be involved in cell cycle regulation, 
transcription control, protein import and signalling (Cliff et al., 2005). Thus 
overall, CARP3 looks perfectly structured for a regulatory and signalling role that 
directly fits its importance as the main regulator of downstream cAMP signalling 
and the determinant of the cAMP-dependent phenotype.  
 
CpdA decreases mRNA levels of TbPDEB1 overexpressing in R0.8, similar to 
overexpressing of same in WT s427.  Overexpressing CARP1, 2 and 4 in R0.8 
resulted in increased mRNA levels in the presence of CpdA and significantly so in 
R0.8 CARP1oe and R0.8 CARP4oe. Similarly, there were significant increases in 
mRNA of CARP1, 2, 4 and TbPDEB1 in R0.8 6 h after adding CpdA and up to 48 h 
above pre-incubation levels. However, the levels of CARP3 in untransfected R0.8 
remain steady over 48 h. As of this moment, this is not well understood and 
especially since the basis for CpdA resistance in the R0.8 is yet to be clarified. It 
is expected that, further cellular and functional characterization of the CARPs 
and R0.8, will provide more information that will enable the interpretation of 
the present data.  
 
Preliminary data on localization of the CARPs show localization in different 
places in the trypanosomes. CARP1 localized to discrete regions or organelles in 
the cytosol with some proximity to the basal body and flagellar pocket.  CARP2 
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also seem to localize in discrete cellular compartments in the posterior cytosolic 
region of the trypanosomes. Proteomic data identified CARP2 peptides in both 
plasma membrane and cytoskeleton fractions of BSF (Bridges et al., 2008) and as 
part of the flagellar proteome in the PCF (Broadhead et al., 2006).  
 
CARP3 localizes to the plasma membrane and the flagellum of T. brucei. This 
confirms previous finding of CARP3 peptide fragments in Plasma membrane of 
BSF (Bridges et al., 2008) and enriched in the flagellar proteome of PCF (Subota 
et al., 2014).  
 
Additionally, CARP3 is predicted to undergo protein acylation (N-myristoylation 
and palmitoylation) which has been shown to be important in protein-membrane 
interactions by anchoring of proteins to membranes and stabilization, vesicle 
and protein targeting and cell signalling (Dunphy and Linder, 1998). 
Bioinformatics analysis using NMT algorithm (Maurer-Stroh et al., 2002) predicts 
with high confidence myristoylation on the glycine residue (G2) of the second 
position in the protein sequence (GGGSSVEDK RYSRLFQE). The cysteine residues 
on positions 162 and 256 were predicted as palmitoylation sites by PalmPred 
(Kumari et al., 2014) whilst CSS-Palm algorithm (Ren et al., 2008) predicted both 
sites as well as residue 386. Both myristoylation and palmitoylation together 
have been shown to cause proteins to localize to the flagellum (Emmer et al., 
2011b; Liu et al., 2010). A specific example is protein Present in the Outer 
Membrane Proteome of mitochondrion (POMP39), a protein without the 
canonical mitochondrion membrane-spanning domain  (Niemann et al., 2013), 
which undergoes both myristoylation and palmitoylation and localizes to the 
flagellum besides the mitochondrion (Albisetti et al., 2015). This is similar to 
another mitochondrion outer membrane protein (Tb927.9.4320) (Acestor et al., 
2009) predicted to be palmitoylated (Emmer et al., 2011a; Emmer et al., 2011b) 
and detected in the flagellar proteome (Oberholzer et al., 2011). 
 
IFA using antibody to the N-terminally fused GFP-CARP3 show localization to the 
pellicular plasma membrane confirming the α-CARP3 antibody localization.  
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A summary of biochemical characterization of the various genetically 
manipulated cell lines in both WT s427 and R0.8 strains is presented in Table 
4.1.  
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Table 4.1: Summary of biochemical characterization of the different genetically manipulated cells in WT s427 and R0.8 strains. o.e, over expression; 
+/-, single knockout; -/-, double knockout; Inc., increase; Dec., decrease; Norm, normal; -CpdA, No CpdA; +CpdA, addition of CpdA; Penta, 
Pentamidine; -, experiment not performed 
 
 
Cell lines 
Genetic 
line 
Drug 
sensitivity 
Growth 
Phenotype 
cAMP  
measurements 
mRNA Expression levels 
(qRT-PCR) 
Protein 
Express. 
  CpdA Penta nCpdA +CpdA Intra Extra nCpdA +CpdA  
    nCpdA +CpdA nCpdA +CpdA 0 h 6 h 24 h 48 h - 
 
CARP1 
o.e No No No No Norm Norm Norm Norm Inc. Dec. Dec. Dec. - 
+/- Dec. No No No Norm Norm Norm Norm Dec. - - -  
-/-              
 
CARP2 
o.e No No No No No Norm No Norm Inc. Dec. Dec. Dec. - 
+/- Dec. Inc. No No No Norm No Norm Dec. - - - - 
-/- Dec. Inc. Yes No Inc. Inc. Inc. Inc. - - - - - 
 
CARP3 
o.e Inc. No No Yes Inc. Inc. Norm Inc. Inc. Dec. Dec. Dec. Dec. 
+/- Dec. Inc. No No No Norm No Norm Dec Dec. Dec. Dec. Dec. 
-/- Dec. Inc. No No Inc. Inc. Inc. Inc. - - - - - 
 
CARP4 
o.e No Dec. No No No Norm No Norm Inc. Dec. Dec. Dec.  
+/- Dec. No No No No Norm No Norm Inc. Dec. Dec. Dec.  
-/- Dec. No No No Inc. Inc. Inc. Inc. - - - - - 
 
TbPDEB1 
o.e Dec. No - - Inc. No No No Inc. Dec. Dec. Dec.  
+/- - - - - - - - - - - - - - 
-/- - - - - - - - - - - - - - 
R0.8 Strain 
CARP1 o.e No No No No Norm Norm Norm Norm Inc. Inc. Inc. Inc. - 
CARP2 o.e No No No No Norm Norm Norm Norm Inc. Norm Norm Norm - 
CARP3 o.e Inc. No No Yes No Inc. Inc. Inc. Inc. Dec. Dec. Dec. Dec. 
CARP4 o.e No No No No Norm Norm Norm Norm Inc. Inc. Inc. Inc. - 
TbPDEB1 o.e Dec. No - - Inc. No No No Inc. Inc. Inc. Inc. - 
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4 Proteomic, Genomic and Transcriptomic 
investigations of CARPs and their interactions 
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5.0 Proteomic, Genomic and Transcriptomic 
investigations of CARPs and their interactions 
The “Omics” (genomics, transcriptomics and proteomics) approach makes a most 
powerful tool in understanding the most complex of biological phenomena. This 
is because they form both the basis and the final outcome of the activities that 
underpins these biological processes and interactions. The genes are transcribed 
into RNA of which transcription and regulation is essential for cell survival. RNA 
is then translated into proteins required for structural, enzymatic as well as 
regulatory functions, some with feedback on the transcription process. A 
combination of these proteomic and transcriptomic approaches is expected to 
together confirm the observations seen when the CARPs are genetically 
manipulated as well as provide further targets and interactors of the 
downstream signalling cascade of cAMP in T. brucei.    
 
 
5.1.0 RNA Interference Target Sequencing (RIT-Seq) 
The RNAi knockdown approach is a useful tool that allows for the study of gene 
effects in trypanosomes under selective pressure. This approach has been 
applied severally and successfully (Alsford et al., 2012b; Alsford et al., 2011b; 
Baker et al., 2011), and was also used in identifying the initial downstream 
effectors of cAMP signalling (CARP1-4) from PCR, gel excision and Sanger 
sequencing. This only revealed the very top hits from the knockdown but the 
technique used makes it probable that there could be further important proteins 
with perhaps lower representation in the recovered RNAi sample, which 
contributed to the final phenotype. Thus, in order to maximize the discovery of 
distinct genetically-induced loss of function phenotypes from the complex 
population of RNAi fragment-containing trypanosomes surviving CpdA challenge, 
RIT-Seq was performed on the library elements recovered from the screen.  
 
A total of 51,600,585 reads were obtained from the sequencer. Out of this 
number 1,791,387 of 70 bases per read length were mapped to a coding 
sequence and the genome making a 100% un-paired mapping. The overall coding 
sequence alignment rate was 61.07% (1094006) which was made up of 60.54% 
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(1084575) exactly one time alignment and 0.53% (9431) more than one time 
alignment. About 38.93% (697381) showed no alignment. Whereas 20.35% 
(364474) did not align to the genome sequence, overall, 79.65% (1426913) 
aligned which is made up of 77.16% (1382226) single alignment and 2.49% 
(44687) greater than 1 alignment. About 0.65% (332907) reads mapped to the 
genome but not the coding sequence (Table 5.1).  
 
Mappings Coding Sequence Mapping 
 
Genome mappings 
  
Bases % Bases % 
Read length 70 bases 
 
70 bases 
 
Total Reads 1791387  1791387  
un-paired 1791387 100 1791387 100% 
0% alignment 697381 38.93 364474 20.35 
aligned exactly 1 
time 
1084575 60.54 1382226 77.16 
aligned >1 times 9431 0.53 44687 2.49 
overall alignment 
rate 
1094006 61.07 1426913 79.65 
Table 5.1: Mapping and alignment in RIT-Seq. Majority of both CDS (60.54%) and genome 
(77.16%) mapped exactly once with overall alignment rate at 61.07% and 79.65% for CDS 
and genome mapping respectively. 
 
Above 1190 genes had raw total counts of ≥1 compared with just tetracycline-
induced cells without CpdA selective pressure.  However, after normalized 
mapping, only about 45 genes show ≥0.05 mapping reads (Appendix 2). The top 
20 percentage mapped reads included had CARP1-4 as expected, confirming the 
observation from the PCR and Sanger sequencing reported earlier (Gould et al., 
2013). Although CARP1 remained the highest hit (75.01% of all reads), the next 
two hits Tb927.10.12390 (4.99%) and Tb927. 10.1740 (3.60%) were higher than 
CARP4 (3.26%), CARP3 (2.57%) and CARP2 (0.45%) (Figure 5.1). There were 
additional important hits associated with cAMP signalling such as receptor-type 
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adenylate cyclases, adenylyl cyclases, and protein phosphatases among others 
(Table 5.2).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Distribution of percentage mapped reads among the various top hits in the RIT-
Seq. CARP1 had the highest % Mapped reads (75%) and together with the other CARPs (2-6) 
makes up more than 85% of the reads. Tb927.10.12390 and Tb927. 10.1740 had 3.60% and 
4.99% respectively which is higher than CARP2-4.  
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Gene ID 
% mapped 
bases Annotations 
Tb927.11.16210 75.01 CARP1 - contains putative cyclic nucleotide binding domain; trypanosomatids only 
Tb927.11.12860 0.45 CARP2 conserved hypothetical protein detected in flagellar proteome 
Tb927.7.5340 2.57 CARP3 - tetratricopeptide repeat family, no orthologues outside Trypanosoma spp.; 
possible role in membrane fusion/division (cytokinesis/cell division?). 
Tb927.3.1060 3.26 CARP4 conserved hypothetical protein with three DM10 and one EF-hand domains 
Tb927.10.1740 3.60 Hypothetical protein unknown 
Tb927.10.12390 4.99 Hypothetical protein unknown 
Tb927.11.3910  1.13 Hypothetical protein unknown 
Tb927.4.4450 0.44 adenylyl cyclase (inferred from sequence or structural similarity) 
Tb927.11.7180 0.36 Hypothetical protein unknown 
Tb927.11.17380 0.31 pseudogene? 
Tb927.8.4640 0.27 flagellar protofilament ribbon protein, putative 
Tb927.7.4100 0.20 Hypothetical protein unknown 
Tb927.7.7530 0.32 receptor-type adenylate cyclase GRESAG 4, putative 
Tb927.7.4510 0.10 Hypothetical protein unknown 
Tb927.10.12210 0.06 ribulose-5-phosphate 3-epimerase, putative 
Tb927.10.16200 0.20 Hypothetical protein unknown 
Tb927.8.3700 0.23 Hypothetical protein unknown 
Tb927.11.1780 0.05 protein phopsphatase 
Tb927.4.4460 0.17 adenylyl cyclase (inferred from sequence or structural similarity) 
Tb927.4.4470 0.14 adenylyl cyclase (inferred from sequence or structural similarity) 
Tb927.11.14020 0.03 iron superoxide dismutase 
 1183_genes 6.12 1183_genes 
Table 5.2: Annotation, % mapped reads and gene IDs of the top hits in the RIT-Seq. Four adenylyl cyclases, protein phosphatases, flagellar protein 
among others were among the top hits
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5.2.0 Co-Immunoprecipitation (Co-IP) and Mass Spectrometry 
(MS) 
Most biological processes involve the action of multiple protein complexes in one 
way or another. These complexes are either tightly regulated by a key protein or 
simply by forming complexes. A major goal of cell biology is to identify and 
characterize these protein complexes. The identification of these complexes has 
become more feasibly relevant with the advent and application of Mass 
Spectrometry (MS). Thus using Co-Immunoprecipitation (Co-IP), CARP3 and its 
interactors were pulled-down with α-CARP3 antibody, followed by MS proteomics 
for the identification of proteins that form complexes or tend to bind CARP3 and 
could be important in the observable phenotypes of CARP3 knockout and 
overexpression.  
 
A total of about 200 proteins were pulled-down using anti-CARP3 antibody in the 
three replicates of Co-immunoprecipitation and MS/MS analysis. Cut off for 
significant expect-value was set at <0.05. The criteria of selection of interactors 
were in this order: (i) found in two or more independent experiments, (ii) highly 
significant identification from peptide, (iii) found in RIT-Seq hits (iv) orthology 
to proteins implicated in signalling and (v) presence of domains  involved in 
signalling and/or protein-protein interactions. Additional filtering was performed 
by removing known contaminants of pulldowns as well as comparing proteins to 
those observed in pulldowns of CARP1 (3 replicates) and CARP2 (1 experiment) 
using antibodies designed for either CARPs but not binding to proteins with the 
right Molecular Weight (MW).  
 
The majority (146) of the proteins detected in the Co-IP and MS were found in 
only one of the three replicated pull-down whilst the rest were found in more 
than one. Only five proteins were found in 2 or more replicates and exclusive to 
only CARP3 pulldown (Figure 5.2). These were made up of three adenylate 
cyclases (Tb927.4.4460, Tb927.4.4440, and Tb927.4.4410) with very high expect-
values (3.7 x 10-5) and protein score (75) and 2 hypothetical proteins 
(Tb927.10.1060 and Tb927.9.16060) with protein scores of 80 and 40 
respectively (Table 5.3). There were 12 proteins in two or more CARP3 
pulldowns with relatively high protein and peptide scores that were also found in 
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either CARP1 or CARP2 pulldowns (Appendix 3, Table 1). These include 
hypothetical proteins, variant surface glycoproteins (VSGs) and ribosomal 
proteins and are probably contaminants. Two of the annotated proteins in this 
group, Tb927.9.8740 (DRBD3 RNA-binding protein, putative; DRBD3) and 
Tb927.9.4680 (1L12.525 eukaryotic initiation factor 4a, putative) have been 
shown to drive abnormal phenotypes in RIT-Seq analysis in the different lifecycle 
stages (Alsford et al., 2011b). All the proteins found in all 3 replicates pulldowns 
of CARP3 (apart from CARP3 itself) were present in either CARP1 or CARP2 
pulldowns and are mostly confirmed contaminants of pulldowns and MS 
proteomic data (Adung'a et al., 2013). Thirty-six proteins were pulled down with 
CARP3 in one replicate only out of which 11 were signalling mediated, ATP 
binding and proteasome regulatory proteins.  
 
Two additional proteins Tb927.4.4470 and Tb927.8.7590 both putative receptor-
type adenylate cyclases of the GRESAG 4 family, putative were also detected. 
Tb927.4.4470 had a very high protein (75) and peptide (58) score, and expect-
value of (3.7 x 10-5), the same as that found for Tb927.4.4460, Tb927.4.4440 and 
Tb927.4.4410 that were pulled down in 2 replicates. Tb927.8.7590 had a modest 
protein and peptide score of 30 each and expect-value of 0.032. Seven 
expression site associated gene 3 (ESAG3) and 2 other ESAGs were detected in 
both CARP3 and CARP1 pull downs but not in CARP2. A putative UBA1 ubiquitin-
activating enzyme E1 (Tb927.8.2640) and putative PSA4 proteasome alpha 7 
subunit  (Tb927.11.7020) were both detected in just one replicate of both CARP3 
and CARP2 only. There were additional hits that could be important interactors 
of cAMP signalling cascade that were also found in 1 replicate of CARP1 and 
CARP2 pulldowns (Table 5.4). Overall the identification of several adenylate 
cyclases, signalling mediated proteins, proteasome proteins and phosphatase 
binding proteins suggests a successful identification of important CARP3 
interactors involved in cAMP signalling (Appendix 3: Table 2).     
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Figure 5.2: Distribution of hits from Co-IP and MS using CARP3 antibody and CARP1 and 
CARP2 antibodies as control. A) Majority of proteins (146) were found in just 1 pulled-down 
with CARP3 antibody. B) Of the 146 proteins found in the single pull-down of CARP3, 36 
were unique to CARP3 whilst 61 were also present in CARP1 and CARP2. C) Of the proteins 
found in more than 1 replicate using CARP3 antibody, 6 were unique to CARP3 with the 
majority (26) found also in CARP1 and CARP2.   
 
 
A 
B 
C 
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Gene ID Annotation and Product 
Size 
(kDa) 
 
 
Protein 
Score 
 
 
Peptide 
Score 
 
 
 
Expect 
Sequence 
Coverage 
(%) 
Tb927.7.5340 CARP3 57 78 77.8 4.2 x 10-7 13 
Tb927.4.4460 
 GRESAG 4.4B receptor-type adenylate cyclase 
GRESAG 4, putative 
144 75 58 3.7 x 10-5 6 
Tb927.4.4410 receptor-type adenylate cyclase GRESAG 4, putative 138 75 58 3.7 x 10-5 3 
Tb927.4.4440 receptor-type adenylate cyclase GRESAG 4, putative 138 75 58 3.7 x 10-5 3 
Tb927.10.2610 hypothetical protein, conserved 54 80 55 0.0001 5 
Tb927.9.16060 hypothetical protein 11 40 40 0.0033 10 
Table 5.3: Gene ID, annotations, protein and peptide scores and expect of the 6 unique hits found in more than 1 replicate of CARP3 pulldown. CARP3 
as expected has the highest protein, peptide and expect scores. Three tandemly arranged GRESAG4s followed with high protein score and expect. 
 
 
 
 
 
 
 
Daniel N.A Tagoe      Chapter 5, 153 
 
Table 5.4: Gene ID, annotations, protein and peptide scores and expect of important hits found in only 1 replicate of CARP3 pulldown. The 
presence of RPNs, TbPSA6 and PSA4 all predicted in silico confirms their role in CARP3 protein activity and regulation.  Tb927.4.4470 
(GRESAG4) was one of the hits from RIT-seq whilst CARP3 was predicted to be ubiquitinated.  
 
 
Gene ID Annotation and Product 
Found 
in 
Size 
(kDa) 
 
Protein 
score 
 
Peptide 
score 
 
Expect Sequence 
Coverage (%) 
Tb927.2.2440  RPN6 proteasome regulatory non-ATPase 
subunit 6 
3 only 57 92 67 5.7 x 10-6 5 
Tb927.11.16030  RPN7 proteasome regulatory non-ATP-ase 
subunit 7 
3 only 45 34 34 0.0093 3 
Tb927.10.3030  RPN11 proteasome regulatory non-ATPase 
subunit 11; 19S proteasome regulatory 
subunit, Metallo-peptidase, Clan MP, 
Family M67 
3 only 33 44 44 0.0013 3 
Tb927.9.9670  TbPSA6 proteasome alpha 1 subunit, 
putative; 20S proteasome subunit alpha-6, 
putative 
3 only 27 33 31 0.025 4 
 Tb927.4.4470 receptor-type adenylate cyclase GRESAG 4, 
putative 
3 only 142 75 58 3.7 x 10-5 6 
 Tb927.8.7590 receptor-type adenylate cyclase GRESAG 4, 
putative 
3 only 139 30 30 0.032 4 
Tb927.10.1060  TCP-1-delta t-complex protein 1, delta 
subunit, putative 
3 only 58 88 88 4.8 x 10-8 10 
Tb927.5.3400 calcium-translocating P-type ATPase; 
calcium pump 
3 only 41 53 53 0.00016 9 
Tb927.7.6290 kinesin, putative 3 only 97 30 30 0.031 5 
Tb927.10.2090  TEF1 elongation factor 1-alpha; EF-1-alpha 3 only 37 55 55 7.5 x 10-5 10 
Tb927.11.9530 14-3-3-like protein, putative 3 only 30 29 29 0.035 4 
 Tb927.8.2640  UBA1 ubiquitin-activating enzyme E1, 
putative 
Also in 2 116 73 73 1.4 x 10-6 9 
Tb927.11.7020  PSA4 proteasome alpha 7 subunit, putative Also in 2 27 46 46 0.00071 7 
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An attempt was made to confirm one of the hits from both the RIT-seq and Co-IP 
an adenylate cyclase (Tb927.4.4460; GRESAG4.4). This was based on the 
hypothesis that it could be involved in a feedback loop through interaction with 
CARP3 which in turn regulates its expression. The hypothesis was tested by 
looking at the expression of GRESAG4.4 with and without CpdA (100 nM) added 
for 6 h.  Expression of GRESAG4.4 was higher in CARP3oe (2.3-fold) compared 
with WT s427 at 0 h. However, GRESAG4.4 mRNA levels drop significantly after 6 
h incubation in 100 nM CpdA in CARP3oe to a level similar to the level in WT s427. 
This trend was similar to the significant reduction observed in both transcript 
and protein levels of CARP3 in the same cells under same conditions. Levels of 
GRESAG4.4 in CARP3-/- cells remained virtually unchanged after 6 h incubation in 
CpdA and were not different from that of WT s427 in CpdA. In contrast the levels 
of GRESAG4.4 in WT s427 cells increased significantly 6 h in CpdA (Figure 5.3). 
This clearly shows that the presence and quantity of CARP3 directly affects the 
expression of GRESAG4.4 and that the manipulations of CARP3 reversibly affect 
the expression of GRESAG4.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Expression of GRESAG4 (Tb927.4.4460) in CARP3oe CARP3-/- cells without and 
with 100 nM CpdA for 6 h.  Error bars show ± standard error. T-test single-tailed, unpaired (* 
p>0.05, ** p>0.01, *** p>0.001; n=3). CARP3oe shows a significant increase (no CpdA) and 
decrease in expression of GRESAG4 (CpdA, 6 h). 
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5.3.0 Ribonucleic Acid Sequencing (RNA-Seq) 
Important processes in the life of a parasite such as cell cycle progression, 
transition between cell types and developmental changes are usually 
synonymous with gene expression changes. However, the kinetoplastid lacks 
transcriptional regulation as a consequence of the unusual protein coding 
tandem genome arrangement that ensures polycistronic transcription (Clayton, 
2002; Hall et al., 2003; Kramer, 2012). Yet, steady-state mRNA levels for 
specific genes can be very different in the different life stages, as well as in 
genetically manipulated cells due in part to mRNA stability (Kabani et al., 2009). 
It is this phenomenon, leading to different abundance of mRNA, that in T. brucei 
is referred to as ‘differential expression’.  
 
A total of 312 genes were significantly differentially expressed (Figure 5.4). Out 
of this total of differentially expressed genes, 18.3% (52) have a gene function 
annotation. Applying a cut-off of ±0.5 log2-fold, lead to about 62 genes being 
upregulated whilst 7 genes were down-regulated when CARP3 was overexpressed 
compared with WT s427 (Appendix 4: Table 1 and 2). Of these upregulated 
genes, the majority were annotated genes (16), followed by hypothetical 
proteins and leucine-rich repeat protein (LRRP) (2) (Figure 5.5). Four annotated 
genes and 3 hypothetical proteins were down-regulated. The highest 
upregulated gene was an Expression Site Associated Gene 3 (ESAG3) 
Tb927.9.16700 (1.89) whilst putative 60S ribosomal protein L5 (Tb927.9.15110) 
most downregulated (-3.00). CARP3 had a log2-fold of 1.58, consistent with the 
level of overexpression determined by qRT-PCR (Chapter 4). The majority of 
these changes have very high p-values (Figure 5.6). There were 3 tandemly 
arranged upregulated adenosine transporter proteins TbNT2 (Tb927.2.6150), 
TbNT4 (Tb927.2.6220) and TbNT6 (Tb927.2.6320) with high p-values (5 x 10-5), 1 
nucleoside transporter Tb927.9.15980 and 1 amino acid transporter 
Tb927.11.15960 with the same p-values. Tb927.11.15950, another amino 
transporter tandem to Tb927.11.15960 was down-regulated with the same p-
value (5 x 10-5).  
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Figure 5.4: Scatterplot of log2-fold differential gene expression of overexpressing CARP3 
against WT s427 cells. Majority of genes were about >±0.5 log2-fold expressed. T= Gene ID 
of each differentially expressed gene.  
 
 
 
 
 
 
 
 
 
Daniel N.A Tagoe  Chapter 5, 157 
 
 
Figure 5.5: Scatterplot of log2-fold differential gene expression and distribution of genes 
showing >±0.5 log2-fold expression in overexpressing CARP3 against WT s427 cells. A) 
Majority of genes that were ≥0.5 log2-folds fell within 0.5-1 log2-fold increased expression. 
B) 16 of these genes have annotation and gene function, 15 were hypothetical proteins and 
2 were leucine-rich repeat protein (LRRP). Only 7 genes were ≥0.5 log2-folds lower 
expressed than in the WT control cells (C). 4 were annotated proteins and 3 hypothetical 
proteins (D). RHS (retrotransposon hot spot), ESAG (expression site associated gene), VSG 
(variant surface glycoprotein)  
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Figure 5.6: Scatterplot of p-value of genes >±0.5 log2-fold against log2-fold expression in 
CARP3 overexpressing and WT s427 cells. A-B) Majority of differentially expressed genes 
were highly significantly expressed having p-values of 5 x 10-5. 
 
Significantly more genes were differentially expressed in the R0.8 cells 
compared with those in CARP3oe using WT s427 as a control. A total of 4103 
genes were differentially expressed (Figure 5.7) with 10.4% (427) being 
functionally annotated. Of the differentially expressed genes, cut-off of ±0.5 
log2-fold shows 276 genes as being upregulated whilst 64 genes were down-
regulated in R0.8 relative to WT s427 cells. Due to the large numbers of 
differentially expressed genes, a further filtering was performed using a cut-off 
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of ±0.75 log2-fold. This resulted in 88 genes being upregulated, whilst 16 genes 
were downregulated (Appendix 5: Table 1 and 2). However, the categories of 
differential expressions were similar to that of CARP3oe with majority of the 
highly expressed genes being hypothetical proteins (132), annotated genes (43) 
VSGs (29) and retrotransposon hot spot (RHS) protein, putative (26). Similarly, a 
majority of the down-regulated genes were hypothetical proteins (48) in 
addition to a number of annotated genes (14) (Figure 5.8).  The majority of the 
genes were significantly expressed at p-value 5 x 10-5 (Figure 5.9).  There were 
12 receptor-type adenylate cyclase GRESAG4s that were highly expressed some 
of which were arranged in tandem on their chromosomes (Tb927.4.3860 and 
Tb927.4.3880), (Tb927.6.170, Tb927.6.310 and Tb927.6.3330) and others were 
not. The highest differentially expressed gene was a VSG (Tb927.9.1050) (5.02), 
whilst the lowest was a hypothetical protein (-2.15). The adenosine transporter 
TbNT6 (Tb927.2.6320) that was overexpressed in CARP3oe was down-regulated in 
R0.8 with the same p-value (5 x 10-5).    
 
 
Figure 5.7: Scatterplot of log2-fold differential gene expression of CpdA resistant R0.8 
against WT s427 cells. Majority of genes were about >±0.5 log2-fold expressed. 
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Figure 5.8: Scatterplot of log2-fold differential gene expression and distribution of genes 
showing >±0.5 and 0.75 log2-fold expression in R0.8 against WT s427 cells. A), C) Majority of 
genes were about 1 log2-fold differential expressed when ±0.75 log2-fold expression was 
used as the cut-off. B) 132 hypothetical genes, 43 annotated genes 20 ESAGS (expression 
site associated gene) and 12 GRESAGs (genes related to expression site associated genes) 
were all differentially expressed at a cut-off of >0.5 log2-fold expression.  D) 48 hypothetical 
and 14 annotated genes were differentially expressed >-0.5 log2-fold expression. Leucine-
rich repeat protein (LRRP), RHS (retrotransposon hot spot), ESAG and VSG (variant surface 
glycoprotein). 
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Figure 5.9: Scatterplot of p-value of genes >±0.75 log2-fold against log2-fold expression in 
R0.8 and WT s427 cells. A-B) Majority of differentially expressed genes were highly 
significantly expressed having p-values of 5 x 10-5. 
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5.4 Discussion 
The discovery of all the CARPs in the RIT-seq validates the genome-wide RNAi 
screen. It also confirms the assertion that there are more proteins involved in 
the downstream signalling of cAMP in T. brucei. The presence of adenylyl 
cyclases, (Tb927.4.4460 and Tb927.4.4470), a receptor-type adenylyl cyclase 
(Tb927.7.7530) and protein phosphatase (Tb927.11.1780) all important 
components of the known cAMP signalling cascade further cements the discovery 
of the role of CpdA in stimulating a cAMP release that triggers a downstream 
effector cascade. For example, Tb927.8.4640 was highly represented in the RIT-
seq, indicating that its knockdown is associated with survival of high levels of 
cellular cAMP. This gene product has been annotated as a putative flagellar 
protofilament ribbon protein, which shares a high sequence identity to that of T. 
cruzi believed to be important in the formation and stabilization of doublet and 
triplet microtubule as well as their organization in a three-dimensional  
structure in C. reinhardtii (Norrander et al., 2000).  This is consistent with 
previous findings that cAMP plays important roles in flagellar motility and 
signalling and that too high cAMP concentration disrupt cytokinesis. Additionally, 
in C. reinhardtii, triggering of zygote formation is initiated by cAMP signalling 
response as a result of flagellum adhesion in gametes (Pan and Snell, 2000). This 
together with CARP3 could be important in the CpdA induced phenotype 
observed in bloodstream forms as well as flagella motility. Recently, it has been 
shown that cAMP regulates social motility in procyclic T. brucei, with social 
motility absent when TbrPDEB1 was inhibited by CpdA or knocked down with 
RNAi. The reduction in PDEB activity appeared to disrupt the generation of an 
extracellular signal necessary for the behaviour, as the social motility was 
completely restored in mixed TbrPDEB1 knockdown and wild-type cells 
(Oberholzer et al., 2015). This is similar to social motility observation in 
Dictyostelium discoideum where cAMP signalling is critical for surface motility 
(Firtel and Meili, 2000). It is believed that the social motility exhibited by the 
procyclic forms is essential for their migration from the tsetse midgut to the 
insect’s salivary gland, which allows it to complete it life cycle. In bloodstream 
forms of T. brucei, the most unambiguous role of cAMP is in cytokinesis, as 
either the knockdown of adenylyl cyclases (Salmon et al., 2012a), knockdown of 
TbrPDEB1 and B2 (Oberholzer et al., 2007) or the pharmacological inhibition of 
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these PDEs (de Koning et al., 2012) all lead to severe defects in the cytokinesis 
phase of cell division, resulting in misshaped cells with multiple nuclei and 
kinetoplasts, that are ultimately non-viable. The roles of these new RIT-seq 
proteins are currently being validated.  
 
Co-IP with the CARP3 polyclonal antiserum followed by MS in all three replicates 
pulled down CARP3 protein; CARP3 pull down was not present in pull downs with 
the anti-CARP1 and anti-CARP2 antisera, which incidentally displayed at best 
marginal selectivity for their target proteins. This clearly confirmed that the 
pull-down worked and the technique was sound. At least one peptide sequence 
from the trypsin digest of CARP3 from all three pulldown has either one 
predicted ubiquitination site or is directly flanked by a ubiquitination site 
consistent with the in-silico prediction of ubiquitination as well the potential 
role of ubiquitination in the regulation of CARP3 protein abundance. 
Additionally, three adenylyl cyclases (Tb927.4.4460, Tb927.4.4410 and 
Tb927.4.4440) were pulled-down more than once with CARP3. These have high 
protein score (75), peptide score (58) and expect values (3.7 x 10-5). 
Interestingly, these were unique to CARP3 pulldown only and were not found in 
either CARP1 or CARP2 pulldown assays. Two additional proteins (Tb927.10.2610 
formerly (Tb10.70.5060) and Tb927.9.16060 formerly (Tb09.244.1960) also 
appeared more than once in the pulldown. Domains found on Tb927.10.2610 
(Tb10.70.5060) include 4x Domain of Unknown Function (DUF) which is also 
found in the cysteine protease (Calpain) and a small myristoylated protein. 
Calpains are ubiquitous calcium-dependent cysteine proteases that are thought 
to function in stimulating Ca2+ signalling resulting in a wide-range of cell 
regulation and differentiation processes (Liu et al., 2010). Ersfeld et al, 
classified all calpain-like proteins in the various kinetoplastids into families using 
data mining and sequence analysis with Tb10.70.5060 being classified in the 
class 1 domain of small kinetoplastid calpain-related protein (SKCRP) (Ersfeld et 
al., 2005). The presence of myristoylated protein and its acylation is usually 
know to result in membrane association (Resh, 1999) which was confirmed when 
related SKCRPs localized to flagellar membrane, flagellum and even the tip of 
flagellum (Liu et al., 2010). Thus Tb927.10.2610 could be a very important 
partner of CARP3 in the downstream regulation of cAMP. Tb927.9.16060 however 
is a small protein (11 kDa) with no annotated domains. Twelve proteins that 
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were pulled down more than once with CARP3 were also found in either CARP1 
(10) or CARP2 (2) pulldowns. Five were conserved hypothetical proteins, 3 VSGs, 
1 each of 60S and 40S ribosomal proteins. Two of the proteins Tb927.9.8740 
(DRBD3 RNA-binding protein, putative; DRBD3) and Tb927.9.4680 (1L12.525 
eukaryotic initiation factor 4a, putative) have been shown in an RNAi high 
through put phenotypic screening to cause abnormal cell proliferation in BSF 
(Alsford et al., 2011b).  
 
Thirty-six proteins uniquely co- immunoprecipitated with CARP3. These include 
proteins of the proteasome complex such as Regulatory Protein Network (RPN6, 
RPN7 and RPN11) and TbPSA6 proteasome alpha 1 subunit, putative; 20S 
proteasome subunit alpha-6, putative. The presence of these proteins as 
apparent interactors is consistent with CARP3 domain annotations as well as the 
observed rapid downregulation of CARP3 protein under specific conditions. There 
were also two receptor-type adenylate cyclases Tb927.4.4470 and Tb927.8.7590. 
Tb927.4.4470 had similar protein (75), peptide (58) and expect score (3.7 x 10-5) 
as those found in more than 1 pulldown. Additionally, it was one of the hits in 
the RIT-Seq similar to Tb927.4.4460. The interaction with multiple adenylate 
cyclases further confirms the regulatory role of CARP3 on ACs and hence on 
cAMP production and levels in the cell. Six additional uniquely associated CARP3 
proteins have been shown to have abnormal phenotypes in RIT-seq analysis 
(Alsford et al., 2011b). Tb927.10.1060 (TCP-1-delta t-complex protein 1, delta 
subunit, putative) is detected in plasma membrane fractions of BSF and is 
indicated to be important in translation initiation in eukaryotes (Dhalia et al., 
2005). Tb927.5.3400 (calcium-translocating P-type ATPase; calcium pump) is 
also enriched in BSF plasma membrane fractions is directly involved in ATP-
dependent Calcium transport across the plasma membrane as well as ATP-
biosynthesis. Tb927.7.6290 (kinesin, putative) has been shown to localized 
exclusively to the axoneme and very important in cilium-dependent cell 
movement (Demonchy et al., 2009). Knockdown of Tb927.7.6290 (TbKIF9A) 
although did not affect flagella structure and components resulted in defective 
cell motility (Demonchy et al., 2009). Increase in cAMP due to either knockdown 
of TbPDEB1 or pharmacological inhibition has been shown to significantly inhibit 
cell motility (Oberholzer et al., 2015). Overexpressing CARP3 results in 
significant increase in cAMP and its association with KIF9A could lead to reduced 
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motility. Translation elongation factor 1-alpha; TEF-1-alpha (Tb927.10.2090) 
detected in both BSF cytoskeleton and plasma membrane fractions has been 
shown to experimentally bind to Calmodulin and involved in calcium-mediated 
signalling (Kaur and Ruben, 1994). Tb927.11.7170 (seryl-tRNA synthetase, 
putative) localizes mostly to the cytosol with an aminoacylation site that differ 
from other species. RNAi ablation of this protein results in cell death which is 
indicative of the essentiality of the enzyme (Geslain et al., 2006). 
Tb927.11.9530 (14-3-3-1 like protein, putative) is of a class of highly conserved 
eukaryotic proteins that functions as molecular chaperones involved in important 
cellular processes such as cell survival and signalling through protein-protein 
interaction that inhibits other protein-protein interactions or by causing 
conformational changes (Dougherty and Morrison, 2004; Inoue et al., 2005). In 
trypanosomes the proteins are diffusely distributed and when knocked down 
resulted in cells with defective motility, significant growth rate reduction and 
morphological changes akin to inhibition of cytokinesis and cell cycle progression 
(Inoue et al., 2005). These features were similar to the phenotype observed 
when CARP3 was over expressed in the presence of CpdA. It has been shown that 
mammalian 14-3-3-1 proteins complex with Protein Phosphatase 1 (PP1) and 2A 
(Pozuelo Rubio et al., 2004) both of which play important roles in mammalian 
cell cycle and sperm motility (Huang et al., 2004).  Inhibiting T. brucei and T. 
cruzi protein phosphatases results in multinucleated cells characteristic of cell 
cycle defects (Das et al., 1994; Orr et al., 2000). This suggests that protein 
phosphatases through de-phosphorylation regulate the activity of 14-3-3 proteins 
by disruption protein-protein interactions leading to aberrant cytokinesis and 
cell division. Importantly, CARP3 have a TPR which is believed to be involved in 
protein-protein interaction and important to its regulatory function. 
Interestingly, RIT-seq revealed a protein phosphatase 2 as one of the 
downstream effectors of cAMP signalling. Thus together, CARP3, 14-3-3-1 and 
PP2 could be involved in a complex regulatory mechanism that drives phenotype 
observed in the inhibition of TbPDEB1 with CpdA; this process is exacerbated 
when CARP3 is overexpressed due to its influence on cAMP levels through direct 
interaction with the cyclases, and the concomitant effect on its turnover and 
thus regulatory activity.   
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There were several hypothetical conserved proteins (9) and VSGs (7) that 
immuno-precipitated with CARP3 only were not found in CARP1 or CARP2 pull 
downs. Forty-nine proteins were found in either CARP1 or CARP2 pull-down 
whilst 61 were found in both pull downs.  Further work is ongoing to confirm 
this, among other interactions, to help better define the downstream cAMP 
signalling cascade in T. brucei. 
 
Most of the genes differentially overexpressed in CARP3oe were annotated genes. 
Genes such as Gim5A (Tb927.9.11580) a glycosomal membrane protein and 
CFB1B (Tb927.1.4560) cyclin-like-F-box protein have been implicated in 
abnormal cell proliferation (Alsford et al., 2011a; Alsford et al., 2011b) and 
growth arrest due to inhibition in cytokinesis (Benz and Clayton, 2007). Tb-17, a 
flagellar calcium-binding protein is important in cilium or flagellum dependent 
cell motility through calcium ion transport and binding (Wu et al., 1994). The 
three nucleoside transporters TbNT2/927, TbNT4 and TbNT6 could be important 
components of the extrusion of cAMP from the cell. These transporters have the 
classical transmembrane domains and are involved in an ATP-dependent active 
uptake of purines (de Koning and Jarvis, 1999; Sanchez et al., 1999). They have 
also been linked with nifurtimox efficacy and potential resistance when knocked 
down using RNAi (Alsford et al., 2012b). Another upregulated transporter is the 
nucleoside transporter 1, (Tb927.9.15980) with 11 transmembrane domains and 
similar attributes to that of the other transporters. It has previously been 
designated as TbNT11.1 and shown to transport pentamidine in Xenopus oocytes 
(Ortiz et al., 2009). Two tandemly arranged amino acid transporters were found 
to be either overexpressed (Tb927.11.15960) or under expressed 
(Tb927.11.15950). Both genes were found to be curated in a RIT-Seq phenotype 
to have abnormal cell proliferation in bloodstream form trypomastigotes. 
Overexpressing CARP3 results in a significant extrusion of cAMP which results in 
significant increase in extracellular cAMP. Extrusion of cAMP is an ATP-
dependent active process which could be undertaken by one of these 
transporters or possibly one of the hypothetical proteins.  
 
Most of the differentially expressed genes in R0.8, relative to WT s427, displayed 
differences 0.75 log2 fold differential expression and are annotated as 
hypothetical proteins, VSGs, RHS (retrotransposon hot spot) proteins and LRRPs 
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(leucine-rich repeat protein). The few interesting genes include the GRESAG4s. 
These are important because R0.8 has a higher tolerance to cAMP and also 
secretes more extracellular cAMP than WT s427. Thus it is most likely that in the 
process of adapting to higher concentrations of CpdA, during the generation of 
this resistant line, these genes were upregulated. This is similar to the fact that 
besides CARP3 (with log2-fold differential of 0.005) which was not differentially 
expressed, CARP1 (0.26), CARP2 (0.35) and CARP4 (0.21) were all significantly 
log2 differentially expressed although below both 0.5 and 0.75. Additionally, 
both TbPDEB1 (0.09) and TbPDEB2 (0.12) were not differentially expressed. This 
contrasts with the fact that knockout of these CARPs and overexpression of 
TbPDEB1 causes significant resistance to CpdA. It was also previously shown that 
none of the CARPs were mutated in R0.8 cells when the genes were extracted, 
cloned into E. coli and Sanger sequenced (Gould et al., 2013). Thus it is likely 
that resistance to CpdA will involve several protein components of which some 
will be hypothetical proteins, GRESAG4s, possibly ESAGs, CARPs and other 
annotated proteins. The fact that CARP3 and the TbPDEB1/2 were both not 
differentially expressed could be indicative of their importance in the 
manipulation and signalling of cAMP and hence will be under tighter regulation. 
Only a few genes were downregulated. Serine threonine-protein phosphatase 
PP1, putative (Tb927.4.3630) was differentially down regulated with a log2 fold 
of -1.14. It has been implicated in quorum sensing as a component of the stumpy 
induction factor (SIF) signalling pathway (Mony et al., 2014). This could be 
important in the reduced growth rate of R0.8 cells compared with WT s427 as it 
could decrease stumpy formation and thus cell death in in vitro assays. 
Interestingly, one of the nucleoside transporters TbNT6 was also down regulated 
as well as a few hypothetical proteins and ESAGs. 
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6.0 General Discussion 
A major collaborative effort from the WHO and its partners have resulted in a 
drastic decline in the deaths and levels of infection in trypanosomiasis (Simarro 
et al., 2011). This decline has been achieved using the present therapeutic 
options although they are old, toxic and difficult to administer (Barrett, 2010; 
Delespaux and de Koning, 2007; Jacobs et al., 2011a; Kennedy, 2008a).Yet the 
current increase in resistance to these drugs is very worrying (Baker et al., 2013; 
Simarro et al., 2012a; Vincent et al., 2010).Thus the possibility of failure of the 
current treatment options together with previous experiences with recurrent 
epidemics even after near-eradication, migration and the instability in many 
endemic regions calls for caution in relation to the current optimism about 
elimination of the disease (Blum et al., 2012; Mumba et al., 2011; Odiit et al., 
2005; Picozzi et al., 2005). However, the above problems are compounded by 
the fact that almost all of the current drugs used for treatment do not meet 
present day pharmacological standards. This is mostly due to the toxic nature of 
these drugs to humans. Thus the pipeline of drug discovery needs to remain open 
and be filled with potential candidates to ensure that the drive for elimination is 
sustained. To do this, there is a need to understand the cell biology of the 
trypanosomes, so as to develop drugs that are trypanosome target specific and 
therapeutically beneficial. One recent approach was to apply drug repurposing 
which is a cheaper and more affordable way to fill the drug discovery pipeline 
(Pollastri and Campbell, 2011) especially for neglected tropical diseases (NTDs).  
 
One of the more interesting and important candidates for repurposing in 
trypanosome diseases are PDE inhibitors. PDEs have long been recognised as very 
amenable druggable targets (Bender and Beavo, 2006). This is because their 
substrate cAMP and cGMP have been found in every tissue and that their 
degradation can often make a more rapid and larger percentage change in 
concentration than comparable regulation of the rates of synthesis (Bender and 
Beavo, 2006). They are usually large in numbers (11 genes in humans), each of 
which often have unique architecture and quite often physiological function, 
isoform specific and catalytically dependent activity within the same PDE as well 
as tissue or cell specific activity due to compartmentalization (Bender and 
Beavo, 2006; Dorsey et al., 2010; Francis et al., 2011c; Galie et al., 2010; 
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Ghofrani et al., 2006; Jaski et al., 1985; Johner et al., 2006; Maurice et al., 
2014; Omori and Kotera, 2007b). Major efforts, and important successes, are 
ongoing in the pharmacological exploitation of human PDEs (Azam and 
Tripuraneni, 2014; Chen et al.; Fallah, 2015; Maurice et al., 2014). The 
kinetoplastid genomes all code for the same set of cyclic nucleotide-specific 
class 1 type phosphodiesterases with catalytic domains similar to those of the 
human PDEs (Beavo, 1995; Kunz et al., 2006). Trypanosoma brucei codes for 4-5 
PDEs which are TbPDEA, TbPDEB1/B2, TbPDEBC and TbPDED; PDEB1 and B2 are 
almost identical. This, on the one hand makes them great targets for compounds 
or drugs that target human PDEs, whilst on the other, raises the issue of toxicity. 
However, this toxicity could be ameliorated by studying the structure activity 
relationships (SAR) of individual PDEs with the aim of making the PDE inhibitor 
more Trypanosoma PDE specific and reduce potential side effect. Trypanosoma 
brucei PDEB1/2 was previously shown to be essential for cell proliferation with 
both in vitro and in vivo inhibition using RNAi leading to severe cell cycle 
defects and cell death with an attendant several fold increase in cAMP 
(Oberholzer et al., 2007). CpdA, tetrahydrophthalazinone compound was shown 
to inhibit TbPDEB1 and TbPDEB2 at low nanomolar concentrations affecting 
trypanosome viability similar to the RNAi knockdown (de Koning et al., 2012). 
Similarly, CpdA raises cAMP levels several folds resulting in cytokinesis defect 
(de Koning et al., 2012).  
 
Cyclic AMP has been implicated in several developmental and lifecycle effect in 
trypanosomes since it was first discovered. It has been associated together with 
stumpy induction factor “SIF” to be involve in driving differentiation of long 
slender BSF to short stumpy forms (Mancini and Patton, 1981) similar to quorum-
sensing systems found in microbial communities (Waters and Bassler, 2005). 
Some hydrolysable cAMP analogues have been shown to drive differentiation of 
long slender BSF to short stumpy forms together with genes involved in purine 
metabolism and signal transduction (kinases, phosphatases) to gene expression 
regulators (Mony et al., 2014).  Additionally, cAMP regulation through adenylate 
cyclases (ACs) have been implicated in defective cytokinesis and the 
manipulation of the immune response to trypanosome infection (Salmon et al., 
2012b). Cyclic AMP through Protein Kinase A stimulation has been shown to drive 
differentiation in T. cruzi  (Flawia et al., 1997), promastigote proliferation and 
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infectivity in Leishmania amazonensis (Genestra et al., 2004), and flagellar 
motility and signalling in T. brucei procyclics (Oberholzer et al., 2015; Rotureau 
et al., 2009; Tetley and Vickerman, 1985). Pharmacological inhibition of 
TbPDEB1 by CpdA has been shown to disrupt the generation of an extracellular 
signal necessary for social motility (Oberholzer et al., 2015) the behaviour 
confirming the importance of TbPDEB1 inhibition derived increase in cAMP in the 
cellular activity of the trypanosomes.  
 
However, the TbPDEB family has been shown to be pharmacologically highly 
similar to the human PDEs, particularly hPDE4, such that piclamilast, a human 
PDE4 inhibitor and several of its analogues inhibited the TbPDEB isoforms (Bland 
et al., 2011). Furthermore, CpdA the most potent TbPDEB inhibitor discovered to 
date,  was found to be an even more potent inhibitor of human PDE4 (Van der 
Mey et al., 2001a; Van der Mey et al., 2001b). The discovery of P-pocket in the 
crystal structure of the highly conserved catalytic domain of LmjPDEB1 (Wang et 
al., 2007), could theoretically allow for the development of kinetoplastid 
specific PDE inhibitors with minimal or no cross reactivity with mammalian PDEs. 
This provides some optimism that it is feasible, through a structure-driven QSAR 
approach, to develop selective inhibitors of some of the trypanosomatid PDEs 
that have been shown to be essential  (Amata et al., 2015; Amata et al., 2014; 
Blazer et al., 2010; de Koning et al., 2012).  
 
Alternatively, to overcome the lingering potential toxicity effect, proteins 
downstream of TbPDEB1 inhibition and cAMP signalling could offer new 
therapeutic targets that are unique to trypanosomes. Thus using CpdA, Gould et 
al., applied a genome-wide RNAi T. b. brucei RNA library (Alsford et al., 2012b; 
Alsford et al., 2011b; Baker et al., 2011) to select for genes driving resistance 
under CpdA pressure which were designated cAMP Response Proteins (CARPs) 
CARP1-4. Targeted RNAi knockdown of these CARPs confirmed a significant 
increase in resistance to CpdA and to elevated cellular cAMP levels, confirming 
that they are real downstream effectors of cAMP signalling. One of the genes 
knocked down in the CpdA-resistant cultures was Tb427tmp.01.7890 (CARP1; 
Tb927.11.16210 in T. brucei brucei reference strain TREU 927), encoding a 705-
amino-acid protein containing two apparently intact and one partial cyclic AMP 
binding-like domains that is conserved in synteny in each of the kinetoplastid 
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genomes sequenced. Recently, the homolog of CARP1 in T. cruzi 
TcCLB.508523.80 has been revealed to bind cyclic nucleotides, using cAMP and 
cGMP displacement assays (Jäger et al., 2014) further validating the role of 
CARP1 as a downstream cAMP signalling effector. CARP2-4 are proteins of as yet 
unknown functions but some of them have probable flagellar localisation, 
consistent with a role in mediating or regulating a cAMP signal (Gould et al., 
2013). CARP1 and CARP3 are kinetoplastid specific with CARP3 being 
trypanosome specific. CARP2 and CARP4 are well conserved among the 
kinetoplastida but found in other species too. However, it was still important to 
determine which of these CARPs or which combination if any drives the observed 
phenotypic response of cytokinesis defect. Thus the characterization of the 
CARPs could reveal unique kinetoplastid targets for drug discovery and 
dramatically increase our understanding of the downstream cAMP signalling 
cascades, and of the cell biology of the trypanosome.  
 
Single gene deletion of any of the CARPs decreased the sensitivity of T. brucei 
bloodstream forms to CpdA as expected from the RNAi knockdown phenotypes 
(Gould et al., 2013) but not cell growth in standard medium. However, double 
gene deletion resulted in a significant loss of growth fitness in CARP2 null 
mutant cells. This was accompanied by a significant increase in intracellular 
cAMP in these cells compared with WT s427. Either the loss of gene function or 
the sharp increase in cAMP levels, or likely the combination of both, resulted in 
the growth phenotype as the loss of both CARP3 and CARP4 genes and increase 
in cAMP did not show the same phenotype. CpdA causing a cAMP increase in 
these cells restored growth to levels of WT s427 in similar condition and further 
drives cAMP increase in this cell confirming that loss of gene rather than 
increase in cAMP was responsible for the delay in growth in these CARP2 dKO. 
However, significant increase in cAMP in only the null mutants suggests that 
these proteins are important in the downstream dissemination of cAMP. Thus 
inhibition of CARP2 could results in a direct therapeutic intervention in 
trypanosomiasis although CARP2 dKO cells can, with difficulty, be generated. 
This is unsurprising since CARP2 has been detected in proteomes of T. brucei 
brucei flagellum (Broadhead et al., 2006) and of cytoskeletal and plasma 
membrane fractions (Bridges et al., 2008), as well as in an in silico predicted 
proteome of the flagellar and basal body of Chlamydomonas reinhardtii (Li et 
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al., 2004; Merchant et al., 2007). The flagellum is a very essential feature in 
flagellated organisms. For example it is commonly believed that the flagellum, 
as an important host-parasite interface, has essential sensory functions 
(Rotureau et al., 2009; Tetley and Vickerman, 1985). For example in C. 
reinhardtii, triggering of zygote formation is initiated by cAMP signalling 
response as a result of flagellum adhesion in gametes (Pan and Snell, 2000). 
However, there is no known function, and no recognizable functional domains 
identified in any of the homologues of CARP2. Thus it is annotated to have a 
Domain of Unknown Function (DUF) of which there are about 3600 (Punta et al., 
2012) and about 1,500 in eukaryotes (Goodacre et al., 2014). Thus there would 
be a high potential of off target effect especially since there are similar 
homologues in other organisms.  
 
Overexpressing of CARP1, 2 and 4 did not result in any differences in cAMP levels 
compared with WT s427. The cells were not sensitized to CpdA and their growth 
with or without CpdA were not significantly affected. However, their expression 
levels decreased significantly in WT s427 cells but increased significantly in R0.8 
cells when CpdA was added to the medium. In contrast, overexpressing CARP3 
results in a growth phenotype in the presence of CpdA, significant 
sensitivitization to CpdA, an increase in both the basal and CpdA-induced 
intracellular and extracellular concentrations of cAMP, and a significant 
decrease in mRNA and protein levels in CpdA in both WT s427 and R0.8 cells. The 
fact that both the sensitization to CpdA and growth are associated with dramatic 
increases in cAMP levels and decrease in CARP3 transcript and protein levels 
suggests that both factors are required for these observations to occur. This was 
further confirmed in both the WT s427 and R0.8 control cells which , in the 
presence of CpdA, both CARP3 transcript and protein levels decreasing (WT s427) 
or unchanged (R0.8) unlike the other CARPs in either WT s427 or R0.8. 
 
In silico predictions of CARP3 motif and annotations shows the presence of 
tetratricopeptide repeat (TPR) and Protein database (PDB) annotations such as 
signalling protein, membrane protein, protein binding/transport protein, 
Peroxisome Targeting Signal 1 Receptor (PEX5), Regulatory Protein and 
ubiquitination sites among others (Biasini et al., 2014; Kelley and Sternberg, 
2009; Radivojac et al., 2010; Yang et al., 2015).  These predictions were 
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validated in the Co-IP and MS of CARP3 with the detection of several proteasome 
regulatory proteins (RPNs), PSA4 proteasome alpha 7 subunit, UBA1 ubiquitin-
activating enzyme E1, putative, membrane and flagellar binding proteins, 
GRESAG4s and ESAGs and signalling proteins. Thus it is likely that cAMP above a 
certain threshold will cause ubiquitination of CARP3, priming it for transport to 
the proteasome for degradation. CARP3 protein degradation in turn could signal 
a reduction in the production of CARP3 through a reduced steady-state level of 
its mRNA. This would explain both the down regulation and CARP3 protein turn 
over after the addition of CpdA. Thus clearly, the presence of CARP3 and an 
increase in cAMP to a certain threshold level is required to cause the phenotype 
of cytokinesis defect which results in growth delays. Importantly, the GRESAG4s 
(Tb927.4.4460 and Tb927.4.4470) were also hits in the RIT-seq among several 
important signalling mediated proteins. The fact that these GRESAG4s were only 
found in the CARP3 pulldown and not in any of the CARPs pulldown validates the 
role of CARP3 as a protein involve in a protein-protein interaction as well as a 
regulator of cAMP levels through regulation of ACs. This explains why CARP3 was 
the only CARP that significantly increased cAMP when overexpressed. The 
regulation of GRESAG4 (Tb927.4.4460) was validated by showing that there is a 
direct relation of reduction in CARP3 mRNA and protein levels, and the 
abundance of GRESAG4 (Tb927.4.4460) transcript.  
 
Preliminary IFA show CARP3 localizes to the plasma membrane confirming 
previous observations of CARP3 peptide detection in the plasma membrane and 
flagellar of both BSF and PCF (Bridges et al., 2008; Subota et al., 2014). 
Prediction analysis indicates the possibility of CARP3 undergoing both 
myristoylation and palmitoylation both of which could lead to dual localization 
as observed for POMP39  (Albisetti et al., 2015).  
Overexpressing CARP3 led to significant overexpressing of Gim5A 
(Tb927.9.11580) a glycosomal membrane protein and CFB1B (Tb927.1.4560) 
cyclin-like-F-box protein among several hypothetical proteins and nucleoside and 
amino acid transporters. RNAi against Gim5A  have been implicated in abnormal 
cell proliferation (Alsford et al., 2011b) whilst overexpression of CFB1B results in 
reduced cell proliferation and growth arrest due to inhibition in cytokinesis 
(Benz and Clayton, 2007) similar to CpdA effect. Tb-17, a flagellar calcium-
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binding protein is important in cilium or flagellum dependent cell motility 
through calcium ion transport and binding (Wu et al., 1994). Both CARP3 (0.005) 
and TbPDEB1 (0.09) were not significantly differentially expressed in R0.8 cells 
probably indicative of their importance in cAMP manipulation and regulation.  
 
6.1 Proposed model of the role of CARP3 in the regulation and 
downstream signalling of cAMP in Trypanosoma brucei 
Based on the above findings, we proposed a role for CARP3 as an important and 
integral component of the downstream signalling of cAMP in T. brucei. The 
addition of CpdA inhibits TbPDEB1 which leads to an accumulation of cAMP. The 
accumulation of intracellularly cAMP subsequently causes an increase in 
extrusion of cAMP from the cell. The accumulation of cAMP above a certain 
threshold possibly causes CARP3 to be ubiquitinated leading to it being likely 
targeted to the proteasome to be degraded. This proposed degradation is 
thought to subsequently result in a significant reduction in mRNA of 
Tb927.4.4460 (GRESAG4.4B), although it is unclear at this moment by which 
mechanism. Reduction of (GRESAG4.4B mRNA) should in turn decrease the 
conversion of ATP into cAMP. Finally, degradation of CARP3 is conjectured to 
lead to disruption of CARP3-protein interactions which probably drives cellular 
regulation processes such as cytokinesis, cell motility and other important 
flagellum functions. 
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Figure 6.1:  Proposed model of the role of CARP3 in the regulation and downstream 
signalling of cAMP in Trypanosoma brucei. The figure shows CARP3 interacting with the 
various components of the cAMP signalling and the role of CpdA in triggering this cascade 
that leads to cellular regulation. 
 
The crystal structure of CARP3 is presently being determined in collaboration 
with Dr David Brown of the University of Kent. This will provide a structure of 
CARP3 and further confirm the various annotated regions determined from the in 
silico modelling as well as from the various hits from the Co-IP and MS. With the 
structure in place, potential experiments to validate certain components of the 
model will include, 
1. Expressing a truncated version of CARP3 without the TPR to confirm its 
involvement in a protein-protein interaction, or alternatively, a mutated 
version with a disrupted TPR domain 
2.  Use of a proteasome inhibitor to confirm or otherwise proteasome 
mediated CARP3 degradation 
3. Yeast-2-Hybrid analysis of CARP3 and some of the key proteins from both 
the Co-IP and RNA-seq.  
Finally, the arrangement (positioning) of the various CARP proteins downstream 
of the signalling cascade (stream) will provide very interesting answers as to how 
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cAMP is signalled down after TbPDEB1 inhibition. The confirmation of 
interactions of CARP3 with if any of the other CARPs or, our investigation 
indicates, interaction with other proteins would provide valuable insights into 
the downstream cascade of cAMP of trypanosomes.  
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Appendix 1: Table of primers used in genetic manipulation of T. brucei. 
Table 1.1: Primers for amplification of Untranslated Regions (UTRs) of the CARPs for the 
making of pMB homologous gene replacement of antibiotic constructs   
Gene Primer 
name 
Position Res. 
site 
Sequence 
 
CARP1 
HDK369 5’Forward NotI 5′- CGCGGCCGCGGCATGGAAGCAAACCA-3′ 
HDK370 5’Reverse XbaI 5′- CGTCTAGAGCCAACCACCAGTTGTGG-3′ 
HDK371 3’Forward NsiI 5′- GATGCATAGATGTGAAGCGGACACC-3′ 
HDK372 3’Reverse XhoI 5′- GCTCGAGACTGCCCATACATTGCGG-3′, 
 
 
CARP2 
HDK372 5’Forward NotI 5′- CGCGGCCGCAGGGGACCGCAGTTGCA-3′’ 
HDK374 5’Reverse XbaI 5′- CGTCTAGAGGATACGGCACCACCGGG-3′ 
HDK375 3’Forward NsiI 5′- GATGCATCCCTAGCTTTTACCTTGG-3′ 
HDK376 3’Reverse XhoI 5′- GCTCGAGATTGTGTTGAGGGAGCCC-3′ 
 
 
CARP3 
HDK377 5’Forward NotI 5′- CGCGGCCGCGCCGCCGCATTATCACT-3′ 
HDK378 5’Reverse XbaI 5′- CGTCTAGACAAGCGTGACAATTGCAC-3′ 
HDK379 3’Forward NsiI 5′- GATGCATGGATGGGTGGATGTGAGA-3′ 
HDK380 3’Reverse XhoI 5’- GCTCGAGATATTTCCGCCCGCTCCT-3′ 
 
 
CARP4 
HDK471 5’Forward NotI 5′-GATCGCGGCCGCCTTGCCCCATATAAC-3′ 
HDK472 5’Reverse XbaI 5′-GATCTCTAGATGCAACTAATTAAAATC-3′ 
HDK589 3’Forward NsiI 5′-GCCTATGCATGGTGGATACACATCTTGTC-3′ 
HDK590 3’Reverse XhoI 5′-GATCCTCGAGTCAACGGATTTATACCA-3′ 
 
Table 1.2: Primers for amplification of Open Reading Frame (ORF) of the CARP genes, for 
making of pHD1336 over-expression constructs 
Gene Primer 
name 
Position Res. 
site 
Sequence 
CARP1 
HDK361 Forward ApaI 5′-GGGGCCCATGGGTAGTTATGAATACCC-3′ 
HDK362 Reverse BamHI 5′-GGGATCCTTACCTTTTCGCCATGAACT-3′ 
CARP2 
HDK363 Forward ApaI 5′-GGGGCCCATGCGAATACTTGCAGACTT-3′ 
HDK364 Reverse BamHI 5′-GGGATCCCTAGTTCTTACGGCGCGTAA-3′ 
CARP3 
HDK365 Forward ApaI 5′-GGGGCCCATGGGAGGAGGTTCATCCGT-3′ 
HDK366 Reverse BamHI 5′-GGGATCCTTAGTTCAATTGGTCATCAA-3′ 
CARP4 
HDK475 Forward ApaI 5′-GATCGGGCCCATGAAGAACAGTGTTGC-3′ 
HDK591 Reverse BamHI 5′-GATCGGATCCTTCGTTCTTCATGTAAC-3′ 
TbPDEB1 
HDK367 Forward ApaI 5′-GGGGCCCATGTTCATGAACAAGCCCTT-3′ 
HDK368 Reverse BamHI 5′-GGGATCCTCAACGAGTACTGCTGTTGT-3′ 
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Table 1.3: Primers for making N-Terminal GFP-tagged construct in pRPa  
Gene Primer 
name 
Position Res. 
site 
Sequence 
CARP1 
HDK421 Forward XbaI 5′-GGTCTAGAATGGGTAGTTATGAATACCC-3′ 
HDK362 Reverse BamHI 5′-GGGATCCTTACCTTTTCGCCATGAACT-3′ 
CARP2 
HDK422 Forward XbaI 5′-GGTCTAGAATGCGAATACTTGCAGACTT-3′ 
HDK364 Reverse BamHI 5′-GGGATCCCTAGTTCTTACGGCGCGTAA-3′ 
CARP3 
HDK423 Forward XbaI 5′-GGTCTAGAATGGGAGGAGGTTCATCCGT-3′ 
HDK366 Reverse BamHI 5′-GGGATCCTTAGTTCAATTGGTCATCAA-3′ 
 
 
Table 1.4: Primers used to check for correct integration of KO UTRs and antibiotics in CARP 
KO cells 
Gene Primer 
name 
Position Sequence 
CARP1 
HDK0405 Forward 5′-GGGGCCGATTGCATCAAAA-3′ 
HDK0408 Reverse 5′-TTGCCTTGAATAGACCATACG-3′ 
CARP2 
HDK0409 Forward 5′-TTTCCCTCCCTCTTTCCCA-3′ 
HDK0412 Reverse 5′-GCAAACAGACATACAAACG-3′ 
CARP3 
HDK0413 Forward 5′-CTACCTGTCAGGTTGGACT-3′ 
HDK0416 Reverse 5′-TCGCCCTCAACTTTGCCAA-3′ 
CARP4 
HDK509 Forward 5′-CTTGGGCAGGAGGTCCTATTTC-3′ 
HDK0655 Reverse 5′-ATGACGGCATTCACGTCAC-3′ 
Blasticidin 
HDK0282 Forward 5′-ATGGCCAAGCCTTTGTCT-3′ 
HDK0283 Reverse 5′-TATGTGTGGGAGGGC-3′ 
Neomycin 
HDK0284 Forward 5′-CGAATTCATGATTGAACAAGATGGAT-3′ 
HDK0285 Reverse 5′-CGAATTCTCAGAAGAACTCGTCAAGA-3′ 
Hygromycin 
MB0416 Forward 5′-ATGAAAAAGCCTGAACTCAC-3′ 
MB0415 Reverse 5′-CGTCCGAGGGCAAAGGAATA-3′ 
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Table 1.5: Primers used for qRT-PCR after genetic manipulation of the CARPs 
Gene Primer name Position Sequence 
CARP1 
qCARP1F Forward 5′-GTTTTTTGATGGATGGCCAAA-3′ 
qCARP1R Reverse 5′-ACGAGCCCTCCTTCAGATACAG-3′ 
CARP2 
qCARP2F Forward 5′-GGTGTCCGCCTACATCGATT-3′ 
qCARP2R Reverse 5′-CGGTGGAAGTAGTCGGAGAAGT-3′ 
CARP3 
qCARP3F Forward 5′-TCAGTTGCGCACCGACAT-3′ 
qCARP3R Reverse 5′-TGCTCGTGTGCCTCTTCGT-3′ 
CARP4 
qCARP4F Forward 5′-TGAGGAAGGTTTGCATTCGTT-3′ 
qCARP4R Reverse 5′-GCTTCGCCTCTTGCACAGAT-3′ 
TbPDEB1 
qTbPDEB1F Forward 5′-CAAAGCGGATTTACTCCAACAAG-3′ 
qTbPDEB1R Reverse 5′-TGCGTCATTGTGTGCTCCAT-3′ 
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Appendix 2: Table showing hits from RIT-Seq with normalized reads ≥0.05  
Gene ID Gene Name Raw-total counts Transcript length Normalised 
mapping 
Tb927.11.16210 CARP1 74563689.000 2119 353.9897 
Tb927.10.12390 Hypothetical protein unknown 4958603.000 778 64.1171 
Tb927.10.1740 Hypothetical protein unknown 3574752.000 1150 31.2710 
Tb927.7.5340 CARP3 2552287.000 1498 17.1400 
Tb927.11.17380 Pseudogene? 310784.000 561 5.5730 
Tb927.11.12860 CARP2 447275.000 910 4.9446 
Tb927.11.3910 Hypothetical protein unknown 1127550.000 3328 3.4084 
Tb927.3.1040/60 CARP4 3235998 2340 3.2603 
Tb927.8.4640 Flagellar protofilament ribbon protein 263956.000 1159 2.2911 
Tb927.11.7180 Hypothetical protein unknown 354258.000 1963 1.8155 
Tb927.7.4100 Hypothetical protein unknown 196944.000 1504 1.3173 
Tb927.4.4450 Adenylyl cyclase  439975.000 3733 1.1857 
Tb927.7.7530 
Receptor-type adenylate cyclase 
GRESAG 4 322614.000 3733 0.8694 
Tb927.7.4510 Hypothetical protein unknown 97169.000 1225 0.7980 
Tb927.10.12210 Ribulose-5-phosphate 3-epimerase 58772.000 742 0.7968 
Tb927.10.16200 Hypothetical protein unknown 202451.000 3070 0.6634 
Tb927.8.3700 Hypothetical protein unknown 225999.000 4462 0.5095 
Tb927.11.1780 Protein phosphatase 46503.000 1006 0.4650 
Tb927.4.4460 Adenylyl cyclase 168889.000 3868 0.4392 
Tb927.4.4470 Adenylyl cyclase 143705.000 3817 0.3787 
Tb927.11.14020 Iron superoxide dismutase 28601.000 841 0.3421 
Tb927.7.5860 Hypothetical protein 18943.000 580 0.3286 
Tb927.9.13300 Ring finger domain containing protein 50885.000 1582 0.3236 
Tb927.10.1750 Hypothetical protein 21966.000 730 0.3027 
Tb927.11.14010 Hypothetical protein 22112.000 760 0.2927 
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Gene ID  Raw-total counts Transcript length Normalised 
mapping 
Tb927.10.16210 Hypothetical protein 25512.000 910 0.2820 
Tb927.7.2320 
Cyclic nucleotide-binding domain 
containing protein 48420.000 1819 0.2678 
Tb927.11.10430 Hypothetical protein 31264.000 1708 0.1841 
Tb927.2.2860 Hypothetical protein 19175.000 1108 0.1741 
Tb927.7.4600 
Calponin homology (CH) domain 
containing protein 47836.000 2833 0.1699 
Tb927.10.14460 Leucine-rich repeat protein (LRRP) 40057.000 3040 0.1326 
Tb927.3.1630 Casein kinase 1 15708.000 1204 0.1312 
Tb927.9.12800 Hypothetical protein 35544.000 3181 0.1124 
Tb927.11.3710 Hypothetical protein 13073.000 1549 0.0849 
Tb927.3.5010 Hypothetical protein 4914.000 583 0.0848 
Tb927.8.4660 Hypothetical protein 26676.000 3166 0.0848 
Tb927.10.6910 Sterol methyltransferase 7983.000 1081 0.0743 
Tb927.4.890 
Small nuclear ribonucleoprotein 
SmD3 2377.000 349 0.0685 
Tb927.10.13950 Tubulin-specific chaperone 4338.000 700 0.0623 
Tb927.2.2950 Nop14-like family 17572.000 2869 0.0616 
Tb927.7.2310 DNA primase small subunit 6952.000 1267 0.0552 
Tb927.11.2700 Hypothetical protein 9586.000 1891 0.0510 
Tb927.11.11410 Trans-sialidase 10355.000 2047 0.0509 
Tb927.6.1890 Hypothetical protein 9034.000 1810 0.0502 
Tb927.10.4150 Hypothetical protein 1738.000 391 0.0447 
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Appendix 3: Table showing hits from Co-IP AND MS of CARP3 with expect ≤0.05 compared with CARP1 and CARP2  
Table 3.1: Hits found in more than 1 Co-IP and MS of CARP3 compared with CARP1 and CARP2 
 
Gene ID 
 
Annotation and Product 
 
Found in 
 
Size 
(kDa) 
 
Protein 
Score 
 
Peptide 
Score 
 
Expect 
 
Sequence 
Coverage (%) 
Tb927.7.5340 CARP3 3 only 57 78 77.8 4.2 x 10-7 13 
Tb927.4.4460 GRESAG 4.4B receptor-type adenylate cyclase 
GRESAG 4, putative 
3 only 144 75 58 3.7 x 10-5 6 
Tb927.4.4410 receptor-type adenylate cyclase GRESAG 4, 
putative 
3 only 138 75 58 3.7 x 10-5 3 
Tb927.4.4440 receptor-type adenylate cyclase GRESAG 4, 
putative 
3 only 138 75 58 3.7 x 10-5 3 
Tb927.10.2610 hypothetical protein, conserved 3 only 54 80 55 0.0001 5 
Tb927.9.16060 hypothetical protein 3 only 11 40 40 0.0033 10 
Tb927.9.8740 DRBD3 RNA-binding protein, putative; DRBD3 Also in 1 40 62 62 2.1 x 10-5 7 
Tb927.9.4680 1L12.525 eukaryotic initiation factor 4a, putative Also in 1 45 36 36 0.0079 6 
Tb927.2.2550 10C8.75 hypothetical protein, conserved Also in 1 57 39 33 0.016 1 
Tb927.10.3010 hypothetical protein, conserved Also in 1 133 38 38 0.0046 3 
Tb927.1.1330 hypothetical protein, conserved Also in 1 46 36 36 0.0098 7 
Tb927.10.14320 hypothetical protein, conserved Also in 1 121 35 33 0.015 3 
Tb927.10.4660 hypothetical protein, conserved Also in 1 20 30 30 0.038 4 
Tb927.11.17780 variant surface glycoprotein (VSG, pseudogene), 
putative 
Also in 1 54 36 36 0.0076 7 
Tb11.0640 variant surface glycoprotein (VSG, pseudogene), 
putative 
Also in 1 53 31 33 0.016 5 
Tb927.8.320 variant surface glycoprotein (VSG, pseudogene), 
putative 
Also in 1 51 28 28 0.043 14 
Tb927.3.5050 60S ribosomal protein L4 Also in 2 42 44 44 0.00081 7 
Tb927.11.6140 40S ribosomal protein S15a, putative Also in 2 14 28 28 0.037 10 
Tb927.11.7460 glucose-regulated protein 78, putative; luminal 
binding protein 1 (BiP), putative 
1 & 2 71 1427 113 1 x 10-10 37 
Tb927.9.12570 glk1 glycerol kinase, glycosomal 1 & 2 56 534 101 1.6 x 10-9 23 
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Gene ID Annotation and Product Found in 
Size 
(kDa) 
 
Protein 
Score 
 
Peptide 
Score 
 
 
Expect 
Sequence 
Coverage (%) 
Tb927.3.3270  TbPFK ATP-dependent phosphofructokinase 1 & 2 53 225 58 6.5 x 10-5 18 
Tb927.10.14140  PYK1 pyruvate kinase 1 1 & 2 38 201 91 1.8 x 10-8 16 
Tb927.4.2530 hypothetical protein, conserved 1 & 2 16 161 68 5.2 x 10-6 24 
Tb927.11.11290 heat shock protein 70, putative 1 & 2 73 124 102 2 x 10-9 8 
Tb927.11.11680 2-oxoglutarate dehydrogenase, E2 component, 
dihydrolipoamide succinyltransferase, putative 1 & 2 41 95 69 8.9 x 10-6 6 
Tb927.1.700  PGKC phosphoglycerate kinase 1 & 2 47 77 49 0.00032 9 
Tb927.5.1210 short-chain dehydrogenase, putative 1 & 2 33 56 40 0.0031 8 
Tb927.2.5160  30J2.30 chaperone protein DnaJ, putative 1 & 2 44 43 43 0.0011 9 
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Table 3.2: Hits found in only 1 Co-IP and MS of CARP3 CARP1 and CARP2 
 
 
Gene ID Annotation and Product 
Found 
in 
Size 
(kDa) 
 
Protein 
score 
 
Peptide 
score 
 
 
Expect 
Sequence 
Coverage (%) 
Tb927.2.2440 RPN6 proteasome regulatory non-ATPase subunit 6 3 only 57 92 67 5.7 x 10-6 5 
Tb927.11.16030 RPN7 proteasome regulatory non-ATP-ase subunit 7 3 only 45 34 34 0.0093 3 
Tb927.10.3030 RPN11 proteasome regulatory non-ATPase subunit 11; 19S 
proteasome regulatory subunit, Metallo-peptidase, Clan MP, 
Family M67 
3 only 33 44 44 0.0013 3 
Tb927.9.9670 TbPSA6 proteasome alpha 1 subunit, putative; 20S 
proteasome subunit alpha-6, putative 
3 only 27 33 31 0.025 4 
Tb927.4.4470 receptor-type adenylate cyclase GRESAG 4, putative 3 only 142 75 58 3.7 x 10-5 6 
Tb927.8.7590 receptor-type adenylate cyclase GRESAG 4, putative 3 only 139 30 30 0.032 4 
Tb927.10.1060 TCP-1-delta t-complex protein 1, delta subunit, putative 3 only 58 88 88 4.8 x 10-8 10 
Tb927.5.3400 calcium-translocating P-type ATPase; calcium pump 3 only 41 53 53 0.00016 9 
Tb927.7.6290 kinesin, putative 3 only 97 30 30 0.031 5 
Tb927.10.2090 TEF1 elongation factor 1-alpha; EF-1-alpha 3 only 37 55 55 7.5 x 10-5 10 
Tb927.11.9530 14-3-3-like protein, putative 3 only 30 29 29 0.035 4 
Tb927.11.7170 seryl-tRNA synthetase, putative 3 only 53 27 27 0.039 3 
Tb927.1.3300 zinc-binding phosphatase, putative 3 only 97 96 52 0.00021 10 
Tb927.2.820 3B10.365 retrotransposon hot spot protein (RHS, 
pseudogene), putative 
3 only 60 50 50 0.00024 10 
Tb927.1.420 retrotransposon hot spot (RHS) protein, putative; 
retrotransposon hot spot protein 5 (RHS5), putative 
3 only 76 33 33 0.014 8 
Tb927.5.2570 translation initiation factor, putative 3 only 80 50 50 0.00025 11 
Tb927.3.4500 fumarate hydratase, putative 3 only 62 27 27 0.033 5 
Tb927.11.2990 KREPB4 RNA-editing complex protein; KREPB4 3 only 46 38 34 0.014 1 
Tb927.10.1100 ribosomal protein L9, putative 3 only 21 30 30 0.027 7 
Tb927.5.3810 orotidine-5-phosphate decarboxylase/orotate 
phosphoribosyltransferase, putative 
3 only 50 33 33 0.019 9 
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Gene ID Annotation and Product 
Found 
in 
Size 
(kDa) 
 
Protein 
score 
 
Peptide 
score 
 
 
Expect 
Sequence 
Coverage (%) 
 
       
Tb927.11.16340 hypothetical protein, conserved 3 only 124 59 43 0.0023 2 
Tb927.5.1220 hypothetical protein, conserved 3 only 21 33 33 0.018 4 
Tb927.3.2190 hypothetical protein, conserved 3 only 29 30 30 0.031 10 
Tb927.11.10550 hypothetical protein, conserved 3 only 90 33 33 0.015 2 
Tb927.9.14190 hypothetical protein, conserved 3 only 146 29 29 0.036 3 
Tb927.3.5250 hypothetical protein, conserved 3 only 61 28 29 0.042 14 
Tb927.7.6560 hypothetical protein, conserved 3 only 25 40 33 0.02 15 
Tb927.6.2930 hypothetical protein, conserved 3 only 50 32 32 0.02 13 
Tb927.11.9320 hypothetical protein, conserved 3 only 60 30 30 0.034 12 
Tb927.8.420 variant surface glycoprotein (VSG, pseudogene), putative 3 only 56 28 28 0.047 15 
Tb927.11.4080 variant surface glycoprotein (VSG)-related, putative 3 only 41 52 52 0.00015 3 
Tb927.8.440 variant surface glycoprotein (VSG, pseudogene), putative 3 only 54 33 30 0.029 4 
Tb10.v4.0091 variant surface glycoprotein (VSG, pseudogene), putative 3 only 54 33 33 0.015 7 
Tb927.4.5700 variant surface glycoprotein (VSG, atypical), putative 3 only 50 33 33 0.016 3 
Tb927.6.5230 variant surface glycoprotein (VSG, pseudogene), putative 3 only 53 29 29 0.039 13 
Tb927.6.5730 variant surface glycoprotein (VSG, pseudogene), putative 3 only 53 27 27 0.038 7 
Tb927.9.6250 AK arginine kinase 14394319:14395431 forward MW:41597 Also in 1 41 324 79 1.4 x 10-7 22 
Tb927.8.5460 TB-44A flagellar calcium-binding protein TB-44A Also in 1 45 198 88 3.5 x 10-8 8 
Tb927.11.9420 ATP synthase, putative Also in 1 25 144 99 2.1 x 10-9 31 
Tb927.9.5150 NHP2 ribosomal protein S6, putative; NHP2/RS6-like 
protein 
Also in 1 13 141 91 8.8 x 10-8 12 
Tb927.10.6510 HSP60 chaperonin Hsp60, mitochondrial precursor Also in 1 59 117 48 0.00061 8 
Tb927.1.720 PGKA phosphoglycerate kinase Also in 1 56 77 49 0.00032 14 
Tb927.10.200 vacuolar ATP synthase, putative Also in 1 19 75 75 8.6 x 10-7 21 
Tb927.3.930 dynein heavy chain, putative Also in 1 53 69 52 0.00022 6 
        
 
 
 
 
Daniel N.A Tagoe       Appendix 
 
 
 
Gene ID Annotation and Product 
Found 
in 
Size 
(kDa) 
 
Protein 
score 
 
Peptide 
score 
 
 
Expect 
Sequence 
Coverage (%) 
Tb927.1.2570 beta-coP coatomer beta subunit Also in 1 46 36 36 0.0096 3 
Tb927.10.3990 DHH1 ATP-dependent DEAD-box RNA helicase, putative; 
DHH1 
Also in 1 46 81 63 1.5 x 10-5 8 
Tb927.11.10910 40S ribosomal protein SA, putative Also in 1 31 46 47 0.00067 6 
Tb927.9.2520 GB4 mitotubule-associated protein Gb4, putative; dynein 
heavy chain, cytosolic, putative; microtubule- associated 
protein 
Also in 1 92 51 37 0.002 0 
Tb927.11.740 eIF-5A eukaryotic translation initiation factor 5a, putative Also in 1 17 39 28 0.03 27 
Tb927.11.16140 minichromosome maintenance (MCM) complex subunit, 
putative 
Also in 1 81 31 31 0.033 6 
Tb10.v4.0147 variant surface glycoprotein (VSG, pseudogene), putative Also in 1 33 46 46 0.00088 21 
Tb09.v4.0115 expression site-associated gene (ESAG, pseudogene), 
putative; expression site-associated gene 3 (ESAG3), 
pseudogene 
Also in 1 38 46 46 0.00088 17 
Tb927.9.1220 expression site-associated gene 3 (ESAG3, pseudogene), 
putative 
Also in 1 35 46 46 0.00088 26 
Tb927.9.1220 expression site-associated gene (ESAG, pseudogene), 
putative; expression site-associated gene 3 (ESAG3), 
frameshifted and degenerate 
Also in 1 39 46 46 0.00088 15 
Tb11.0700 expression site-associated gene (ESAG, pseudogene), 
putative; expression site-associated gene 3 (ESAG3), 
degenerate 
Also in 1 21 46 46 0.00088 11 
Tb927.9.620 expression site-associated gene (ESAG, pseudogene), 
putative; expression site-associated gene 3 (ESAG3), 
pseudogene 
Also in 1 32 46 46 0.00088 7 
Tb927.11.19900 expression site-associated gene (ESAG, pseudogene), 
putative; expression site-associated gene 3 (ESAG3), 
degenerate and frameshifted 
Also in 1 40 46 46 0.00088 26 
Tb927.9.16260 expression site-associated gene 3 (ESAG3, pseudogene), 
putative 
Also in 1 31 46 46 0.00088 10 
Tb08.27P2.520 expression site-associated gene (ESAG, pseudogene), 
putative 
Also in 1 38 46 46 0.00088 21 
Tb08.27P2.160 expression site-associated gene (ESAG, pseudogene), 
putative 
Also in 1 41 46 46 0.00088 11 
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Tb927.7.3330 hypothetical protein, conserved Also in 1 502 133 56 6.6 x 10-5 3 
Tb11.02.3760 hypothetical protein, conserved Also in 1 11 127 92 1.3 x 10-8 20 
Tb927.4.2740 hypothetical protein, conserved Also in 1 16 61 44 0.0012 37 
 Tb927.3.4080 hypothetical protein, conserved Also in 1 62 39 39 0.001 10 
 Tb927.7.2570 hypothetical protein, conserved Also in 1 52 30 30 0.033 4 
 Tb927.6.1220 hypothetical protein, conserved Also in 1 65 28 28 0.039 3 
 Tb927.3.3580 LPG3 lipophosphoglycan biosynthetic protein, putative Also in 2 88 136 85 8.7 x 10-8 12 
 Tb927.7.4180 fatty acid elongase, putative Also in 2 33 95 95 1.1 x 10-8 8 
 Tb927.4.2070 antigenic protein, putative Also in 2 511 80 47 0.00063 3 
Tb927.10.3660 aspartate aminotransferase Also in 2 45 76 52 0.00017 8 
 Tb927.2.5660 1F7.200 adenylate kinase, putative Also in 2 29 73 49 0.0004 9 
 Tb927.8.2640 UBA1 ubiquitin-activating enzyme E1, putative Also in 2 116 73 73 1.4 x 10-6 9 
 Tb927.5.1300 vacuolar proton translocating ATPase subunit A, putative Also in 2 89 66 44 0.00057 7 
Tb927.10.1230 hypothetical protein, conserved Also in 2 37 64 43 0.001 11 
Tb927.9.15050 trypanin-related protein, putative Also in 2 54 58 43 0.0014 7 
Tb927.5.2960 PRS phosphoribosylpyrophosphate synthetase, putative Also in 2 110 54 54 8.4 x 10-5 4 
Tb927.9.6070 RPS3 40S ribosomal protein S3, putative Also in 2 30 49 49 0.00034 10 
 Tb927.4.1270 RuvB-like DNA helicase, putative Also in 2 50 48 48 0.0004 10 
Tb927.11.7020 PSA4 proteasome alpha 7 subunit, putative Also in 2 27 46 46 0.00071 7 
 Tb927.7.4170 fatty acid elongase, putative Also in 2 30 46 46 0.000585 11 
Tb927.11.2670 hypothetical protein, conserved Also in 2 58 44 44 0.0012 4 
 Tb927.4.3550 ribosomal protein L13a, putative Also in 2 39 42 33 0.012 10 
Tb927.11.4770 retrotransposon hot spot protein (RHS, pseudogene), 
putative; retrotransposon hot spot protein (RHS), 
degenerate 
Also in 2 85 33 33 0.014 19 
 Tb927.2.1170 retrotransposon hot spot (RHS) protein, putative Also in 2 76 33 33 0.014 11 
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Tb927.2.1080 retrotransposon hot spot (RHS) protein, putative Also in 2 76 33 33 0.014 6 
Tb927.8.4430 nucleoside phosphorylase, putative Also in 2 36 26 26 0.026 13 
Tb927.10.2110 TEF1 elongation factor 1-alpha Also in 2 49 42 42 0.0014 11 
Tb927.10.4570 elongation factor 2 1 & 2 94 445 80 2.3 x 10-7 29 
Tb927.11.5520 TIM triosephosphate isomerase 22070477:22071229 
forward MW:26819 
1 & 2 26 317 71 2.0 x 10-6 21 
Tb927.6.3840 reticulon domain protein 1 & 2 21 264 123 7.3 x 10-12 25 
Tb927.7.710 HSP70 heat shock 70 kDa protein, putative 1 & 2 70 223 75 7.4 x 10-7 15 
Tb927.7.3440 I/6 autoantigen 1 & 2 27 211 108 3.1 x10-10 23 
Tb927.10.8230 BS2 protein disulfide isomerase; bloodstream- specific 
protein 2 precursor 
1 & 2 55 208 67 3.6 x 10-6 25 
Tb927.8.5440 TB-24 flagellar calcium-binding protein TB-24 1 & 2 24 198 88 3.5 x 10-8 18 
Tb927.11.1740 TbIFT88 intraflagellar transport protein IFT88, putative 1 & 2 89 57 42 0.001 19 
Tb927.4.4380 PPase1 vacuolar-type proton translocating 
pyrophosphatase 1, putative 
1 & 2 86 163 78 4.8 x 10-7 9 
Tb927.11.15910 iron superoxide dismutase 1 & 2 22 161 101 2.0 x 10-9 12 
Tb927.5.1810 lysosomal/endosomal membrane protein p67; lysosomal 
membrane glycoprotein 
1 & 2 72 156 53 0.00013 15 
Tb927.3.3760 TRYP1 tryparedoxin 1 & 2 15 44 35 0.01 7 
Tb927.8.1990 TRYP2 tryparedoxin peroxidase 1 & 2 25 154 93 1.6 x 10-8 6 
Tb927.4.5010 calreticulin, putative 1 & 2 45 142 72 1.1 x 10-6 11 
Tb927.10.16120 inosine-5'-monophosphate dehydrogenase; IMP 
dehydrogenase 
1 & 2 48 168 82 1.2 x 10-7 15 
Tb927.3.2960 IAGNH inosine-adenosine-guanosine-nucleosidehydrolase 1 & 2 35 123 74 6.3 x 10-7 14 
Tb927.7.4420 proteasome alpha 3 subunit, putative 1 & 2 32 56 56 5.6 x 10-6 13 
Tb927.10.15720 RPN9 proteasome regulatory non-ATP-ase subunit 9; 19S 
proteasome regulatory subunit 
1 & 2 45 122 74 9.7 x 10-7 14 
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Tb927.11.13020 calmodulin 1 & 2 16 93 59 2.7 x 10-5 11 
Tb927.1.2430 histone H3, putative 1 & 2 15 109 78 1.8 x 10-7 19 
Tb927.8.1870 tGLP1 Golgi/lysosome glycoprotein 1 1 & 2 67 109 79 3.3 x 10-7 11 
Tb927.2.4210 glycosomal phosphoenolpyruvate carboxykinase 1 & 2 58 103 93 9.1 x 10-7 18 
Tb927.11.4610 PKA-R protein kinase A regulatory subunit 1 & 2 56 89 89 3.1 x 10-8 15 
Tb927.11.7380 glycerol-3-phosphate dehydrogenase, putative 1 & 2 67 83 83 1.4 x 10-7 11 
Tb927.10.6050 CHC clathrin heavy chain 1 & 2 190 69 52 0.00018 9 
Tb927.5.4170 histone H4, putative 1 & 2 11 67 55 0.0001 13 
Tb927.10.3210 delta-1-pyrroline-5-carboxylate dehydrogenase, putative 1 & 2 62 66 37 0.0054 6 
Tb927.1.3950 alanine aminotransferase, putative 1 & 2 63 64 44 0.0012 11 
Tb927.10.14170 aquaporin 9, putative 1 & 2 33 97 69 3.8 x 10-6 4 
Tb927.6.1520 AQP3 aquaporin 3, putative 1 & 2 35 62 41 0.0031 11 
Tb927.8.7610 AATP1 amino acid transporter 1, putative 1 & 2 50 60 60 1.9 x 10-5 19 
Tb927.10.5770 VCP valosin-containing protein homolog; Transitional 
endoplasmic reticulum ATPase, putative 
1 & 2 85 50 50 0.0001 4 
Tb927.10.2440 MCA4 metacaspase MCA4; cysteine peptidase, Clan CD, 
family C13, putative 
1 & 2 39 50 43 0.00078 11 
Tb927.11.3250 dynein heavy chain, putative 1 & 2 53 49 49 0.00041 9 
Tb927.1.3830 PGI glucose-6-phosphate isomerase, glycosomal 1 & 2 67 47 34 0.01 9 
Tb927.3.290 expression site-associated gene (ESAG, pseudogene), 
putative 
1 & 2 36 33 35 0.0076 18 
Tb927.11.1090 calpain-like protein, putative; cytoskeleton assocociated 
protein, putative 
1 & 2 658 47 39 0.0022 2 
Tb927.11.1100 calpain, putative; cysteine peptidase, Clan CA, family C2, 
putative 
1 & 2 158 47 39 0.0022 7 
Tb927.10.1390 hypoxanthine-guanine phosphoribosyltransferase, putative 1 & 2 26 45 35 0.0098 23 
Tb927.4.1080 V-type ATPase, A subunit, putative 1 & 2 67 45 37 0.007 10 
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Tb927.11.1710 GBP21 mitochondrial RNA binding protein 1; gBP21, MRP1 1 & 2 23 41 41 0.0023 9 
Tb927.11.9590 S-adenosylhomocysteine hydrolase, putative 1 & 2 48 39 39 0.0047 3 
Tb927.5.2140 regulator of nonsense transcripts 1, putative 1 & 2 93 38 34 0.013 6 
Tb927.10.14710 RPS2 40S ribosomal protein S2, putative 1 & 2 28 37 37 0.0076 21 
Tb927.8.3770 mitogen-activated protein kinase, putative 1 & 2 47 33 33 0.017 14 
Tb927.11.11520 PEX11 glycosomal membrane protein, putative 1 & 2 24 32 32 0.035 12 
Tb927.1.2100 calpain-like cysteine peptidase, putative; cysteine peptidase, 
Clan CA, family C2, putative 
1 & 2 126 29 29 0.032 2 
Tb927.10.12510 P-type H+-ATPase, putative 1 & 2 100 28 28 0.036 2 
Tb927.9.12550 glk1 glycerol kinase, glycosomal 1 & 2 56 502 101 2.1 x 10-9 19 
Tb927.11.8060 hypothetical protein, conserved 1 & 2 63 107 67 5.0 x 10-6 8 
Tb927.3.3000 hypothetical protein, conserved 1 & 2 65 81 50 0.00023 6 
Tb927.10.12820 hypothetical protein, conserved 1 & 2 110 76 76 6.7 x 10-6 6 
Tb927.3.3560 hypothetical protein, conserved 1 & 2 69 72 48 0.00025 9 
Tb927.7.4500 hypothetical protein, conserved 1 & 2 58 44 30 0.047 3 
Tb927.7.3550 hypothetical protein, conserved 1 & 2 138 154 58 4.5 x 10-5 11 
Tb927.3.5490 hypothetical protein, conserved 1 & 2 77 207 87 4.4 x 10-8 18 
Tb927.11.13520 hypothetical protein, conserved 1 & 2 105 64 64 9.6 x 10-6 11 
Tb927.9.2470 hypothetical protein, conserved 1 & 2 85 491 80 2.5 x 10-7 24 
Tb927.7.6090 hypothetical protein, conserved 1 & 2 88 40 32 0.018 14 
Tb927.3.4070 hypothetical protein, conserved 1 & 2 64 39 39 0.001 7 
Tb927.10.13790 hypothetical protein, conserved 1 & 2 74 35 27 0.047 8 
Tb927.3.4110 hypothetical protein, conserved 1 & 2 65 39 39 0.001 11 
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Appendix 4: Log2 fold differentials (±0.05) of RNA-Seq of overexpressing 
CARP3 and WT s427  
Table 4.1: +0.5 log2 fold differential of overexpressing CARP3 against WT s427 
Gene ID Gene Name s427 
OE-
CARP3 
log2 
(fold-change) p-value 
Tb927.9.16700 ESAG3 0.343901 1.2715 1.88646 0.0037 
Tb927.7.5340 CARP3 29.7763 88.9473 1.57879 0.00005 
Tb927.5.5530 VSG 0.40614 1.18043 1.53927 0.0004 
Tb927.4.220 RHS, Pseudogene 5.22031 13.1233 1.32992 0.00005 
Tb927.6.5170 RHS, Pseudogene 0.619013 1.4864 1.26378 0.001 
Tb927.2.960 hypothetical protein 31.8733 65.7177 1.04393 0.00125 
Tb927.8.2861 SRP RNA, 7SL 26.2085 51.3994 0.971715 0.00005 
Tb927.2.6220 TbNT4 5.0098 9.61724 0.94087 0.00005 
Tb927.1.340 hypothetical protein, 
unlikely 
6.10631 11.6435 0.931155 0.00065 
Tb927.6.210 LRRP, Pseudogene 1.93026 3.58458 0.893007 0.00005 
Tb927.9.7400 ESAG11 6.4085 11.8263 0.883938 0.00005 
Tb927.1.280 hypothetical protein, 
conserved 
9.64932 17.7809 0.881826 0.00005 
Tb927.9.11580 gim5A 27.5732 50.1524 0.863054 0.00005 
Tb927.1.80 hypothetical protein, 
unlikely 
16.9237 30.6398 0.856361 0.00075 
Tb927.10.110 RHS2, Pseudogene 3.89419 6.95334 0.836383 0.00005 
Tb927.5.160 VSG pseugogene 2.47355 4.39907 0.830612 0.00225 
Tb927.3.3420 hypothetical protein, 
pseudogene 
2.06463 3.549 0.781526 0.00125 
Tb927.2.200 ESAG 332.242 566.152 0.768955 0.00005 
Tb927.4.190 RHS, Pseudogene 2.76645 4.70199 0.765235 0.0029 
Tb927.9.15980 nucleoside transporter 1, 
putative 
3.59757 6.08911 0.759207 0.00005 
Tb927.2.1130 RHS, Pseudogene 2.32881 3.91355 0.748885 0.00245 
Tb927.2.6320 TbNT6 11.8535 19.8695 0.745238 0.00005 
Tb927.9.5910 hypothetical protein, 
unlikely 
241.798 404.398 0.741973 0.00005 
Tb927.4.300 RHS3, Pseudogene 0.915806 1.50728 0.718831 0.001 
Tb927.2.1120 ESAG 18.7378 30.1322 0.685354 0.00005 
Tb927.11.20150 ESAG 11.2034 17.9423 0.67943 0.00005 
Tb927.10.5700 hypothetical protein, 
conserved 
7.72748 12.3655 0.678245 0.00005 
Tb927.2.1050 RHS, Pseudogene 51.5513 82.1089 0.671529 0.00005 
Tb927.4.240 RHS, Pseudogene 1.35628 2.14634 0.662219 0.0001 
Tb927.3.1490 LRRP, putative 4.59357 7.22206 0.652796 0.00005 
Tb927.5.3990 VSG, atypical 1.28877 2.00508 0.637668 0.00155 
Tb927.1.4560 CFB1B 1.79656 2.79366 0.636918 0.00045 
Tb927.2.3340 hypothetical protein 26.729 40.9477 0.615381 0.00005 
Tb927.1.360 hypothetical protein, 
unlikely 
56.6585 86.6425 0.612783 0.00005 
Tb927.1.60 RNA polymerase 
(pseudogene), putative 
26.322 40.2484 0.612664 0.00005 
Tb927.11.15960 amino acid transporter, 
putative 
46.7084 71.3685 0.611604 0.00005 
Tb927.9.10460 hypothetical protein, 
unlikely 
23.7993 36.2961 0.608897 0.00005 
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Tb927.11.18700 hypothetical protein, 
conserved 
19.5244 29.6746 0.60395 0.00005 
Tb927.3.1510 VSG-related 2.6023 3.95193 0.602772 0.00075 
Tb927.2.490 RNA polymerase 
(pseudogene), putative 
17.7934 26.9248 0.597595 0.00005 
Tb927.2.1110 DNA-directed RNA 
polymerase III subunit 2, 
16.2711 24.5716 0.594674 0.00005 
Tb927.4.230 DNA-directed RNA 
polymerase, pseudogene, 
putative 
19.3689 29.2276 0.593589 0.00005 
Tb11.v5.0295 RHS, protein 30.5424 45.9625 0.589642 0.00005 
Tb927.11.18650 ESAG1 4.23939 6.37474 0.588509 0.0002 
Tb927.1.70 RHS, protein 12.8655 19.3172 0.586376 0.00005 
Tb927.6.4110 hypothetical protein 13.1428 19.6785 0.582351 0.0005 
Tb927.9.15940 ESAG 22.0071 32.7919 0.575369 0.00005 
Tb927.1.5200 ESAG1 11.9938 17.774 0.567477 0.00005 
Tb927.6.150 RHS4, putative 5.447 8.05795 0.564949 0.00005 
Tb927.2.6150 TbNT2/927 20.0136 29.5518 0.562269 0.00005 
Tb927.3.700 hypothetical protein, 
conserved 
26.6346 39.0503 0.55203 0.00005 
Tb927.10.100 ESAG, pseudogene 3.39762 4.97662 0.550642 0.0003 
Tb927.9.7410 ESAG2 2.58216 3.77491 0.547863 0.0006 
Tb927.1.4130 hypothetical protein, 
unlikely 
20.1061 29.2134 0.538994 0.00305 
Tb927.1.490 hypothetical protein 53.6021 77.5351 0.532561 0.00005 
Tb927.2.6180 iron/ascorbate 
oxidoreductase family 
protein, putative 
21.558 31.1431 0.530689 0.00005 
Tb11.v5.0559 oligosaccharyl transferase 
subunit, putative 
12.7276 18.3433 0.527292 0.00005 
Tb927.1.5340 ESAG, pseudogene 23.8772 34.3639 0.525258 0.00005 
Tb927.6.5490 ESAG, pseudogene 44.1351 63.3958 0.522461 0.00005 
Tb927.4.210 RHS, Pseudogene 22.3444 32.0327 0.519635 0.00005 
Tb927.8.5470 Tb-17 38.8959 55.1547 0.503865 0.00005 
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Table 4.2: -0.5 log2 fold differential of overexpressing CARP3 against WT s427 
Gene ID Gene Name s427 
OE-
CARP3 
log2 
(fold- change) p-value 
Tb927.11.1920 hypothetical protein 8.66682 5.93331 -0.54667 0.0016 
Tb927.11.4440 hypothetical protein 8.66392 5.6805 -0.609 0.0013 
Tb927.10.10260 EP1 15.891 10.3839 -0.61386 0.00265 
Tb927.11.15950 amino acid transporter, 
putative 
97.4208 59.4573 -0.71238 0.00005 
Tb927.11.16180 hypothetical protein 8.65323 4.71196 -0.87691 0.00005 
Tb927.7.6500 VSG, putative 2.46698 1.17863 -1.06563 0.00005 
Tb927.9.15110 60S ribosomal protein L5, 
putative 
17.939 2.2377 -3.00301 0.00005 
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Appendix 5: Log2 fold differentials (+0.75) of RNA-Seq of R0.8 and WT s427  
Table 5.1: +0.75 log2 fold differential of R0.8 against WT s427 
Gene ID Gene name s427 R0.8 
log2 
(fold-change) p-value 
Tb927.9.1050 VSG, putative 0.048476 1.56992 5.01727 0.0197 
Tb927.9.16890 VSG, pseudogene 0.054673 1.67525 4.9374 0.01815 
Tb927.5.5530 VSG, putative 0.415451 5.74266 3.78897 0.00005 
Tb927.7.150 VSG, pseudogene 0.181801 1.74576 3.26343 0.00005 
Tb927.7.6500 VSG, putative 2.52418 11.5266 2.19108 0.00005 
Tb927.7.6530 VSG, pseudogene 0.467402 2.02578 2.11574 0.00005 
Tb11.v5.0693 hypothetical protein, unlikely 0.938157 3.80605 2.02039 0.00005 
Tb927_10_v4 term=C/D snoRNA 1019.7 3978.84 1.96421 0.00055 
Tb927.7.6520 VSG, pseudogene 0.642037 2.48225 1.95092 0.00005 
Tb927.9.18120 VSG, pseudogene 0.467699 1.56721 1.74454 0.00005 
Tb927.10.140 hypothetical protein 1.63901 5.29894 1.69288 0.0012 
Tb927.7.6510 VSG, degenerate 0.373812 1.06534 1.51093 0.0008 
Tb927.10.130 hypothetical protein 1.53737 4.23115 1.46059 0.0114 
Tb927.6.5170 RHS, pseudogene 0.633076 1.74229 1.46053 0.00025 
Tb11.v5.1024 VSG, atypical, putative 0.24986 0.662572 1.40696 0.00755 
Tb927.1.4990 hypothetical protein, unlikely 82.6458 216.325 1.38818 0.00005 
Tb11.v5.0638 CBP1 1.23866 3.23741 1.38606 0.00005 
Tb927.9.16640 VSG, putative 0.262018 0.674071 1.36323 0.003 
Tb927.4.5400 VSG, atypical, putative 0.341849 0.873698 1.35378 0.00045 
Tb927.11.17840 RHS, degenerate 2.431 5.93722 1.28824 0.0208 
Tb927.9.5940 hypothetical protein, unlikely 368.859 897.534 1.2829 0.00005 
Tb11.v5.0719 hypothetical protein, 
conserved 
0.944579 2.29342 1.27976 0.00005 
Tb927.2.1350 RHS, pseudogene 13.8481 33.5092 1.27487 0.00005 
Tb11.v5.0495 RHS, putative 9.9415 23.7722 1.25774 0.00005 
Tb927.8.520 hypothetical protein 1.9615 4.67578 1.25325 0.0003 
Tb11.v5.0294 RHS, putative 10.1764 24.2239 1.2512 0.00005 
Tb927.1.80 hypothetical protein, unlikely 17.3136 40.9293 1.24123 0.00005 
Tb927.6.210 hypothetical protein 1.97477 4.65171 1.23608 0.00005 
Tb927.4.5440 hypothetical protein 0.420056 0.986892 1.23231 0.04345 
Tb927.4.150 hypothetical protein 1.89431 4.42133 1.22281 0.0053 
Tb927.9.1280 VSG, atypical, putative 0.837446 1.94752 1.21757 0.00005 
Tb927.6.540 VSG-related, putative 0.746857 1.69513 1.18249 0.0001 
Tb927.8.500 hypothetical protein 0.595478 1.34594 1.17649 0.0019 
Tb927.4.220 RHS, pseudogene 5.34082 11.9006 1.1559 0.00005 
Tb927.1.4120 hypothetical protein, unlikely 1659.45 3659.06 1.14077 0.00005 
Tb927.3.2540 VSG-related, putative 0.99338 2.16546 1.12426 0.00005 
Tb927.2.1380 LRRP, putative 29.4909 63.9276 1.11617 0.00005 
Tb927.1.3320 LRRP, putative 3.32492 7.13982 1.10257 0.00005 
Tb11.v5.0778 chaperone protein DNAj, 
putative 
0.587261 1.25476 1.09534 0.00075 
Tb927.5.5540 VSG, putative 0.594143 1.26471 1.08992 0.00025 
Tb927.5.160 RHS, pseudogene 2.53116 5.37182 1.08561 0.00005 
Tb927.9.6760 hypothetical protein, 
conserved 
7.83192 16.5144 1.07629 0.00005 
Tb927.3.2510 ESAG2 0.61905 1.29656 1.06656 0.0054 
Tb927.1.1040 hypothetical protein, unlikely 1.44096 2.95267 1.03498 0.01475 
Tb927.5.5560 VSG, putative 0.573179 1.17291 1.03304 0.00085 
Tb927.6.130 LRRP, putative 4.56388 9.26546 1.0216 0.00005 
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Tb927.1.2760 hypothetical protein 1032.42 2087.8 1.01595 0.00005 
Tb927.9.7290 VSG-related, putative 4.13381 8.3255 1.01007 0.00005 
Tb927.10.110 RHS2, pseudogene 3.98447 7.97086 1.00035 0.00005 
Tb927.1.70 RHS4, pseudogene 13.1622 26.138 0.989752 0.00005 
Tb927.11.1500 LRRP, pseudogene 2.48759 4.88224 0.972795 0.00005 
Tb11.v5.0551 LRRP, putative 6.78665 13.2031 0.960102 0.00005 
Tb927.6.150 RHS4, putative 5.57164 10.8177 0.95722 0.00005 
Tb927.4.240 RHS, pseudogene 1.38761 2.68864 0.954279 0.00005 
Tb927.1.3380 hypothetical protein, unlikely 2.20352 4.21291 0.935008 0.0104 
Tb927.2.6350 VSG pseudogene, putative 1.66711 3.16501 0.924862 0.00005 
Tb11.v5.0886 hypothetical protein, 
conserved 
0.624996 1.18364 0.921314 0.00015 
Tb927.9.4730 hypothetical protein, unlikely 5425.06 10137.8 0.902027 0.00005 
Tb11.v5.0448 LRRP, putative 5.42209 10.1072 0.898458 0.00005 
Tb927.1.280 hypothetical protein, 
conserved 
9.86678 18.3012 0.891287 0.00005 
Tb927.11.1510 LRRP, putative 0.68728 1.2617 0.876395 0.0001 
Tb927.11.12710 VSG-related, putative 12.6667 23.0622 0.864485 0.00005 
Tb927.9.3150 hypothetical protein, unlikely 50.1277 91.1697 0.862946 0.01805 
Tb927.9.9490 hypothetical protein, unlikely 53.4073 96.6069 0.85509 0.00005 
Tb927.6.5180 RHS, pseudogene 1.05016 1.89704 0.853134 0.0004 
Tb927.11.4060 LRRP, putative 9.04306 16.2723 0.847531 0.00005 
Tb927.5.170 hypothetical protein, 
conserved 
6.07009 10.8667 0.840121 0.00005 
Tb927.9.16000 hypothetical protein, unlikely 20.3637 36.3842 0.837313 0.0085 
Tb927.11.8680 DNA polymerase kappa, 
putative 
0.478067 0.853718 0.836548 0.0049 
Tb927.3.570 ESAG2, putative 10.6121 18.9365 0.83546 0.00005 
Tb11.v5.0470 GRESAG4 1.37722 2.45491 0.833915 0.00005 
Tb927.3.5670 hypothetical protein 7.4402 13.2442 0.831953 0.00005 
Tb927.3.2590 hypothetical protein 7.08592 12.6003 0.830432 0.00005 
Tb927.8.530 LRRP, putative 5.2968 9.41799 0.830297 0.00005 
Tb927.8.510 hypothetical protein 1.93839 3.41989 0.819093 0.00015 
Tb927.6.240 hypothetical protein, 
conserved 
13.0102 22.9478 0.818716 0.00005 
Tb927.11.19030 ESAG1 1.09264 1.91245 0.807603 0.02745 
Tb927.7.4770 PPIase 1.33156 2.31599 0.798513 0.02845 
Tb927.9.7530 hypothetical protein, unlikely 4.27885 7.42405 0.794984 0.0019 
Tb927.9.7410 ESAG2, putative 2.6414 4.57494 0.792446 0.00005 
Tb927.4.300 RHS3, putative 0.936807 1.60912 0.780445 0.0003 
Tb927.9.7370 ESAG9, putative 8.73607 14.9635 0.776387 0.00005 
Tb927.5.5500 VSG, putative 0.395005 0.675697 0.774507 0.0325 
Tb927.6.350 hypothetical protein, 
conserved 
23.8299 40.362 0.760222 0.00005 
Tb927.7.6080 receptor-type adenylate 
cyclase GRESAG 4, putative 
5.74798 9.71703 0.757459 0.00005 
Tb927.3.5690 hypothetical protein, 
conserved 
9.95538 16.814 0.756112 0.00005 
 
Tb927.7.4840 hypothetical protein, 
conserved 
0.850276 1.43069 0.750704 0.0184 
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Table 5.2: -0.75 log2 fold differential of R0.8 against WT s427 
Gene ID 
 
Gene name s427 R0.8 
log2 
(fold-change) p-value 
Tb927.9.2820 hypothetical protein, unlikely 184.187 109.003 -0.7568 0.00005 
Tb927.1.4020 hypothetical protein 21.1541 12.4736 -0.76206 0.00005 
Tb927.10.1640 hypothetical protein 32.8647 19.3234 -0.76619 0.00005 
Tb927.1.1460 hypothetical protein, unlikely 3.08374 1.77217 -0.79916 0.04045 
Tb927.8.2861 SRP RNA, 7SL 26.8248 14.9675 -0.84174 0.00095 
Tb927.2.6320 TbNT6 12.1216 6.45919 -0.90815 0.00005 
Tb927.1.2950 hypothetical protein, unlikely 17.147 8.50618 -1.01137 0.0012 
Tb11.v5.0869 cystathione gamma lyase, 
putative 
1.69441 0.834595 -1.02164 0.0244 
Tb927.11.7980 hypothetical protein 5.82784 2.85976 -1.02707 0.0118 
Tb927.8.2864 small nuclear RNA 224.871 106.254 -1.08157 0.00065 
Tb927.1.3590 hypothetical protein, unlikely 13.4306 6.24659 -1.10438 0.0035 
Tb927.4.3630 serine threonine-protein 
phosphatase PP1, putative 
(Inferred from Sequence 
Alignment) 
24.2375 10.9643 -1.14442 0.00005 
Tb927.9.7340 ESAG9, putative 1.96185 0.852413 -1.20259 0.0023 
Tb927.9.5140 hypothetical protein, unlikely 15.3513 4.51661 -1.76505 0.01565 
Tb927.1.2620 hypothetical protein, unlikely 2.73468 0.614812 -2.15316 0.0124 
 
 
 
 
 
 
 
Daniel N.A Tagoe  Review on cAMP signalling 
References: 
Acestor, N., Panigrahi, A.K., Ogata, Y., Anupama, A., Stuart, K.D., 2009. Protein 
composition of Trypanosoma brucei mitochondrial membranes. Proteomics 
9, 5497-5508. 
 
Adung'a, V.O., Gadelha, C., Field, M.C., 2013. Proteomic analysis of clathrin 
interactions in trypanosomes reveals dynamic evolution of endocytosis. 
Traffic 14, 440-457. 
 
Ahlstrom, M., Lamberg-Allardt, C., 1999. Regulation of adenosine 3',5'-cyclic 
monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells: 
role of cAMP-phosphodiesterase and cAMP efflux. Biochem Pharmacol 58, 
1335-1340. 
 
Albisetti, A., Wiese, S., Schneider, A., Niemann, M., 2015. A component of the 
mitochondrial outer membrane proteome of T. brucei probably contains 
covalent bound fatty acids. Experimental Parasitology 155, 49-57. 
 
Ali, J.A., Tagoe, D.N., Munday, J.C., Donachie, A., Morrison, L.J., de Koning, 
H.P., 2013. Pyrimidine biosynthesis is not an essential function for 
Trypanosoma brucei bloodstream forms. PLoS One 8, e58034. 
 
Alonso, G.D., Schoijet, A.C., Torres, H.N., Flawia, M.M., 2006. TcPDE4, a novel 
membrane-associated cAMP-specific phosphodiesterase from Trypanosoma 
cruzi. Mol Biochem Parasitol 145, 40-49. 
 
Alonso, G.D., Schoijet, A.C., Torres, H.N., Flawia, M.M., 2007. TcrPDEA1, a 
cAMP-specific phosphodiesterase with atypical pharmacological properties 
from Trypanosoma cruzi. Mol Biochem Parasitol 152, 72-79. 
 
Alsford, S., Eckert, S., Baker, N., Glover, L., Sanchez-Flores, A., Leung, K.F., 
Turner, D.J., Field, M.C., Berriman, M., Horn, D., 2012a. High-throughput 
decoding of antitrypanosomal drug efficacy and resistance. Nature 482, 
232-236. 
 
Alsford, S., Eckert, S., Baker, N., Glover, L., Sanchez-Flores, A., Leung, K.F., 
Turner, D.J., Field, M.C., Berriman, M., Horn, D., 2012b. High-throughput 
decoding of antitrypanosomal drug efficacy and resistance. Nature 482, 
232-236. 
 
Alsford, S., Kawahara, T., Glover, L., Horn, D., 2005. Tagging a T. brucei RRNA 
locus improves stable transfection efficiency and circumvents inducible 
expression position effects. Mol Biochem Parasitol 144, 142-148. 
 
Alsford, S., Turner, D.J., Obado, S.O., Sanchez-Flores, A., Glover, L., Berriman, 
M., Hertz-Fowler, C., Horn, D., 2011a. High-throughput phenotyping using 
parallel sequencing of RNA interference targets in the African 
trypanosome. Genome Research 21, 915-924. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Alsford, S., Turner, D.J., Obado, S.O., Sanchez-Flores, A., Glover, L., Berriman, 
M., Hertz-Fowler, C., Horn, D., 2011b. High-throughput phenotyping using 
parallel sequencing of RNA interference targets in the African 
trypanosome. Genome Res 21, 915-924. 
 
Amata, E., Bland, N.D., Campbell, R.K., Pollastri, M.P., 2015. Evaluation of 
pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal 
phosphodiesterase B1 (TbrPDEB1). Tetrahedron Lett 56, 2832-2835. 
 
Amata, E., Bland, N.D., Hoyt, C.T., Settimo, L., Campbell, R.K., Pollastri, M.P., 
2014. Repurposing human PDE4 inhibitors for neglected tropical diseases: 
Design, synthesis and evaluation of cilomilast analogues as Trypanosoma 
brucei PDEB1 inhibitors. Bioorganic & Medicinal Chemistry Letters 24, 
4084-4089. 
 
Ang, K.-L., Antoni, F.A., 2002. Reciprocal regulation of calcium dependent and 
calcium independent cyclic AMP hydrolysis by protein phosphorylation. 
Journal of Neurochemistry 81, 422-433. 
 
Aravind, L., Ponting, C.P., 1997. The GAF domain: an evolutionary link between 
diverse phototransducing proteins. Trends Biochem Sci 22, 458-459. 
 
Archer, S.K., Inchaustegui, D., Queiroz, R., Clayton, C., 2011. The cell cycle 
regulated transcriptome of Trypanosoma brucei. PLoS One 6, e18425. 
 
Azam, M.A., Tripuraneni, N.S., 2014. Selective Phosphodiesterase 4B Inhibitors: 
A Review. Sci Pharm 82, 453-481. 
 
Baker, D.A., 2010. Malaria gametocytogenesis. Mol Biochem Parasitol 172, 57-65. 
Baker, N., Alsford, S., Horn, D., 2011. Genome-wide RNAi screens in African 
trypanosomes identify the nifurtimox activator NTR and the eflornithine 
transporter AAT6. Mol Biochem Parasitol 176, 55-57. 
 
Baker, N., de Koning, H.P., Maser, P., Horn, D., 2013. Drug resistance in African 
trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol 
29, 110-118. 
 
Baldauf, S.L., 2003. The deep roots of eukaryotes. Science 300, 1703-1706. 
Banerjee, C., Sarkar, D., 1992. Isolation and characterization of a cyclic 
nucleotide-independent protein kinase from Leishmania donovani. Mol 
Biochem Parasitol 52, 195-205. 
 
Bao, Y., Weiss, L.M., Braunstein, V.L., Huang, H., 2008. Role of protein kinase A 
in Trypanosoma cruzi. Infect Immun 76, 4757-4763. 
 
Bao, Y., Weiss, L.M., Hashimoto, M., Nara, T., Huang, H., 2009. Protein kinase A 
regulatory subunit interacts with P-Type ATPases in Trypanosoma cruzi. 
Am J Trop Med Hyg 80, 941-943. 
 
Bao, Y., Weiss, L.M., Ma, Y.F., Kahn, S., Huang, H., 2010. Protein kinase A 
catalytic subunit interacts and phosphorylates members of trans-sialidase 
super-family in Trypanosoma cruzi. Microbes Infect 12, 716-726. 
Daniel N.A Tagoe  Review on cAMP signalling 
Barrett, M.P., 2010. Potential new drugs for human African trypanosomiasis: 
some progress at last. Curr Opin Infect Dis 23, 603-608. 
 
Barrett, M.P., Boykin, D.W., Brun, R., Tidwell, R.R., 2007. Human African 
trypanosomiasis: pharmacological re-engagement with a neglected 
disease. British Journal of Pharmacology 152, 1155-1171. 
 
Barrett, M.P., Croft, S.L., 2012. Management of trypanosomiasis and 
leishmaniasis. Br Med Bull 104, 175-196. 
 
Barry, J.D., McCulloch, R., 2001. Antigenic variation in trypanosomes: enhanced 
phenotypic variation in a eukaryotic parasite. Adv Parasitol 49, 1-70. 
 
Beavo, J.A., 1995. Cyclic nucleotide phosphodiesterases: functional implications 
of multiple isoforms. Physiol Rev 75, 725-748. 
 
Bender, A.T., Beavo, J.A., 2006. Cyclic nucleotide phosphodiesterases: 
molecular regulation to clinical use. Pharmacol Rev 58, 488-520. 
 
Benz, C., Clayton, C.E., 2007. The F-box protein CFB2 is required for cytokinesis 
of bloodstream-form Trypanosoma brucei. Molecular and Biochemical 
Parasitology 156, 217-224. 
 
Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., 
Bartholomeu, D.C., Lennard, N.J., Caler, E., Hamlin, N.E., Haas, B., 
Bohme, U., Hannick, L., Aslett, M.A., Shallom, J., Marcello, L., Hou, L., 
Wickstead, B., Alsmark, U.C., Arrowsmith, C., Atkin, R.J., Barron, A.J., 
Bringaud, F., Brooks, K., Carrington, M., Cherevach, I., Chillingworth, 
T.J., Churcher, C., Clark, L.N., Corton, C.H., Cronin, A., Davies, R.M., 
Doggett, J., Djikeng, A., Feldblyum, T., Field, M.C., Fraser, A., 
Goodhead, I., Hance, Z., Harper, D., Harris, B.R., Hauser, H., Hostetler, 
J., Ivens, A., Jagels, K., Johnson, D., Johnson, J., Jones, K., Kerhornou, 
A.X., Koo, H., Larke, N., Landfear, S., Larkin, C., Leech, V., Line, A., 
Lord, A., Macleod, A., Mooney, P.J., Moule, S., Martin, D.M., Morgan, 
G.W., Mungall, K., Norbertczak, H., Ormond, D., Pai, G., Peacock, C.S., 
Peterson, J., Quail, M.A., Rabbinowitsch, E., Rajandream, M.A., Reitter, 
C., Salzberg, S.L., Sanders, M., Schobel, S., Sharp, S., Simmonds, M., 
Simpson, A.J., Tallon, L., Turner, C.M., Tait, A., Tivey, A.R., Van Aken, 
S., Walker, D., Wanless, D., Wang, S., White, B., White, O., Whitehead, 
S., Woodward, J., Wortman, J., Adams, M.D., Embley, T.M., Gull, K., 
Ullu, E., Barry, J.D., Fairlamb, A.H., Opperdoes, F., Barrell, B.G., 
Donelson, J.E., Hall, N., Fraser, C.M., Melville, S.E., El-Sayed, N.M., 2005. 
The genome of the African trypanosome Trypanosoma brucei. Science 
309, 416-422. 
 
Bhattacharya, A., Biswas, A., Das, P.K., 2009. Role of a differentially expressed 
cAMP phosphodiesterase in regulating the induction of resistance against 
oxidative damage in Leishmania donovani. Free Radic Biol Med 47, 1494-
1506. 
 
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., 
Kiefer, F., Cassarino, T.G., Bertoni, M., Bordoli, L., Schwede, T., 2014. 
Daniel N.A Tagoe  Review on cAMP signalling 
SWISS-MODEL: modelling protein tertiary and quaternary structure using 
evolutionary information. Nucleic Acids Res 42, W252-258. 
 
Biebinger, S., Wirtz, L.E., Lorenz, P., Clayton, C., 1997. Vectors for inducible 
expression of toxic gene products in bloodstream and procyclic 
Trypanosoma brucei. Mol Biochem Parasitol 85, 99-112. 
 
Bieger, B., Essen, L.O., 2001. Structural analysis of adenylate cyclases from 
Trypanosoma brucei in their monomeric state, Vol 20, 433-445 pp. 
 
Bland, N.D., Wang, C., Tallman, C., Gustafson, A.E., Wang, Z., Ashton, T.D., 
Ochiana, S.O., McAllister, G., Cotter, K., Fang, A.P., Gechijian, L., 
Garceau, N., Gangurde, R., Ortenberg, R., Ondrechen, M.J., Campbell, 
R.K., Pollastri, M.P., 2011. Pharmacological validation of Trypanosoma 
brucei phosphodiesterases B1 and B2 as druggable targets for African 
sleeping sickness. J Med Chem 54, 8188-8194. 
 
Blazer, L.L., Roman, D.L., Chung, A., Larsen, M.J., Greedy, B.M., Husbands, 
S.M., Neubig, R.R., 2010. Reversible, Allosteric Small-Molecule Inhibitors 
of Regulator of G. Mol Pharmacol 78, 524-533. 
 
Blum, J.A., Neumayr, A.L., Hatz, C.F., 2012. Human African trypanosomiasis in 
endemic populations and travellers. Eur J Clin Microbiol Infect Dis 31, 
905-913. 
 
Borland, G., Bird, R.J., Palmer, T.M., Yarwood, S.J., 2009. Activation of protein 
kinase Calpha by EPAC1 is required for the ERK- and CCAAT/enhancer-
binding protein beta-dependent induction of the SOCS-3 gene by cyclic 
AMP in COS1 cells. J Biol Chem 284, 17391-17403. 
 
Bos, J.L., 2006. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 
31, 680-686. 
 
Bradley, P., Misura, K.M.S., Baker, D., 2005. Toward High-Resolution de Novo 
Structure Prediction for Small Proteins. Science 309, 1868-1871. 
 
Bray, P.G., Barrett, M.P., Ward, S.A., de Koning, H.P., 2003. Pentamidine 
uptake and resistance in pathogenic protozoa: past, present and future. 
Trends in Parasitology 19, 232-239. 
 
Breidbach, T., Ngazoa, E., Steverding, D., 2002. Trypanosoma brucei: in vitro 
slender-to-stumpy differentiation of culture-adapted, monomorphic 
bloodstream forms. Exp Parasitol 101, 223-230. 
 
Bridges, D.J., Pitt, A.R., Hanrahan, O., Brennan, K., Voorheis, H.P., Herzyk, P., 
de Koning, H.P., Burchmore, R.J., 2008. Characterisation of the plasma 
membrane subproteome of bloodstream form Trypanosoma brucei. 
Proteomics 8, 83-99. 
 
Broadhead, R., Dawe, H.R., Farr, H., Griffiths, S., Hart, S.R., Portman, N., 
Shaw, M.K., Ginger, M.L., Gaskell, S.J., McKean, P.G., Gull, K., 2006. 
Flagellar motility is required for the viability of the bloodstream 
trypanosome. Nature 440, 224-227. 
Daniel N.A Tagoe  Review on cAMP signalling 
Brun, R., Blum, J., Chappuis, F., Burri, C., 2010. Human African 
trypanosomiasis. Lancet 375, 148-159. 
 
Brun, R., Don, R., Jacobs, R.T., Wang, M.Z., Barrett, M.P., 2011. Development 
of novel drugs for human African trypanosomiasis. Future Microbiol 6, 677-
691. 
 
Burgin, A.B., Magnusson, O.T., Singh, J., Witte, P., Staker, B.L., Bjornsson, 
J.M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A.S., 
Stewart, L.J., Gurney, M.E., 2010. Design of phosphodiesterase 4D 
(PDE4D) allosteric modulators for enhancing cognition with improved 
safety. Nat Biotechnol 28, 63-70. 
 
Burri, C., 2010. Chemotherapy against human African trypanosomiasis: is there a 
road to success? Parasitology 137, 1987-1994. 
 
Burri, C., Brun, R., 2003. Eflornithine for the treatment of human African 
trypanosomiasis. Parasitol Res 90 Supp 1, S49-52. 
 
Chappuis, F., Loutan, L., Simarro, P., Lejon, V., Buscher, P., 2005. Options for 
field diagnosis of human african trypanosomiasis. Clin Microbiol Rev 18, 
133-146. 
 
Chatelain, E., Ioset, J.R., 2011. Drug discovery and development for neglected 
diseases: the DNDi model. Drug Des Devel Ther 5, 175-181. 
 
Chen, L., Staubli, S.E.L., Schneider, M.P., Kessels, A.G., Ivic, S., Bachmann, 
L.M., Kessler, T.M., Phosphodiesterase 5 Inhibitors for the Treatment of 
Erectile Dysfunction: A Trade-off Network Meta-analysis. European 
Urology. 
 
Clayton, C.E., 2002. Life without transcriptional control? From fly to man and 
back again. EMBO J 21, 1881-1888. 
 
Cliff, M.J., Williams, M.A., Brooke-Smith, J., Barford, D., Ladbury, J.E., 2005. 
Molecular recognition via coupled folding and binding in a TPR domain. J 
Mol Biol 346, 717-732. 
 
Conti, M., Beavo, J., 2007. Biochemistry and physiology of cyclic nucleotide 
phosphodiesterases: essential components in cyclic nucleotide signaling. 
Annu Rev Biochem 76, 481-511. 
 
D'Andrea, L.D., Regan, L., 2003. TPR proteins: the versatile helix. Trends 
Biochem Sci 28, 655-662. 
 
D'Angelo, M.A., Montagna, A.E., Sanguineti, S., Torres, H.N., Flawia, M.M., 2002. 
A novel calcium-stimulated adenylyl cyclase from Trypanosoma cruzi, 
which interacts with the structural flagellar protein paraflagellar rod. J 
Biol Chem 277, 35025-35034. 
 
D'Angelo, M.A., Sanguineti, S., Reece, J.M., Birnbaumer, L., Torres, H.N., 
Flawia, M.M., 2004. Identification, characterization and subcellular 
Daniel N.A Tagoe  Review on cAMP signalling 
localization of TcPDE1, a novel cAMP-specific phosphodiesterase from 
Trypanosoma cruzi. Biochem J 378, 63-72. 
 
Das, A., Gale, M., Carter, V., Parsons, M., 1994. The protein phosphatase 
inhibitor okadaic acid induces defects in cytokinesis and organellar 
genome segregation in Trypanosoma brucei. Journal of Cell Science 107, 
3477-3483. 
 
Das, R., Esposito, V., Abu-Abed, M., Anand, G.S., Taylor, S.S., Melacini, G., 
2007. cAMP activation of PKA defines an ancient signaling mechanism. 
Proceedings of the National Academy of Sciences 104, 93-98. 
 
de Koning, H.P., Gould, M.K., Sterk, G.J., Tenor, H., Kunz, S., Luginbuehl, E., 
Seebeck, T., 2012. Pharmacological validation of Trypanosoma brucei 
phosphodiesterases as novel drug targets. J Infect Dis 206, 229-237. 
 
de Koning, H.P., Jarvis, S.M., 1999. Adenosine Transporters in Bloodstream 
Forms of Trypanosoma brucei brucei: Substrate Recognition Motifs and 
Affinity for Trypanocidal Drugs. Molecular Pharmacology 56, 1162-1170. 
 
de Rooij, J., Rehmann, H., van Triest, M., Cool, R.H., Wittinghofer, A., Bos, 
J.L., 2000. Mechanism of Regulation of the Epac Family of cAMP-
dependent RapGEFs. Journal of Biological Chemistry 275, 20829-20836. 
 
Delbridge, L.M., O'Riordan, M.X., 2007. Innate recognition of intracellular 
bacteria. Curr Opin Immunol 19, 10-16. 
 
Delespaux, V., de Koning, H.P., 2007. Drugs and drug resistance in African 
trypanosomiasis. Drug Resist Updat 10, 30-50. 
 
Demonchy, R., Blisnick, T., Deprez, C., Toutirais, G., Loussert, C., Marande, W., 
Grellier, P., Bastin, P., Kohl, L., 2009. Kinesin 9 family members perform 
separate functions in the trypanosome flagellum. The Journal of Cell 
Biology 187, 615-622. 
 
Dessauer, C.W., 2009. Adenylyl Cyclase–A-kinase Anchoring Protein Complexes: 
The Next Dimension in cAMP Signaling. Molecular Pharmacology 76, 935-
941. 
 
Dhalia, R., Reis, C.R.S., Freire, E.R., Rocha, P.O., Katz, R., Muniz, J.R.C., 
Standart, N., de Melo Neto, O.P., 2005. Translation initiation in 
Leishmania major: characterisation of multiple eIF4F subunit homologues. 
Molecular and Biochemical Parasitology 140, 23-41. 
 
Diaz-Benjumea, R., Laxman, S., Hinds, T.R., Beavo, J.A., Rascon, A., 2006. 
Characterization of a novel cAMP-binding, cAMP-specific cyclic nucleotide 
phosphodiesterase (TcrPDEB1) from Trypanosoma cruzi. Biochem J 399, 
305-314. 
 
Dorsey, P., Keel, C., Klavens, M., Hellstrom, W.J., 2010. Phosphodiesterase type 
5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin 
Pharmacother 11, 1109-1122. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Dougherty, M.K., Morrison, D.K., 2004. Unlocking the code of 14-3-3. Journal of 
Cell Science 117, 1875-1884. 
 
Duncan, R., Alvarez, R., Jaffe, C.L., Wiese, M., Klutch, M., Shakarian, A., 
Dwyer, D., Nakhasi, H.L., 2001. Early response gene expression during 
differentiation of cultured Leishmania donovani. Parasitol Res 87, 897-
906. 
 
Dunphy, J.T., Linder, M.E., 1998. Signalling functions of protein palmitoylation. 
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 
1436, 245-261. 
 
Emes, R.D., Yang, Z., 2008. Duplicated paralogous genes subject to positive 
selection in the genome of Trypanosoma brucei. PLoS One 3, e2295. 
 
Emmer, B.T., Nakayasu, E.S., Souther, C., Choi, H., Sobreira, T.J., Epting, C.L., 
Nesvizhskii, A.I., Almeida, I.C., Engman, D.M., 2011a. Global analysis of 
protein palmitoylation in African trypanosomes. Eukaryot Cell 10, 455-
463. 
 
Emmer, B.T., Nakayasu, E.S., Souther, C., Choi, H., Sobreira, T.J.P., Epting, 
C.L., Nesvizhskii, A.I., Almeida, I.C., Engman, D.M., 2011b. Global 
Analysis of Protein Palmitoylation in African Trypanosomes. Eukaryotic 
Cell 10, 455-463. 
 
Engstler, M., Thilo, L., Weise, F., Grunfelder, C.G., Schwarz, H., Boshart, M., 
Overath, P., 2004. Kinetics of endocytosis and recycling of the GPI-
anchored variant surface glycoprotein in Trypanosoma brucei. J Cell Sci 
117, 1105-1115. 
 
Eperon, G., Balasegaram, M., Potet, J., Mowbray, C., Valverde, O., Chappuis, 
F., 2014. Treatment options for second-stage gambiense human African 
trypanosomiasis. Expert Review of Anti-infective Therapy 12, 1407-1417. 
 
Ersfeld, K., Barraclough, H., Gull, K., 2005. Evolutionary relationships and 
protein domain architecture in an expanded calpain superfamily in 
kinetoplastid parasites. J Mol Evol 61, 742-757. 
 
Fairlamb, A.H., 2003. Chemotherapy of human African trypanosomiasis: current 
and future prospects. Trends Parasitol 19, 488-494. 
 
Fairlamb, A.H., Henderson, G.B., Cerami, A., 1989. Trypanothione is the primary 
target for arsenical drugs against African trypanosomes. Proc Natl Acad 
Sci U S A 86, 2607-2611. 
 
Fallah, F., 2015. Recent strategies in treatment of pulmonary arterial 
hypertension, a review. Glob J Health Sci 7, 40643. 
 
Farber, D.B., Danciger, M., 1997. Identification of genes causing photoreceptor 
degenerations leading to blindness. Curr Opin Neurobiol 7, 666-673. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Fevre, E.M., Coleman, P.G., Odiit, M., Magona, J.W., Welburn, S.C., Woolhouse, 
M.E., 2001. The origins of a new Trypanosoma brucei rhodesiense sleeping 
sickness outbreak in eastern Uganda. Lancet 358, 625-628. 
 
Fevre, E.M., Picozzi, K., Jannin, J., Welburn, S.C., Maudlin, I., 2006. Human 
African trypanosomiasis: Epidemiology and control. Adv Parasitol 61, 167-
221. 
 
Firtel, R.A., Meili, R., 2000. Dictyostelium: a model for regulated cell movement 
during morphogenesis. Curr Opin Genet Dev 10, 421-427. 
 
Flawia, M.M., Tellez-Inon, M.T., Torres, H.N., 1997. Signal transduction 
mechanisms in Trypanosoma cruzi. Parasitol Today 13, 30-33. 
 
Forman, H.J., 2009. Signal transduction and reactive species. Free Radic Biol 
Med 47, 1237-1238. 
 
Francis, S., Houslay, M., Conti, M. 2011a. Phosphodiesterase Inhibitors: Factors 
That Influence Potency, Selectivity, and Action, In:  Francis, S.H., Conti, 
M., Houslay, M.D. (Eds.) Phosphodiesterases as Drug Targets. Springer 
Berlin Heidelberg, 47-84. 
 
Francis, S.H., Blount, M.A., Corbin, J.D., 2011b. Mammalian Cyclic Nucleotide 
Phosphodiesterases: Molecular Mechanisms and Physiological Functions, 
Vol 91, 651-690 pp. 
 
Francis, S.H., Houslay, M.D., Conti, M., 2011c. Phosphodiesterase inhibitors: 
factors that influence potency, selectivity, and action. Handb Exp 
Pharmacol, 47-84. 
 
Gadelha, C., Rothery, S., Morphew, M., McIntosh, J.R., Severs, N.J., Gull, K., 
2009. Membrane domains and flagellar pocket boundaries are influenced 
by the cytoskeleton in African trypanosomes. Proc Natl Acad Sci U S A 
106, 17425-17430. 
 
Galie, N., Rubin, L.J., Simonneau, G., 2010. Phosphodiesterase inhibitors for 
pulmonary hypertension. N Engl J Med 362, 559-560; author reply 560. 
 
Garbers, D.L., Chrisman, T.D., Wiegn, P., Katafuchi, T., Albanesi, J.P., Bielinski, 
V., Barylko, B., Redfield, M.M., Burnett, J.C., Jr., 2006. Membrane 
guanylyl cyclase receptors: an update. Trends Endocrinol Metab 17, 251-
258. 
 
Garcia, E.S., Gonzalez, M.S., de Azambuja, P., Baralle, F.E., Fraidenraich, D., 
Torres, H.N., Flawia, M.M., 1995. Induction of Trypanosoma cruzi 
metacyclogenesis in the gut of the hematophagous insect vector, 
Rhodnius prolixus, by hemoglobin and peptides carrying alpha D-globin 
sequences. Exp Parasitol 81, 255-261. 
 
Garland, S.L., 2013. Are GPCRs Still a Source of New Targets? Journal of 
Biomolecular Screening 18, 947-966. 
Daniel N.A Tagoe  Review on cAMP signalling 
Genestra, M., Cysne-Finkelstein, L., Leon, L., 2004. Protein kinase A activity is 
associated with metacyclogenesis in Leishmania amazonensis. Cell 
Biochem Funct 22, 315-320. 
 
Germain, P., Chambon, P., Eichele, G., Evans, R.M., Lazar, M.A., Leid, M., De 
Lera, A.R., Lotan, R., Mangelsdorf, D.J., Gronemeyer, H., 2006. 
International Union of Pharmacology. LX. Retinoic acid receptors. 
Pharmacol Rev 58, 712-725. 
 
Geslain, R., Aeby, E., Guitart, T., Jones, T.E., de Moura, M.C., Charrière, F., 
Schneider, A., de Pouplana, L.R., 2006. Trypanosoma Seryl-tRNA 
Synthetase Is a Metazoan-like Enzyme with High Affinity for tRNASec. 
Journal of Biological Chemistry 281, 38217-38225. 
 
Ghofrani, H.A., Osterloh, I.H., Grimminger, F., 2006. Sildenafil: from angina to 
erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug 
Discov 5, 689-702. 
 
Gong, K.W., Kunz, S., Zoraghi, R., Kunz Renggli, C., Brun, R., Seebeck, T., 2001. 
cAMP-specific phosphodiesterase TbPDE1 is not essential in Trypanosoma 
brucei in culture or during midgut infection of tsetse flies. Mol Biochem 
Parasitol 116, 229-232. 
 
Goodacre, N.F., Gerloff, D.L., Uetz, P., 2014. Protein Domains of Unknown 
Function Are Essential in Bacteria. mBio 5. 
 
Gould, M.K., Bachmaier, S., Ali, J.A., Alsford, S., Tagoe, D.N., Munday, J.C., 
Schnaufer, A.C., Horn, D., Boshart, M., de Koning, H.P., 2013. Cyclic AMP 
effectors in African trypanosomes revealed by genome-scale RNA 
interference library screening for resistance to the phosphodiesterase 
inhibitor CpdA. Antimicrob Agents Chemother 57, 4882-4893. 
 
Gould, M.K., de Koning, H.P., 2011. Cyclic-nucleotide signalling in protozoa. 
FEMS Microbiol Rev 35, 515-541. 
 
Grab, D.J., Nikolskaia, O.V., Inoue, N., Thekisoe, O.M., Morrison, L.J., Gibson, 
W., Dumler, J.S., 2011. Using detergent to enhance detection sensitivity 
of African trypanosomes in human CSF and blood by loop-mediated 
isothermal amplification (LAMP). PLoS Negl Trop Dis 5, e1249. 
 
Gross-Langenhoff, M., Hofbauer, K., Weber, J., Schultz, A., Schultz, J.E., 2006. 
cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 
10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol 
Chem 281, 2841-2846. 
 
Grunfelder, C.G., Engstler, M., Weise, F., Schwarz, H., Stierhof, Y.D., Boshart, 
M., Overath, P., 2002. Accumulation of a GPI-anchored protein at the cell 
surface requires sorting at multiple intracellular levels. Traffic 3, 547-
559. 
 
Gu, Z.C., Enenkel, C., 2014. Proteasome assembly. Cell Mol Life Sci 71, 4729-
4745. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Gull, K., 2003. Host-parasite interactions and trypanosome morphogenesis: a 
flagellar pocketful of goodies. Curr Opin Microbiol 6, 365-370. 
 
Haimeur, A., Ouellette, M., 1998. Gene amplification in Leishmania tarentolae 
selected for resistance to sodium stibogluconate. Antimicrob Agents 
Chemother 42, 1689-1694. 
 
Hainard, A., Tiberti, N., Robin, X., Lejon, V., Ngoyi, D.M., Matovu, E., Enyaru, 
J.C., Fouda, C., Ndung'u, J.M., Lisacek, F., Muller, M., Turck, N., 
Sanchez, J.C., 2009. A combined CXCL10, CXCL8 and H-FABP panel for the 
staging of human African trypanosomiasis patients. PLoS Negl Trop Dis 3, 
e459. 
 
Hall, N., Berriman, M., Lennard, N.J., Harris, B.R., Hertz-Fowler, C., Bart-
Delabesse, E.N., Gerrard, C.S., Atkin, R.J., Barron, A.J., Bowman, S., 
Bray-Allen, S.P., Bringaud, F., Clark, L.N., Corton, C.H., Cronin, A., 
Davies, R., Doggett, J., Fraser, A., Gruter, E., Hall, S., Harper, A.D., Kay, 
M.P., Leech, V., Mayes, R., Price, C., Quail, M.A., Rabbinowitsch, E., 
Reitter, C., Rutherford, K., Sasse, J., Sharp, S., Shownkeen, R., MacLeod, 
A., Taylor, S., Tweedie, A., Turner, C.M., Tait, A., Gull, K., Barrell, B., 
Melville, S.E., 2003. The DNA sequence of chromosome I of an African 
trypanosome: gene content, chromosome organisation, recombination and 
polymorphism. Nucleic Acids Res 31, 4864-4873. 
 
Hamedi, A., Botelho, L., Britto, C., Fragoso, S.P., Umaki, A.C., Goldenberg, S., 
Bottu, G., Salmon, D., 2015. In vitro metacyclogenesis of Trypanosoma 
cruzi induced by starvation correlates with a transient adenylyl cyclase 
stimulation as well as with a constitutive upregulation of adenylyl cyclase 
expression. Mol Biochem Parasitol. 
 
Hamet, P., Pang, S.C., Tremblay, J., 1989. Atrial natriuretic factor-induced 
egression of cyclic guanosine 3':5'-monophosphate in cultured vascular 
smooth muscle and endothelial cells. J Biol Chem 264, 12364-12369. 
 
Hammarton, T.C., Clark, J., Douglas, F., Boshart, M., Mottram, J.C., 2003. 
Stage-specific differences in cell cycle control in Trypanosoma brucei 
revealed by RNA interference of a mitotic cyclin. J Biol Chem 278, 22877-
22886. 
 
Handa, N., Mizohata, E., Kishishita, S., Toyama, M., Morita, S., Uchikubo-Kamo, 
T., Akasaka, R., Omori, K., Kotera, J., Terada, T., Shirouzu, M., 
Yokoyama, S., 2008. Crystal structure of the GAF-B domain from human 
phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 283, 
19657-19664. 
 
Hanna, M.H., Nowicki, J.J., Fatone, M.A., 1984. Extracellular cyclic AMP during 
development of the cellular slime mold Polysphondylium violaceum: 
comparison of accumulation in the wild type and an aggregation-defective 
mutant. J Bacteriol 157, 345-349. 
 
Hayakawa, A., Hayes, S., Leonard, D., Lambright, D., Corvera, S., 2007. 
Evolutionarily conserved structural and functional roles of the FYVE 
domain. Biochem Soc Symp, 95-105. 
Daniel N.A Tagoe  Review on cAMP signalling 
Hotez, P.J., Fenwick, A., Savioli, L., Molyneux, D.H., 2009. Rescuing the bottom 
billion through control of neglected tropical diseases. Lancet 373, 1570-
1575. 
 
Hotez, P.J., Molyneux, D.H., Fenwick, A., Kumaresan, J., Sachs, S.E., Sachs, 
J.D., Savioli, L., 2007. Control of neglected tropical diseases. N Engl J 
Med 357, 1018-1027. 
 
Hotez, P.J., Molyneux, D.H., Fenwick, A., Ottesen, E., Ehrlich Sachs, S., Sachs, 
J.D., 2006. Incorporating a rapid-impact package for neglected tropical 
diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 
3, e102. 
 
Houslay, M.D., Baillie, G.S., Maurice, D.H., 2007. cAMP-Specific 
phosphodiesterase-4 enzymes in the cardiovascular system: a molecular 
toolbox for generating compartmentalized cAMP signaling. Circ Res 100, 
950-966. 
 
Huang, H., 2011. Signal transduction in Trypanosoma cruzi. Adv Parasitol 75, 
325-344. 
 
Huang, H., Weiss, L.M., Nagajyothi, F., Tanowitz, H.B., Wittner, M., Orr, G.A., 
Bao, Y., 2006. Molecular cloning and characterization of the protein 
kinase A regulatory subunit of Trypanosoma cruzi. Mol Biochem Parasitol 
149, 242-245. 
 
Huang, H., Werner, C., Weiss, L.M., Wittner, M., Orr, G.A., 2002. Molecular 
cloning and expression of the catalytic subunit of protein kinase A from 
Trypanosoma cruzi. Int J Parasitol 32, 1107-1115. 
 
Huang, R., Martinez-Ferrando, I., Cole, P.A., 2010. Enhanced interrogation: 
emerging strategies for cell signaling inhibition. Nat Struct Mol Biol 17, 
646-649. 
 
Huang, Z., Myers, K., Khatra, B., Vijayaraghavan, S., 2004. Protein 14-3-3ζ Binds 
to Protein Phosphatase PP1γ2 in Bovine Epididymal Spermatozoa. Biology 
of Reproduction 71, 177-184. 
 
Inoue, M., Nakamura, Y., Yasuda, K., Yasaka, N., Hara, T., Schnaufer, A., 
Stuart, K., Fukuma, T., 2005. The 14-3-3 Proteins of Trypanosoma brucei 
Function in Motility, Cytokinesis, and Cell Cycle. Journal of Biological 
Chemistry 280, 14085-14096. 
 
Jacobs, R.T., Nare, B., Phillips, M.A., 2011a. State of the art in African 
trypanosome drug discovery. Curr Top Med Chem 11, 1255-1274. 
 
Jacobs, R.T., Nare, B., Wring, S.A., Orr, M.D., Chen, D., Sligar, J.M., Jenks, 
M.X., Noe, R.A., Bowling, T.S., Mercer, L.T., Rewerts, C., Gaukel, E., 
Owens, J., Parham, R., Randolph, R., Beaudet, B., Bacchi, C.J., Yarlett, 
N., Plattner, J.J., Freund, Y., Ding, C., Akama, T., Zhang, Y.K., Brun, R., 
Kaiser, M., Scandale, I., Don, R., 2011b. SCYX-7158, an Orally-Active 
Benzoxaborole for the Treatment of Stage 2 Human African 
Trypanosomiasis. PLoS Negl Trop Dis 5, e1151. 
Daniel N.A Tagoe  Review on cAMP signalling 
Jäger, A.V., De Gaudenzi, J.G., Mild, J.G., Cormack, B.M., Pantano, S., 
Altschuler, D.L., Edreira, M.M., 2014. Identification of novel cyclic 
nucleotide binding proteins in Trypanosoma cruzi. Molecular and 
Biochemical Parasitology 198, 104-112. 
 
Jansen, C., Wang, H., Kooistra, A.J., de Graaf, C., Orrling, K.M., Tenor, H., 
Seebeck, T., Bailey, D., de Esch, I.J., Ke, H., Leurs, R., 2013. Discovery of 
novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual 
screening against the unliganded TbrPDEB1 crystal structure. J Med Chem 
56, 2087-2096. 
 
Jaski, B.E., Fifer, M.A., Wright, R.F., Braunwald, E., Colucci, W.S., 1985. 
Positive inotropic and vasodilator actions of milrinone in patients with 
severe congestive heart failure. Dose-response relationships and 
comparison to nitroprusside. J Clin Invest 75, 643-649. 
 
Jin, S.L., Bushnik, T., Lan, L., Conti, M., 1998. Subcellular localization of 
rolipram-sensitive, cAMP-specific phosphodiesterases. Differential 
targeting and activation of the splicing variants derived from the PDE4D 
gene. J Biol Chem 273, 19672-19678. 
 
Johner, A., Kunz, S., Linder, M., Shakur, Y., Seebeck, T., 2006. Cyclic nucleotide 
specific phosphodiesterases of Leishmania major. BMC Microbiol 6, 25. 
 
Kabani, S., Fenn, K., Ross, A., Ivens, A., Smith, T.K., Ghazal, P., Matthews, K., 
2009. Genome-wide expression profiling of in vivo-derived bloodstream 
parasite stages and dynamic analysis of mRNA alterations during 
synchronous differentiation in Trypanosoma brucei. BMC Genomics 10, 
427. 
 
Kaiser, M., Bray, M.A., Cal, M., Bourdin Trunz, B., Torreele, E., Brun, R., 2011. 
Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug 
Candidate for Treatment of Sleeping Sickness. Antimicrobial Agents and 
Chemotherapy 55, 5602-5608. 
 
Kaneko, T., Hamazaki, J., Iemura, S., Sasaki, K., Furuyama, K., Natsume, T., 
Tanaka, K., Murata, S., 2009. Assembly pathway of the Mammalian 
proteasome base subcomplex is mediated by multiple specific chaperones. 
Cell 137, 914-925. 
 
Kaur, K.J., Ruben, L., 1994. Protein translation elongation factor-1 alpha from 
Trypanosoma brucei binds calmodulin. Journal of Biological Chemistry 
269, 23045-23050. 
 
Ke, H., Wang, H., 2007. Crystal structures of phosphodiesterases and 
implications on substrate specificity and inhibitor selectivity. Curr Top 
Med Chem 7, 391-403. 
 
Kelley, L.A., Sternberg, M.J., 2009. Protein structure prediction on the Web: a 
case study using the Phyre server. Nat Protoc 4, 363-371. 
 
Kennedy, P.G., 2004. Human African trypanosomiasis of the CNS: current issues 
and challenges. J Clin Invest 113, 496-504. 
Daniel N.A Tagoe  Review on cAMP signalling 
Kennedy, P.G., 2006. Diagnostic and neuropathogenesis issues in human African 
trypanosomiasis. Int J Parasitol 36, 505-512. 
 
Kennedy, P.G., 2008a. The continuing problem of human African trypanosomiasis 
(sleeping sickness). Ann Neurol 64, 116-126. 
 
Kennedy, P.G., 2008b. Diagnosing central nervous system trypanosomiasis: two 
stage or not to stage? Trans R Soc Trop Med Hyg 102, 306-307. 
Kennedy, P.G., 2012. An alternative form of melarsoprol in sleeping sickness. 
Trends Parasitol 28, 307-310. 
 
Keravis, T., Lugnier, C., 2010. Cyclic nucleotide phosphodiesterases (PDE) and 
peptide motifs. Curr Pharm Des 16, 1114-1125. 
 
Keravis, T., Lugnier, C., 2012. Cyclic nucleotide phosphodiesterase (PDE) 
isozymes as targets of the intracellular signalling network: benefits of PDE 
inhibitors in various diseases and perspectives for future therapeutic 
developments. British Journal of Pharmacology 165, 1288-1305. 
 
Kolev, N.G., Franklin, J.B., Carmi, S., Shi, H., Michaeli, S., Tschudi, C., 2010. 
The Transcriptome of the Human PathogenTrypanosoma brucei at Single-
Nucleotide Resolution. PLoS Pathog 6, e1001090. 
 
Kramer, S., 2012. Developmental regulation of gene expression in the absence of 
transcriptional control: The case of kinetoplastids. Molecular and 
Biochemical Parasitology 181, 61-72. 
 
Krishnamurthy, S., Moorthy, B.S., Xin Xiang, L., Xin Shan, L., Bharatham, K., 
Tulsian, N.K., Mihalek, I., Anand, G.S., 2014. Active site coupling in 
PDE:PKA complexes promotes resetting of mammalian cAMP signaling. 
Biophys J 107, 1426-1440. 
 
Kuboki, N., Inoue, N., Sakurai, T., Di Cello, F., Grab, D.J., Suzuki, H., Sugimoto, 
C., Igarashi, I., 2003. Loop-mediated isothermal amplification for 
detection of African trypanosomes. J Clin Microbiol 41, 5517-5524. 
 
Kuepfer, I., Hhary, E.P., Allan, M., Edielu, A., Burri, C., Blum, J.A., 2011. 
Clinical presentation of T.b. rhodesiense sleeping sickness in second stage 
patients from Tanzania and Uganda. PLoS Negl Trop Dis 5, e968. 
 
Kumari, B., Kumar, R., Kumar, M., 2014. PalmPred: An SVM Based Palmitoylation 
Prediction Method Using Sequence Profile Information. PLoS ONE 9, 
e89246. 
 
Kunz, S., Beavo, J.A., D'Angelo, M.A., Flawia, M.M., Francis, S.H., Johner, A., 
Laxman, S., Oberholzer, M., Rascon, A., Shakur, Y., Wentzinger, L., 
Zoraghi, R., Seebeck, T., 2006. Cyclic nucleotide specific 
phosphodiesterases of the kinetoplastida: a unified nomenclature. Mol 
Biochem Parasitol 145, 133-135. 
 
Kunz, S., Oberholzer, M., Seebeck, T., 2005. A FYVE-containing unusual cyclic 
nucleotide phosphodiesterase from Trypanosoma cruzi. FEBS J 272, 6412-
6422. 
Daniel N.A Tagoe  Review on cAMP signalling 
la Cour, T., Gupta, R., Rapacki, K., Skriver, K., Poulsen, F.M., Brunak, S., 2003. 
NESbase version 1.0: a database of nuclear export signals. Nucleic Acids 
Research 31, 393-396. 
 
Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., 2009. Ultrafast and 
memory-efficient alignment of short DNA sequences to the human 
genome. Genome Biol 10, R25. 
 
Langousis, G., Hill, K.L., 2014. Motility and more: the flagellum of Trypanosoma 
brucei. Nat Rev Microbiol 12, 505-518. 
 
Laxman, S., Beavo, J.A., 2007. Cyclic nucleotide signaling mechanisms in 
trypanosomes: possible targets for therapeutic agents. Mol Interv 7, 203-
215. 
 
Laxman, S., Rascon, A., Beavo, J.A., 2005. Trypanosome cyclic nucleotide 
phosphodiesterase 2B binds cAMP through its GAF-A domain. J Biol Chem 
280, 3771-3779. 
 
Laxman, S., Riechers, A., Sadilek, M., Schwede, F., Beavo, J.A., 2006. Hydrolysis 
products of cAMP analogs cause transformation of Trypanosoma brucei 
from slender to stumpy-like forms. Proc Natl Acad Sci U S A 103, 19194-
19199. 
 
Lejon, V., Buscher, P., Sema, N.H., Magnus, E., Van Meirvenne, N., 1998. Human 
African trypanosomiasis: a latex agglutination field test for quantifying 
IgM in cerebrospinal fluid. Bull World Health Organ 76, 553-558. 
 
Lejon, V., Legros, D., Richer, M., Ruiz, J.A., Jamonneau, V., Truc, P., Doua, F., 
Dje, N., N'Siesi, F.X., Bisser, S., Magnus, E., Wouters, I., Konings, J., 
Vervoort, T., Sultan, F., Buscher, P., 2002. IgM quantification in the 
cerebrospinal fluid of sleeping sickness patients by a latex card 
agglutination test. Trop Med Int Health 7, 685-692. 
 
Lejon, V., Reiber, H., Legros, D., Dje, N., Magnus, E., Wouters, I., Sindic, C.J., 
Buscher, P., 2003. Intrathecal immune response pattern for improved 
diagnosis of central nervous system involvement in trypanosomiasis. J 
Infect Dis 187, 1475-1483. 
 
Li, E., Hristova, K., 2006. Role of receptor tyrosine kinase transmembrane 
domains in cell signaling and human pathologies. Biochemistry 45, 6241-
6251. 
 
Li, J.B., Gerdes, J.M., Haycraft, C.J., Fan, Y., Teslovich, T.M., May-Simera, H., 
Li, H., Blacque, O.E., Li, L., Leitch, C.C., Lewis, R.A., Green, J.S., 
Parfrey, P.S., Leroux, M.R., Davidson, W.S., Beales, P.L., Guay-Woodford, 
L.M., Yoder, B.K., Stormo, G.D., Katsanis, N., Dutcher, S.K., 2004. 
Comparative genomics identifies a flagellar and basal body proteome that 
includes the BBS5 human disease gene. Cell 117, 541-552. 
 
Li, Z., Wang, C.C., 2003. A PHO80-like cyclin and a B-type cyclin control the cell 
cycle of the procyclic form of Trypanosoma brucei. J Biol Chem 278, 
20652-20658. 
Daniel N.A Tagoe  Review on cAMP signalling 
Liu, W., Apagyi, K., McLeavy, L., Ersfeld, K., 2010. Expression and cellular 
localisation of calpain-like proteins in Trypanosoma brucei. Molecular and 
Biochemical Parasitology 169, 20-26. 
 
Lopez, M.A., Saada, E.A., Hill, K.L., 2015. Insect stage-specific adenylate 
cyclases regulate social motility in African trypanosomes. Eukaryot Cell 
14, 104-112. 
 
Luttrell, L.M., Maudsley, S., Bohn, L.M., 2015. Fulfilling the Promise of 'Biased' 
GPCR Agonism. Molecular Pharmacology. 
 
MacGregor, P., Szoor, B., Savill, N.J., Matthews, K.R., 2012. Trypanosomal 
immune evasion, chronicity and transmission: an elegant balancing act. 
Nat Rev Microbiol 10, 431-438. 
 
MacLean, L., Chisi, J.E., Odiit, M., Gibson, W.C., Ferris, V., Picozzi, K., 
Sternberg, J.M., 2004. Severity of human african trypanosomiasis in East 
Africa is associated with geographic location, parasite genotype, and host 
inflammatory cytokine response profile. Infect Immun 72, 7040-7044. 
 
MacLean, L.M., Odiit, M., Chisi, J.E., Kennedy, P.G., Sternberg, J.M., 2010. 
Focus-specific clinical profiles in human African Trypanosomiasis caused 
by Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis 4, e906. 
 
MacLeod, E.T., Maudlin, I., Welburn, S.C., 2008. Effects of cyclic nucleotides on 
midgut infections and maturation of T. b. brucei in G. m. morsitans. 
Parasit Vectors 1, 5. 
 
Magnus, E., Vervoort, T., Van Meirvenne, N., 1978. A card-agglutination test 
with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. 
gambiense trypanosomiasis. Ann Soc Belg Med Trop 58, 169-176. 
 
Malki-Feldman, L., Jaffe, C.L., 2009. Leishmania major: effect of protein kinase 
A and phosphodiesterase activity on infectivity and proliferation of 
promastigotes. Exp Parasitol 123, 39-44. 
 
Mancini, P.E., Patton, C.L., 1981. Cyclic 3',5'-adenosine monophosphate levels 
during the developmental cycle of Trypanosoma brucei brucei in the rat. 
Mol Biochem Parasitol 3, 19-31. 
 
Martinez, S.E., Heikaus, C.C., Klevit, R.E., Beavo, J.A., 2008. The structure of 
the GAF A domain from phosphodiesterase 6C reveals determinants of 
cGMP binding, a conserved binding surface, and a large cGMP-dependent 
conformational change. J Biol Chem 283, 25913-25919. 
 
Matthews, K.R., 2005. The developmental cell biology of Trypanosoma brucei. J 
Cell Sci 118, 283-290. 
 
Maurer-Stroh, S., Eisenhaber, B., Eisenhaber, F., 2002. N-terminal N-
myristoylation of proteins: prediction of substrate proteins from amino 
acid sequence1. Journal of Molecular Biology 317, 541-557. 
Daniel N.A Tagoe  Review on cAMP signalling 
Maurice, D.H., Ke, H., Ahmad, F., Wang, Y., Chung, J., Manganiello, V.C., 2014. 
Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug 
Discov 13, 290-314. 
 
Merchant, S.S., Prochnik, S.E., Vallon, O., Harris, E.H., Karpowicz, S.J., 
Witman, G.B., Terry, A., Salamov, A., Fritz-Laylin, L.K., Marechal-
Drouard, L., Marshall, W.F., Qu, L.H., Nelson, D.R., Sanderfoot, A.A., 
Spalding, M.H., Kapitonov, V.V., Ren, Q., Ferris, P., Lindquist, E., 
Shapiro, H., Lucas, S.M., Grimwood, J., Schmutz, J., Cardol, P., Cerutti, 
H., Chanfreau, G., Chen, C.L., Cognat, V., Croft, M.T., Dent, R., Dutcher, 
S., Fernandez, E., Fukuzawa, H., Gonzalez-Ballester, D., Gonzalez-
Halphen, D., Hallmann, A., Hanikenne, M., Hippler, M., Inwood, W., 
Jabbari, K., Kalanon, M., Kuras, R., Lefebvre, P.A., Lemaire, S.D., 
Lobanov, A.V., Lohr, M., Manuell, A., Meier, I., Mets, L., Mittag, M., 
Mittelmeier, T., Moroney, J.V., Moseley, J., Napoli, C., Nedelcu, A.M., 
Niyogi, K., Novoselov, S.V., Paulsen, I.T., Pazour, G., Purton, S., Ral, 
J.P., Riano-Pachon, D.M., Riekhof, W., Rymarquis, L., Schroda, M., Stern, 
D., Umen, J., Willows, R., Wilson, N., Zimmer, S.L., Allmer, J., Balk, J., 
Bisova, K., Chen, C.J., Elias, M., Gendler, K., Hauser, C., Lamb, M.R., 
Ledford, H., Long, J.C., Minagawa, J., Page, M.D., Pan, J., Pootakham, 
W., Roje, S., Rose, A., Stahlberg, E., Terauchi, A.M., Yang, P., Ball, S., 
Bowler, C., Dieckmann, C.L., Gladyshev, V.N., Green, P., Jorgensen, R., 
Mayfield, S., Mueller-Roeber, B., Rajamani, S., Sayre, R.T., Brokstein, P., 
Dubchak, I., Goodstein, D., Hornick, L., Huang, Y.W., Jhaveri, J., Luo, Y., 
Martinez, D., Ngau, W.C., Otillar, B., Poliakov, A., Porter, A., Szajkowski, 
L., Werner, G., Zhou, K., Grigoriev, I.V., Rokhsar, D.S., Grossman, A.R., 
2007. The Chlamydomonas genome reveals the evolution of key animal 
and plant functions. Science 318, 245-250. 
 
Molyneux, D.H., Hotez, P.J., Fenwick, A., 2005. "Rapid-impact interventions": 
how a policy of integrated control for Africa's neglected tropical diseases 
could benefit the poor. PLoS Med 2, e336. 
 
Mony, B.M., MacGregor, P., Ivens, A., Rojas, F., Cowton, A., Young, J., Horn, D., 
Matthews, K., 2014. Genome-wide dissection of the quorum sensing 
signalling pathway in Trypanosoma brucei. Nature 505, 681-685. 
 
Moore, D.A., Edwards, M., Escombe, R., Agranoff, D., Bailey, J.W., Squire, S.B., 
Chiodini, P.L., 2002. African trypanosomiasis in travelers returning to the 
United Kingdom. Emerg Infect Dis 8, 74-76. 
 
Mugasa, C.M., Adams, E.R., Boer, K.R., Dyserinck, H.C., Buscher, P., Schallig, 
H.D., Leeflang, M.M., 2012. Diagnostic accuracy of molecular 
amplification tests for human African trypanosomiasis--systematic review. 
PLoS Negl Trop Dis 6, e1438. 
 
Mumba, D., Bohorquez, E., Messina, J., Kande, V., Taylor, S.M., Tshefu, A.K., 
Muwonga, J., Kashamuka, M.M., Emch, M., Tidwell, R., Buscher, P., 
Meshnick, S.R., 2011. Prevalence of human African trypanosomiasis in the 
Democratic Republic of the Congo. PLoS Negl Trop Dis 5, e1246. 
 
Munday, J.C., Rojas López, K.E., Eze, A.A., Delespaux, V., Van Den Abbeele, J., 
Rowan, T., Barrett, M.P., Morrison, L.J., de Koning, H.P., 2013. 
Daniel N.A Tagoe  Review on cAMP signalling 
Functional expression of TcoAT1 reveals it to be a P1-type nucleoside 
transporter with no capacity for diminazene uptake. International Journal 
for Parasitology: Drugs and Drug Resistance 3, 69-76. 
 
Munday, J.C., Tagoe, D.N.A., Eze, A.A., Krezdorn, J.A.M., Rojas López, K.E., 
Alkhaldi, A.A.M., McDonald, F., Still, J., Alzahrani, K.J., Settimo, L., De 
Koning, H.P., 2015. Functional analysis of drug resistance-associated 
mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and 
the proposal of a structural model for the protein. Molecular 
Microbiology, n/a-n/a. 
 
Naula, C., Schaub, R., Leech, V., Melville, S., Seebeck, T., 2001. Spontaneous 
dimerization and leucine-zipper induced activation of the recombinant 
catalytic domain of a new adenylyl cyclase of Trypanosoma brucei, 
GRESAG4.4B. Mol Biochem Parasitol 112, 19-28. 
 
Naula, C., Seebeck, T., 2000. Cyclic AMP signaling in trypanosomatids. Parasitol 
Today 16, 35-38. 
 
Nett, I.R., Martin, D.M., Miranda-Saavedra, D., Lamont, D., Barber, J.D., 
Mehlert, A., Ferguson, M.A., 2009. The phosphoproteome of bloodstream 
form Trypanosoma brucei, causative agent of African sleeping sickness. 
Mol Cell Proteomics 8, 1527-1538. 
 
Niemann, M., Wiese, S., Mani, J., Chanfon, A., Jackson, C., Meisinger, C., 
Warscheid, B., Schneider, A., 2013. Mitochondrial Outer Membrane 
Proteome of Trypanosoma brucei Reveals Novel Factors Required to 
Maintain Mitochondrial Morphology. Molecular & Cellular Proteomics 12, 
515-528. 
 
Nikawa, J., Cameron, S., Toda, T., Ferguson, K.M., Wigler, M., 1987. Rigorous 
feedback control of cAMP levels in Saccharomyces cerevisiae. Genes Dev 
1, 931-937. 
 
Njiru, Z.K., 2012. Loop-mediated isothermal amplification technology: towards 
point of care diagnostics. PLoS Negl Trop Dis 6, e1572. 
 
Norrander, J.M., deCathelineau, A.M., Brown, J.A., Porter, M.E., Linck, R.W., 
2000. The Rib43a protein is associated with forming the specialized 
protofilament ribbons of flagellar microtubules in Chlamydomonas. 
Molecular biology of the cell 11, 201-215. 
 
O'Hara, B.P., Wilson, S.A., Lee, A.W., Roe, S.M., Siligardi, G., Drew, R.E., Pearl, 
L.H., 2000. Structural adaptation to selective pressure for altered ligand 
specificity in the Pseudomonas aeruginosa amide receptor, amiC. Protein 
Eng 13, 129-132. 
 
Oberholzer, M., Langousis, G., Nguyen, H.T., Saada, E.A., Shimogawa, M.M., 
Jonsson, Z.O., Nguyen, S.M., Wohlschlegel, J.A., Hill, K.L., 2011. 
Independent analysis of the flagellum surface and matrix proteomes 
provides insight into flagellum signaling in mammalian-infectious 
Trypanosoma brucei. Mol Cell Proteomics 10, M111 010538. 
Daniel N.A Tagoe  Review on cAMP signalling 
Oberholzer, M., Marti, G., Baresic, M., Kunz, S., Hemphill, A., Seebeck, T., 
2007. The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and 
TbrPDEB2: flagellar enzymes that are essential for parasite virulence. 
FASEB J 21, 720-731. 
 
Oberholzer, M., Saada, E.A., Hill, K.L., 2015. Cyclic AMP Regulates Social 
Behavior in African Trypanosomes. MBio 6. 
 
Ochatt, C.M., Ulloa, R.M., Torres, H.N., Tellez-Inon, M.T., 1993. 
Characterization of the catalytic subunit of Trypanosoma cruzi cyclic AMP-
dependent protein kinase. Mol Biochem Parasitol 57, 73-81. 
 
Ochiana, S.O., Gustafson, A., Bland, N.D., Wang, C., Russo, M.J., Campbell, 
R.K., Pollastri, M.P., 2012. Synthesis and evaluation of human 
phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE 
inhibitors. Part 2. Tadalafil analogs. Bioorganic & Medicinal Chemistry 
Letters 22, 2582-2584. 
 
Odiit, M., Coleman, P.G., Liu, W.C., McDermott, J.J., Fevre, E.M., Welburn, 
S.C., Woolhouse, M.E., 2005. Quantifying the level of under-detection of 
Trypanosoma brucei rhodesiense sleeping sickness cases. Trop Med Int 
Health 10, 840-849. 
 
Ogbadoyi, E.O., Robinson, D.R., Gull, K., 2003. A high-order trans-membrane 
structural linkage is responsible for mitochondrial genome positioning and 
segregation by flagellar basal bodies in trypanosomes. Mol Biol Cell 14, 
1769-1779. 
 
Olefsky, J.M., 2001. Nuclear receptor minireview series. J Biol Chem 276, 36863-
36864. 
 
Omori, K., Kotera, J., 2007a. Overview of PDEs and Their Regulation. Circulation 
Research 100, 309-327. 
 
Omori, K., Kotera, J., 2007b. Overview of PDEs and their regulation. Circ Res 
100, 309-327. 
 
Orr, G.A., Werner, C., Xu, J., Bennett, M., Weiss, L.M., Takvorkan, P., 
Tanowitz, H.B., Wittner, M., 2000. Identification of Novel 
Serine/Threonine Protein Phosphatases inTrypanosoma cruzi: a Potential 
Role in Control of Cytokinesis and Morphology. Infection and Immunity 68, 
1350-1358. 
 
Orrling, K.M., Jansen, C., Vu, X.L., Balmer, V., Bregy, P., Shanmugham, A., 
England, P., Bailey, D., Cos, P., Maes, L., Adams, E., van den Bogaart, E., 
Chatelain, E., Ioset, J.-R., van de Stolpe, A., Zorg, S., Veerman, J., 
Seebeck, T., Sterk, G.J., de Esch, I.J.P., Leurs, R., 2012. Catechol 
Pyrazolinones as Trypanocidals: Fragment-Based Design, Synthesis, and 
Pharmacological Evaluation of Nanomolar Inhibitors of Trypanosomal 
Phosphodiesterase B1. Journal of Medicinal Chemistry 55, 8745-8756. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Ortiz, D., Sanchez, M.A., Quecke, P., Landfear, S.M., 2009. Two novel 
nucleobase/pentamidine transporters from Trypanosoma brucei. 
Molecular and Biochemical Parasitology 163, 67-76. 
 
Overath, P., Engstler, M., 2004. Endocytosis, membrane recycling and sorting of 
GPI-anchored proteins: Trypanosoma brucei as a model system. Mol 
Microbiol 53, 735-744. 
 
Paindavoine, P., Rolin, S., Van Assel, S., Geuskens, M., Jauniaux, J.C., Dinsart, 
C., Huet, G., Pays, E., 1992. A gene from the variant surface glycoprotein 
expression site encodes one of several transmembrane adenylate cyclases 
located on the flagellum of Trypanosoma brucei. Mol Cell Biol 12, 1218-
1225. 
 
Pan, J., Snell, W.J., 2000. Signal transduction during fertilization in the 
unicellular green alga, Chlamydomonas. Curr Opin Microbiol 3, 596-602. 
Panigrahi, A.K., Ogata, Y., Zikova, A., Anupama, A., Dalley, R.A., Acestor, N., 
Myler, P.J., Stuart, K.D., 2009. A comprehensive analysis of Trypanosoma 
brucei mitochondrial proteome. Proteomics 9, 434-450. 
 
Parnell, E., Palmer, T.M., Yarwood, S.J., 2015. The future of EPAC-targeted 
therapies: agonism versus antagonism. Trends in Pharmacological Sciences 
36, 203-214. 
 
Parsons, M., Ruben, L., 2000. Pathways involved in environmental sensing in 
trypanosomatids. Parasitol Today 16, 56-62. 
 
Paterou, A., Walrad, P., Craddy, P., Fenn, K., Matthews, K., 2006. Identification 
and stage-specific association with the translational apparatus of TbZFP3, 
a CCCH protein that promotes trypanosome life-cycle development. J Biol 
Chem 281, 39002-39013. 
 
Pays, E., Tebabi, P., Pays, A., Coquelet, H., Revelard, P., Salmon, D., Steinert, 
M., 1989. The genes and transcripts of an antigen gene expression site 
from T. brucei. Cell 57, 835-845. 
 
Pepin, J., Milord, F., 1994. The treatment of human African trypanosomiasis. 
Adv Parasitol 33, 1-47. 
 
Pepin, J., Milord, F., Meurice, F., Ethier, L., Loko, L., Mpia, B., 1992. High-dose 
nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping 
sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 86, 254-
256. 
 
Pfaffl, M.W., 2001. A new mathematical model for relative quantification in 
real-time RT-PCR. Nucleic Acids Res 29, e45. 
 
Picozzi, K., Fevre, E.M., Odiit, M., Carrington, M., Eisler, M.C., Maudlin, I., 
Welburn, S.C., 2005. Sleeping sickness in Uganda: a thin line between two 
fatal diseases. BMJ 331, 1238-1241. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Pierre, S., Eschenhagen, T., Geisslinger, G., Scholich, K., 2009. Capturing 
adenylyl cyclases as potential drug targets. Nat Rev Drug Discov 8, 321-
335. 
 
Pollastri, M.P., Campbell, R.K., 2011. Target repurposing for neglected diseases. 
Future Med Chem 3, 1307-1315. 
 
Potter, L.R., 2011. Regulation and therapeutic targeting of peptide-activated 
receptor guanylyl cyclases. Pharmacology & Therapeutics 130, 71-82. 
 
Pozuelo Rubio, M., Campbell D , G., Morrice N , A., Mackintosh, C., 2005. 
Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced 
phosphorylation of Ser(428). Biochem J 392, 163-172. 
 
Pozuelo Rubio, M., Geraghty, K.M., Wong, B.H.C., Wood, N.T., Campbell, D.G., 
Morrice, N., Mackintosh, C., 2004. 14-3-3-affinity purification of over 200 
human phosphoproteins reveals new links to regulation of cellular 
metabolism, proliferation and trafficking. Biochemical Journal 379, 395-
408. 
 
Punta, M., Coggill, P.C., Eberhardt, R.Y., Mistry, J., Tate, J., Boursnell, C., 
Pang, N., Forslund, K., Ceric, G., Clements, J., Heger, A., Holm, L., 
Sonnhammer, E.L.L., Eddy, S.R., Bateman, A., Finn, R.D., 2012. The Pfam 
protein families database. Nucleic Acids Research 40, D290-D301. 
 
Radivojac, P., Vacic, V., Haynes, C., Cocklin, R.R., Mohan, A., Heyen, J.W., 
Goebl, M.G., Iakoucheva, L.M., 2010. Identification, analysis, and 
prediction of protein ubiquitination sites. Proteins: Structure, Function, 
and Bioinformatics 78, 365-380. 
 
Radziszewski, W., Chopra, M., Zembowicz, A., Gryglewski, R., Ignarro, L.J., 
Chaudhuri, G., 1995. Nitric oxide donors induce extrusion of cyclic GMP 
from isolated human blood platelets by a mechanism which may be 
modulated by prostaglandins. Int J Cardiol 51, 211-220. 
 
Rascon, A., Soderling, S.H., Schaefer, J.B., Beavo, J.A., 2002. Cloning and 
characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from 
Trypanosoma brucei. Proc Natl Acad Sci U S A 99, 4714-4719. 
 
Ren, J., Wen, L., Gao, X., Jin, C., Xue, Y., Yao, X., 2008. CSS-Palm 2.0: an 
updated software for palmitoylation sites prediction. Protein Engineering 
Design and Selection 21, 639-644. 
 
Resh, M.D., 1999. Fatty acylation of proteins: new insights into membrane 
targeting of myristoylated and palmitoylated proteins. Biochim Biophys 
Acta 1451, 1-16. 
 
Robinson, D.R., Sherwin, T., Ploubidou, A., Byard, E.H., Gull, K., 1995a. 
Microtubule polarity and dynamics in the control of organelle positioning, 
segregation, and cytokinesis in the trypanosome cell cycle. J Cell Biol 
128, 1163-1172. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Robinson, D.R., Sherwin, T., Ploubidou, A., Byard, E.H., Gull, K., 1995b. 
Microtubule polarity and dynamics in the control of organelle positioning, 
segregation, and cytokinesis in the trypanosome cell cycle. The Journal of 
Cell Biology 128, 1163-1172. 
 
Rodbell, M., 1980. The role of hormone receptors and GTP-regulatory proteins in 
membrane transduction. Nature 284, 17-22. 
 
Rolin, S., Hanocq-Quertier, J., Paturiaux-Hanocq, F., Nolan, D., Salmon, D., 
Webb, H., Carrington, M., Voorheis, P., Pays, E., 1996. Simultaneous but 
independent activation of adenylate cyclase and 
glycosylphosphatidylinositol-phospholipase C under stress conditions in 
Trypanosoma brucei. J Biol Chem 271, 10844-10852. 
 
Rolin, S., Paindavoine, P., Hanocq-Quertier, J., Hanocq, F., Claes, Y., Le Ray, 
D., Overath, P., Pays, E., 1993. Transient adenylate cyclase activation 
accompanies differentiation of Trypanosoma brucei from bloodstream to 
procyclic forms. Mol Biochem Parasitol 61, 115-125. 
 
Ross, D.T., Raibaud, A., Florent, I.C., Sather, S., Gross, M.K., Storm, D.R., 
Eisen, H., 1991. The trypanosome VSG expression site encodes adenylate 
cyclase and a leucine-rich putative regulatory gene. EMBO J 10, 2047-
2053. 
 
Rotureau, B., Morales, M.A., Bastin, P., Spath, G.F., 2009. The flagellum-
mitogen-activated protein kinase connection in Trypanosomatids: a key 
sensory role in parasite signalling and development? Cell Microbiol 11, 
710-718. 
 
Rubenstein, L.A., Zauhar, R.J., Lanzara, R.G., 2006. Molecular dynamics of a 
biophysical model for beta2-adrenergic and G protein-coupled receptor 
activation. J Mol Graph Model 25, 396-409. 
 
Saada, E.A., Kabututu, Z.P., Lopez, M., Shimogawa, M.M., Langousis, G., 
Oberholzer, M., Riestra, A., Jonsson, Z.O., Wohlschlegel, J.A., Hill, K.L., 
2014. Insect stage-specific receptor adenylate cyclases are localized to 
distinct subdomains of the Trypanosoma brucei Flagellar membrane. 
Eukaryot Cell 13, 1064-1076. 
 
Sager, G., Ravna, A.W., 2009. Cellular efflux of cAMP and cGMP - a question 
about selectivity. Mini Rev Med Chem 9, 1009-1013. 
 
Salmon, D., Bachmaier, S., Krumbholz, C., Kador, M., Gossmann, J.A., Uzureau, 
P., Pays, E., Boshart, M., 2012a. Cytokinesis of Trypanosoma brucei 
bloodstream forms depends on expression of adenylyl cyclases of the 
ESAG4 or ESAG4-like subfamily. Mol Microbiol 84, 225-242. 
 
Salmon, D., Vanwalleghem, G., Morias, Y., Denoeud, J., Krumbholz, C., 
Lhommé, F., Bachmaier, S., Kador, M., Gossmann, J., Dias, F.B.S., De 
Muylder, G., Uzureau, P., Magez, S., Moser, M., De Baetselier, P., Van 
Den Abbeele, J., Beschin, A., Boshart, M., Pays, E., 2012b. Adenylate 
Cyclases of Trypanosoma brucei Inhibit the Innate Immune Response of 
the Host. Science 337, 463-466. 
Daniel N.A Tagoe  Review on cAMP signalling 
Sanchez, M.A., Ullman, B., Landfear, S.M., Carter, N.S., 1999. Cloning and 
Functional Expression of a Gene Encoding a P1 Type Nucleoside 
Transporter from Trypanosoma brucei. Journal of Biological Chemistry 
274, 30244-30249. 
 
Sanchez, M.A., Zeoli, D., Klamo, E.M., Kavanaugh, M.P., Landfear, S.M., 1995. A 
family of putative receptor-adenylate cyclases from Leishmania donovani. 
J Biol Chem 270, 17551-17558. 
 
Sassone-Corsi, P., 2012. The cyclic AMP pathway. Cold Spring Harb Perspect Biol 
4. 
 
Schaap, P., 2005. Guanylyl cyclases across the tree of life. Front Biosci 10, 1485-
1498. 
 
Schmid, A., Meili, D., Salathe, M., 2014. Soluble adenylyl cyclase in health and 
disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 
1842, 2584-2592. 
 
Seebeck, T., Gong, K., Kunz, S., Schaub, R., Shalaby, T., Zoraghi, R., 2001. 
cAMP signalling in Trypanosoma brucei. Int J Parasitol 31, 491-498. 
 
Seebeck, T., Schaub, R., Johner, A., 2004. cAMP signalling in the kinetoplastid 
protozoa. Curr Mol Med 4, 585-599. 
 
Seebeck, T., Sterk, G.J., Ke, H., 2011. Phosphodiesterase inhibitors as a new 
generation of antiprotozoan drugs: exploiting the benefit of enzymes that 
are highly conserved between host and parasite. Future Med Chem 3, 
1289-1306. 
 
Shakur, Y., de Koning, H.P., Ke, H., Kambayashi, J., Seebeck, T., 2011. 
Therapeutic potential of phosphodiesterase inhibitors in parasitic 
diseases. Handb Exp Pharmacol, 487-510. 
 
Shalaby, T., Liniger, M., Seebeck, T., 2001. The regulatory subunit of a cGMP-
regulated protein kinase A of Trypanosoma brucei. Eur J Biochem 268, 
6197-6206. 
 
Sherwin, T., Gull, K., 1989. Visualization of detyrosination along single 
microtubules reveals novel mechanisms of assembly during cytoskeletal 
duplication in trypanosomes. Cell 57, 211-221. 
 
Siegel, T.N., Hekstra, D.R., Wang, X., Dewell, S., Cross, G.A., 2010a. Genome-
wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma 
brucei and identification of splicing and polyadenylation sites. Nucleic 
Acids Res 38, 4946-4957. 
 
Siegel, T.N., Hekstra, D.R., Wang, X., Dewell, S., Cross, G.A.M., 2010b. 
Genome-wide analysis of mRNA abundance in two life-cycle stages of 
Trypanosoma brucei and identification of splicing and polyadenylation 
sites. Nucleic Acids Research 38, 4946-4957. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
Siman-Tov, M.M., Aly, R., Shapira, M., Jaffe, C.L., 1996. Cloning from 
Leishmania major of a developmentally regulated gene, c-lpk2, for the 
catalytic subunit of the cAMP-dependent protein kinase. Mol Biochem 
Parasitol 77, 201-215. 
 
Siman-Tov, M.M., Ivens, A.C., Jaffe, C.L., 2002. Molecular cloning and 
characterization of two new isoforms of the protein kinase A catalytic 
subunit from the human parasite Leishmania. Gene 288, 65-75. 
 
Simarro, P.P., Diarra, A., Ruiz Postigo, J.A., Franco, J.R., Jannin, J.G., 2011. 
The human African trypanosomiasis control and surveillance programme of 
the World Health Organization 2000-2009: the way forward. PLoS Negl 
Trop Dis 5, e1007. 
 
Simarro, P.P., Franco, J., Diarra, A., Postigo, J.A., Jannin, J., 2012a. Update on 
field use of the available drugs for the chemotherapy of human African 
trypanosomiasis. Parasitology 139, 842-846. 
 
Simarro, P.P., Franco, J.R., Cecchi, G., Paone, M., Diarra, A., Ruiz Postigo, J.A., 
Jannin, J.G., 2012b. Human African trypanosomiasis in non-endemic 
countries (2000-2010). J Travel Med 19, 44-53. 
 
Sprague, G.F., Jr., 1991. Signal transduction in yeast mating: receptors, 
transcription factors, and the kinase connection. Trends Genet 7, 393-
398. 
 
Stich, A., Abel, P.M., Krishna, S., 2002. Human African trypanosomiasis. BMJ 
325, 203-206. 
 
Strickler, J.E., Patton, C.L., 1975. Adenosine 3',5'-monophosphate in reproducing 
and differentiated trypanosomes. Science 190, 1110-1112. 
 
Subota, I., Julkowska, D., Vincensini, L., Reeg, N., Buisson, J., Blisnick, T., 
Huet, D., Perrot, S., Santi-Rocca, J., Duchateau, M., Hourdel, V., 
Rousselle, J.-C., Cayet, N., Namane, A., Chamot-Rooke, J., Bastin, P., 
2014. Proteomic Analysis of Intact Flagella of Procyclic Trypanosoma 
brucei Cells Identifies Novel Flagellar Proteins with Unique Sub-
localization and Dynamics. Molecular & Cellular Proteomics 13, 1769-
1786. 
 
Svobodova, M., Zidkova, L., Cepicka, I., Obornik, M., Lukes, J., Votypka, J., 
2007. Sergeia podlipaevi gen. nov., sp. nov. (Trypanosomatidae, 
Kinetoplastida), a parasite of biting midges (Ceratopogonidae, Diptera). 
Int J Syst Evol Microbiol 57, 423-432. 
 
Taelman, H., Schechter, P.J., Marcelis, L., Sonnet, J., Kazyumba, G., Dasnoy, 
J., Haegele, K.D., Sjoerdsma, A., Wery, M., 1987. 
Difluoromethylornithine, an effective new treatment of Gambian 
trypanosomiasis. Results in five patients. Am J Med 82, 607-614. 
 
Tagoe, D.N.A., Kalejaiye, T.D., De Koning, H.P., 2015. The ever unfolding story 
of cAMP signalling in trypanosomatids: vive la difference! Frontiers in 
Pharmacology 6. 
Daniel N.A Tagoe  Review on cAMP signalling 
Tetley, L., Vickerman, K., 1985. Differentiation in Trypanosoma brucei: host-
parasite cell junctions and their persistence during acquisition of the 
variable antigen coat. J Cell Sci 74, 1-19. 
 
Tiberti, N., Hainard, A., Lejon, V., Courtioux, B., Matovu, E., Enyaru, J.C., 
Robin, X., Turck, N., Kristensson, K., Ngoyi, D.M., Vatunga, G.M., Krishna, 
S., Buscher, P., Bisser, S., Ndung'u, J.M., Sanchez, J.C., 2012. 
Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage 
of Trypanosoma brucei gambiense sleeping sickness. PLoS One 7, e40909. 
 
Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., 
Bray, M.A., Pécoul, B., 2010. Fexinidazole – A New Oral Nitroimidazole 
Drug Candidate Entering Clinical Development for the Treatment of 
Sleeping Sickness. PLoS Negl Trop Dis 4, e923. 
 
Truc, P., Lejon, V., Magnus, E., Jamonneau, V., Nangouma, A., Verloo, D., 
Penchenier, L., Buscher, P., 2002. Evaluation of the micro-CATT, 
CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods 
for serodiagnosis and surveillance of human African trypanosomiasis in 
West and Central Africa. Bull World Health Organ 80, 882-886. 
 
Ulloa, R.M., Mesri, E., Esteva, M., Torres, H.N., Tellez-Inon, M.T., 1988. Cyclic 
AMP-dependent protein kinase activity in Trypanosoma cruzi. Biochem J 
255, 319-326. 
 
van den Abbeele, J., Rolin, S., Claes, Y., Le Ray, D., Pays, E., Coosemans, M., 
1995. Trypanosoma brucei: stimulation of adenylate cyclase by 
proventriculus and esophagus tissue of the tsetse fly, Glossina morsitans 
morsitans. Exp Parasitol 81, 618-620. 
 
Van der Mey, M., Hatzelmann, A., Van der Laan, I.J., Sterk, G.J., Thibaut, U., 
Timmerman, H., 2001a. Novel selective PDE4 inhibitors. 1. Synthesis, 
structure-activity relationships, and molecular modeling of 4-(3,4-
dimethoxyphenyl)-2H-phthalazin-1-ones and analogues. J Med Chem 44, 
2511-2522. 
 
Van der Mey, M., Hatzelmann, A., Van Klink, G.P., Van der Laan, I.J., Sterk, 
G.J., Thibaut, U., Ulrich, W.R., Timmerman, H., 2001b. Novel selective 
PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-
substituted cis-tetra- and cis-hexahydrophthalazinones. J Med Chem 44, 
2523-2535. 
 
Vandamme, J., Castermans, D., Thevelein, J.M., 2012. Molecular mechanisms of 
feedback inhibition of protein kinase A on intracellular cAMP 
accumulation. Cell Signal 24, 1610-1618. 
 
Vassella, E., Reuner, B., Yutzy, B., Boshart, M., 1997. Differentiation of African 
trypanosomes is controlled by a density sensing mechanism which signals 
cell cycle arrest via the cAMP pathway. J Cell Sci 110 ( Pt 21), 2661-2671. 
 
Vaughan, S., Gull, K., 2003. The trypanosome flagellum. J Cell Sci 116, 757-759. 
Vickerman, K., 1985. Developmental cycles and biology of pathogenic 
trypanosomes. Br Med Bull 41, 105-114. 
Daniel N.A Tagoe  Review on cAMP signalling 
Vij, A., Biswas, A., Bhattacharya, A., Das, P.K., 2014. A soluble 
phosphodiesterase in Leishmania donovani negatively regulates cAMP 
signaling by inhibiting protein kinase A through a two way process 
involving catalytic as well as non-catalytic sites. The International Journal 
of Biochemistry & Cell Biology 57, 197-206. 
 
Vincent, I.M., Creek, D., Watson, D.G., Kamleh, M.A., Woods, D.J., Wong, P.E., 
Burchmore, R.J., Barrett, M.P., 2010. A molecular mechanism for 
eflornithine resistance in African trypanosomes. PLoS Pathog 6, e1001204. 
 
Walter, R.D., Buse, E., Ebert, F., 1978. Effect of cyclic AMP on transformation 
and proliferation of leishmania cells. Tropenmed Parasitol 29, 439-442. 
 
Walter, R.D., Nordmeyer, J.P., Konigk, E., 1974. Adenylate cyclase from 
Trypanosoma gambiense. Hoppe Seylers Z Physiol Chem 355, 427-430. 
 
Wang, C., Ashton, T.D., Gustafson, A., Bland, N.D., Ochiana, S.O., Campbell, 
R.K., Pollastri, M.P., 2012. Synthesis and evaluation of human 
phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE 
inhibitors. Part 1. Sildenafil analogs. Bioorganic & Medicinal Chemistry 
Letters 22, 2579-2581. 
 
Wang, H., Yan, Z., Geng, J., Kunz, S., Seebeck, T., Ke, H., 2007. Crystal 
structure of the Leishmania major phosphodiesterase LmjPDEB1 and 
insight into the design of the parasite-selective inhibitors. Mol Microbiol 
66, 1029-1038. 
 
Waters, C.M., Bassler, B.L., 2005. Quorum sensing: cell-to-cell communication in 
bacteria. Annu Rev Cell Dev Biol 21, 319-346. 
 
Welburn, S.C., Picozzi, K., Fevre, E.M., Coleman, P.G., Odiit, M., Carrington, 
M., Maudlin, I., 2001. Identification of human-infective trypanosomes in 
animal reservoir of sleeping sickness in Uganda by means of serum-
resistance-associated (SRA) gene. Lancet 358, 2017-2019. 
 
Wickware, P., 2002. Resurrecting the resurrection drug. Nat Med 8, 908-909. 
Wilson, Z.N., Gilroy, C.A., Boitz, J.M., Ullman, B., Yates, P.A., 2012. Genetic 
dissection of pyrimidine biosynthesis and salvage in Leishmania donovani. 
J Biol Chem 287, 12759-12770. 
 
Wu, Y., Deford, J., Benjamin, R., Lee, M.G., Ruben, L., 1994. The gene family of 
EF-hand calcium-binding proteins from the flagellum of Trypanosoma 
brucei. Biochemical Journal 304, 833-841. 
 
Xie, Z., Cai, T., 2003. Na+-K+--ATPase-mediated signal transduction: from 
protein interaction to cellular function. Mol Interv 3, 157-168. 
 
Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J., Zhang, Y., 2015. The I-TASSER 
Suite: protein structure and function prediction. Nat Methods 12, 7-8. 
 
Zhang, X., Feng, Q., Cote, R.H., 2005. Efficacy and selectivity of 
phosphodiesterase-targeted drugs in inhibiting photoreceptor 
Daniel N.A Tagoe  Review on cAMP signalling 
phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis 
Sci 46, 3060-3066. 
 
Zoraghi, R., Corbin, J.D., Francis, S.H., 2004. Properties and functions of GAF 
domains in cyclic nucleotide phosphodiesterases and other proteins. Mol 
Pharmacol 65, 267-278. 
 
Zoraghi, R., Seebeck, T., 2002. The cAMP-specific phosphodiesterase TbPDE2C is 
an essential enzyme in bloodstream form Trypanosoma brucei. Proc Natl 
Acad Sci U S A 99, 4343-4348. 
 
Daniel N.A Tagoe  Review on cAMP signalling 
 
 
 
 
 
 
 
Review 
The ever unfolding story of cAMP signalling in 
in Trypanosomes: vive la difference! 
